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The main aim of this thesis was to discover and design new ligands for difficult, under-
explored and clinically relevant protein targets. A number of protein-protein interaction 
complexes (PPIs) are introduced as the target focus for the methods employed and developed 
herein. This thesis is separated into two sections to independently address both peptides and 
small molecules as screening agents. The project examines both approaches through 
comprehensive library design strategies and screening by NMR spectroscopic methods.  
 
ATAD2 is the first PPI investigated and was expressed and purified in good yield and was 
also isotopically labelled with Nitrogen-15 for enhanced sensitivity and orthogonal ligand and 
protein-observed NMR methods. A known pentapeptide was synthesised by solid-phase 
peptide synthesis (SPPS) using Fmoc chemistry for target validation and tool compound 
development. A one-bead one-compound (OBOC) tripeptide library was synthesised by SPPS 
in good yield and purity, determined using single-bead labelling techniques with a fluorescent 
dye (TMR) and HPLC analysis. This library contained 3072 unique tripeptides with 12 central 
non-natural, lysine derivatives flanked by 16 natural L amino acids. The library screening 
technique was based on using a fluorescently labelled protein and Confocal Nanoscanning to 
detect binding. However, fluorescent labelling of ATAD2 was unsuccessful due to difficult 
protein handling conditions, therefore this library was not screened. The advent of small 
molecule, high affinity inhibitors of this target protein generated by GSK shifted focus to a 
different PPI target, the ubiquitin conjugating enzyme, UbE2L3. 
 
A novel “on-protein peptide building” approach was introduced with the aim of screening a 
library of fluorinated dipeptides and extending the most potent via the ‘N’ and ‘C’ terminus 
to increase the affinity. A proof-of-concept tetrapeptide to survivin was synthesised by SPPS 
by incorporation of a non-natural, fluorinated amino acid in the known tetrapeptide sequence.  
This fluorinated derivative showed target binding activity by 19F NMR spectroscopy. The 
tripeptide and dipeptide truncates were synthesised by SPPS and binding was still observable 
by 19F NMR. This method was extended to screening a library of synthesised fluorinated 
dipeptides by 19F NMR against UbE2L3. A single dipeptide was identified with low affinity 
and the dipeptide was extended C and N terminally by SPPS to increase affinity. However, 
there were no tripeptides identified for this protein using this method. The proof of concept 
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tetrapeptide was a success, therefore further protein targets are required to conclusively assess 
the viability of the approach. 
Fragment based screening is then introduced as a second approach to novel ligand discovery. 
Coupled with cheminformatics analysis and in silico library design, we created an in-house 
fluorinated fragment library consisting of 109 fluorinated fragments using three parallel 
methods. Compounds were purchased and quality checked by LCMS, HPLC and 19F-NMR. 
These fragment libraries were screened in a 19F NMR assay against the UbE2L3 and 
NusE/NusB protein targets. In a primary mixture screen, two fragment hits were identified 
against the NusE/NusB PPI and there were no fragment hits identified against the UbE2L3 
protein. The two fragments against NusE/NusB were validated using orthogonal ligand-
binding NMR methods. A mini-series, consisting of six commercially available analogues, 
were purchased and two fragment analogues showed increased affinity and were active 
against E. coli in a bacterial inhibition assay. The dissociation constants of the six active 
compounds were determined by 15N-HSQC NMR titration experiments and shown to be in 
100 – 500 μM range. The binding sites of each compound were also determined by 15N-HSQC 
chemical shift mapping. These fragment hits represent a novel chemical scaffold identified 
against the NusE/NusB PPI and demonstrate the potential druggability of this new, complex 
target. 
The use of fluorine as a sensor for binding detection is evaluated by incorporating into both 
peptides and fragments. Through the use of novel library design strategies, a campaign to 
discover novel ligands of difficult protein targets is presented. 
Lay Summary 
Drug discovery is the process by which new candidate medicines are discovered and 
developed. Typically, drugs work by interacting with a biological protein inside cells and 
moderating their function. Crucial to the drug discovery process is to discover new proteins 
that can be targeted with drugs, and one class of increasingly popular targets for drug 
intervention are binding partners of protein-protein interactions (PPIs). There are about 
200,000 PPIs inside cells at any point of time and they are essential for controlling multiple 
cellular functions. Any discrepancies in the function of PPIs can lead to diseases, including: 
cancer, neurodegenerative diseases, infection and many more. Three main types of drugs are 
used on the market. Proteins, peptides and their structural elements, and small molecules. 
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One of the most common ways to discover a new drug is to screen many thousands of 
compounds (called a library) simultaneously against the target of interest and determine 
which one has the largest effect. 
In this project, the aim was to develop novel, more efficient ways, of designing libraries of 
compounds, of both peptides and small molecules, which would maximise the chances of 
finding a potential drug lead. The new libraries were then evaluated for potential interaction 
with a number of different PPI targets using a sensitive physical technique known as Nuclear 
Magnetic Resonance spectroscopy (NMR). This technique can measure compounds that have 
a very weak interaction with the target of interest, therefore further maximising the chances 
of finding a potential starting point for drug development. The chosen PPI targets for this 
project have previously been classed as difficult to find chemical starting points, therefore the 
combination of efficient library design and a sensitive detection method, was applied to 
maximise the chances of finding a molecule which would bind to the target. One of the PPIs 
introduced as target in this thesis is important for the growth of E. coli bacteria, called 
NusE/NusB. Finding a potential drug compound for this will disrupt the growth and prevent 
bacterial infection. From our novel libraries two small molecules were identified which bind 
to this important regulator of bacterial growth, NusE/NusB. These small molecules had 
affected the growth of E. coli bacteria, and therefore represent starting points for further 
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This thesis is focussed on the discovery of new ligands for difficult, under-explored protein 
targets by strategic development and application of methods in library design and NMR-
based screening approaches. This chapter begins with a general project overview and aims of 
the research. Then a brief introduction to the supporting background of the drug discovery 




1.0 General Project Outline 
Drug discovery is the process by which new candidate medicines are discovered and 
developed. Discovery of new and improved therapeutics involves an extensive pipeline from 
target validation and hit discovery to clinical trials. Target validation is crucial to find the right 
starting points for the initial hit and lead discovery phase. The most challenging target class 
for drug intervention are protein-protein interactions (PPIs). The main aim of this work is to 
discover and design new ligands using novel methods of library design and to evaluate these 
libraries against difficult, under-explored and clinically relevant PPI targets. This is achieved 
through a combination of two approaches: peptides and fragments. Both approaches involve 
the design of fluorinated compound libraries and subsequent screening of protein targets by 
ligand-observed 19Fluorine NMR.  
The first approach describes the synthesis of novel, target focussed ‘One Bead One 
Compound’ (OBOC) peptidomimetic libraries that can be used for screening of novel binders. 
The aim of this work is to discover novel, non-natural tripeptides and peptidomimetics 
designed to bind to the epigenetic, cancer target ATAD2 (ATPase AAA Domain Containing 
2). Firstly, the synthesis of a known peptide ligand to ATAD2 is described and NMR methods 
for binding detection are reported. For ligand discovery, a focussed, one-bead one-compound 
peptide library is synthesised by a solid-phase combinatorial split-and-mix strategy using 
Fmoc chemistry. Methods for screening and binding detection are described in this section. 
An alternative peptidic approach to discover and build novel peptide ligands, named ‘On 
Protein Peptide Growing’, using chemical libraries of fluorinated peptides is also described in 
chapter 2. Exploiting the high sensitivity of NMR-based detection methods, a fluorinated 
tetrapeptide, to the cancer target survivin, is used to assess the feasibility of the approach. The 
method involves the synthesis of an initial fluorinated dipeptide of the N-terminus of the 
known tetrapeptide. This is then extended by iterative ‘C’ terminal addition of amino acids, 
into a novel peptide building approach. Binding of the fluorinated dipeptide is detected by 19F 
NMR and increasing binding affinity is observed after C-terminal extension towards the final 
tetrapeptide. The approach was then applied to a validated, difficult target, the ubiquitin 
conjugating enzyme, UbE2L3. An initial dipeptide library consisting of a fluorinated 
phenylalanine and a natural L amino acid were screened for binding activity. The fluorine 
chemical shift of the fluorinated phenylalanine present in peptides with different amino acid 
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composition and/or length is distinctly different to measure in a screening approach. Multiple 
libraries of C- and N-terminal extended tripeptides were synthesised, to discover a new ligand 
for this target. 
The second approach presents fluorinated fragments as compounds for screening campaigns. 
The aim of this work was to design, collect and evaluate the fragment libraries to discover 
new, fragment hit compounds against orphan, clinically relevant PPI drug targets, including: 
UbE2L3 and NusE/NusB. The design of fragment libraries was critical to the success of the 
approach and a novel method for fragment library design was introduced. A concise 
description of practical aspects to screening by NMR and optimisation of assay parameters for 
a known fluorinated fragment-sized ligand for HSA is included. 
The in-house, designed fragment libraries were screened against the next-generation bacterial 
PPI target, NusE/NusB. Hit fragments identified by 19F NMR CSP were validated by secondary 
NMR methods, including T2 relaxation and 15N-HSQC, and a propriety version of biochemical 
assay, quantitative microdialysis (qμD). Also, structure-guided approaches to hit fragment 
development were employed, including a SAR by catalogue approach. The binding sites of 
hit compounds and analogues were mapped using the assigned, backbone amide residues of 
15N-HSQC chemical shift perturbation data. The hit fragments and analogues were also tested 
for bactericidal activity on E. coli cells in a plate-based bacterial growth inhibition assay.  
The objective of this thesis is in the design, collection and analysis of fluorine-based chemical 
libraries and to evaluate them against clinically relevant protein targets. This thesis is 
organised as follows: 
Chapter 1 – Begins with a general project outline and aims of the research. Then a brief 
introduction to drug discovery and a background to the theory of peptide and fragment-based 
screening methods. 
Chapter 2 – Introduces peptides as therapeutic agents and methods of peptide screening. The 
results section describes the synthesis of peptides for tool compound development for ATAD2 
and survivin. The various methods used to design, synthesise and evaluate peptide libraries 
into a novel “peptide building” approach are also described in this chapter. 
Chapter 3 - A comprehensive review of commercial fragment libraries and a novel approach 
to fragment library design is discussed in chapter 3. 
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Chapter 4 – Establishment of the designed, in-house CTB fluorinated fragment libraries is 
described and evaluation against the UbE2L3 protein target is presented. 
Chapter 5 – Evaluation and screening of the fragment libraries against a bacterial PPI target 
NusE-NusB is described. Chemical and biological validation and follow-up of hit compounds 
is also presented. 
Chapter 6 – Concluding remarks and future outlook. 
 
This workflow illustrates the methods employed in this thesis and their application to a 




1.1 Introduction and background 
1.1.1 What is drug discovery? 
It is an axiom to suggest that the discovery of new drugs is paramount to the continued 
existence of the human race. For centuries, medicines derived from natural sources – either 
discovered by mistake or analytically through testing – have been used to cure various 
ailments and diseases. One of the most significant and earliest examples (ca. 1552) of drug 
discovery is morphine, isolated as the first active alkaloid from the opium poppy plant in 1824 
(Figure 1.1).1  
 
 Figure 1.1: Chemical structure of morphine, currently marketed under many trade names.  
The late 19th century saw sufficient advances in chemical science to isolate compounds and 
determine chemical structures. The Merck Group (est. 1668) was one of the first companies to 
move into large scale drug production. Until the mid-twentieth century drugs were 
discovered primarily by testing analogues of known drugs and their metabolites on animal 
models. Chemical and molecular biology revolutionised the field of drug discovery in the late 
1980’s via the rapid improvements in understanding the molecular basis of disease. The 
introduction of computational modelling and rational chemical methods improved the drug 
design process. New technologies, such as high throughput screening (HTS) and 
combinatorial chemistry enhanced the discovery process by being able to screen millions of 
compounds, and the number of emerging technologies continues to grow.2 The modern drug 
discovery process involves the identification of screening hits and subsequent optimisation by 
medicinal chemistry to increase the pharmacological profile of the final drug compound. 
1.1.2 Drug-like Compounds and Properties 
The drug discovery process is plagued with high attrition rates; in a typical drug discovery 
process > 90% of drug candidates fail to reach market.3 The main reason for this is that many 
new drugs have no efficacious advantage over existing ones. Drug molecules have to have 
sufficient activity and efficacy at the site of action to moderate the target. There are various 
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metrics used to optimise the compounds during the drug discovery process, the most 
important of which are described in table 1.1. 
Metric Description 
Affinity The strength of the interaction between the ligand and protein. The 
dissociation constant, Kd, is the most common measure of the binding 
strength. A low Kd = high affinity. 
Efficacy A measure of the maximum response achieved with an applied dose 
of drug compound. 
Selectivity The ability of a drug to preferentially target a particular a site of action, 
relative to other sites. 
Pharmacokinetics The effect the body has on a drug compound, also referred to as 
ADME (Absorption, Distribution, Metabolism and Excretion). 
Toxicity This is a broad description, however, mainly refers to how harmful the 
drug is at therapeutic doses. 
Table 1.1: The various metrics used to characterise a drug compound during development. 
There are two main, distinct types of drug molecules used in development of clinical 
candidates: peptides and small molecules. The following sections introduces both peptides 
and small molecules and focusses on the main differences and the medicinal potential of each. 
1.1.3 Small Molecules 
It is without question the drug market is dominated by small molecule (SM) compounds. In 
2014, five of the top ten selling drugs were small molecules4: aripiprazole (Abilify, $7.2 billion), 
esomeprazole (Nexium, $6.3 billion), rosuvastatin (Crestor, $5.6 billion), fluticasone 
propionate (Advair Diskus, $5.0 billion), and sofosbuvir (Sovaldi, $4.4 billion). The SM class 
of drug compounds represents an almost infinitely diverse set of molecules that are waiting 
to be discovered.  
 
Figure 1.2: Chemical structures of 1) paracetamol and 2) ibuprofen. 
Two of the most recognised and simplest examples of SM drugs are paracetamol and 
ibuprofen (Figure 1.2). These are the most widely available over the counter analgesics in the 
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world today, despite being available since the 1950’s.5 However, SM drugs continue to lead 
the way in number of new compounds brought to market, a leading example of a modern SM 
drug is Vertex Pharmaceuticals’ Ivacaftor (Figure 1.3). Approved in 2012, it is the first drug to 
treat the underlying cause of patients with cystic fibrosis.6 
 
Figure 1.3: Chemical structure of Ivacaftor. Used to treat patients with cystic fibrosis caused 
by certain mutations in the CFTR (Cystic Fibrosis Transmembrane Conductance Regulator) 
gene. 
Classic drug development of SMs involves synthesis by well-defined chemical reactions and 
they can be easily characterised by standard analytical methods. Also, ADME testing of SMs 
is generally much easier (than peptides) due to predictable physiochemical properties and a 
reduced structural complexity.7 They are also preferred, over peptides, primarily due to ease 
of production, simplicity of administration (oral availability) and their superior 
pharmacological properties to peptides. However, the high financial expenses associated with 
SM drug development has reduced the number of approved drugs reaching the market. 
Currently, the pharmaceutical industry is undergoing a paradigm shift towards peptides as 
therapeutic agents coinciding with the advances in molecular and synthetic biology.8 
1.1.4 Peptide Therapeutics 
Recently, there has been a substantial increase in the use of peptides as therapeutic agents.9 In 
general, peptides are typically short-chains of amino acids that bind to cell surface receptors, 
such as GPCRs or ion-channels, where they mediate intracellular signalling pathways. A host 
of functions have been identified for naturally occurring peptides including: hormones, 
growth factors, neurotransmitters, and ion channel ligands.8 Their high target specificity, 
efficacy and safety generally makes them a more attractive choice of treatment than small 
molecule drugs.10 However, naturally occurring peptides are generally unsuitable due to 
suboptimal chemical and physical stability, and a poor bioavailability.11 Therefore, rational 
techniques to alleviate these issues is a large area of research. The motivation for pursuing 
peptides as therapeutics is the ease of synthesis and scope for novel modifications. A 
traditional structure-based design strategy to establish structure-activity relations (SAR) of 
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natural peptides is called ‘alanine scanning’. This is an approach used to identify the amino 
acids in a known peptide sequence that are essential for the peptide’s stability and function. 
Sequential replacement with an alanine residue in the peptide sequence indicates the 
contribution of each residue to the binding interaction.12 In this way, peptides can be modified 
with, for example, non-natural amino acids to advantageously alter the chemical and physical 
properties, such as stability and biological activity, these are called peptidomimetics. In 2004, 
Walensky et al reported the synthesis of a ‘stabilised alpha-helix of BCL-2 domains’ (SAHBs) 
which mimic the BH3 segment in BCL-2 regulated apoptosis.13 Covalent helix stabilisation 
was achieved by replacement of two amino acids in the backbone of a known α-helix 23mer 
with olefinic containing amino acids and subsequent cross-linking by ruthenium-catalysed 
olefin metathesis (Figure 1.4). This led to an enhanced affinity, helicity, protease resistance 




Native BH3 peptide EDIIRNIARHLAQVGDSNLDRSIW 
SAHBA EDIIRNIARHLA*VGD*NLDRSIW 
* = olefinic containing amino acid, NL = norleucine  
 Figure 1.4: Top: Covalent helix stabilisation of an α-helix by inclusion of non-natural amino 
acids and subsequent crosslinking reaction. Bottom: table shows the native sequence and 
synthetic sequence of the final peptidomimetic. Adapted from Walensky, 2004.13 
There are many examples of including non-natural amino acids to modify peptide properties, 





1.1.5 Drug Discovery Pipeline 
A modern view of the drug discovery process can be illustrated by a drug pipeline (Figure 
1.5). It consists of five major stages: target identification, hit generation, hit-to-lead, lead 
optimisation and preclinical development. This is a broad overview and ultimately depends 
on the nature of the project, e.g. compounds based on known drugs already have a validated 
target. 
 
Figure 1.5: Drug Discovery Pipeline. The first stage of a drug discovery campaign is to identify 
a target. This is followed by hit identification and optimisation of this hit into a potent lead 
compound. At this stage the compound enters preclinical development followed by clinical 
trials. 
There are a plethora of challenges facing the pharmaceutical industry in development of new 
therapeutics, ranging from antibacterial resistance to translating in vitro efficacy to animal 
models.14 The major challenge facing modern drug discovery is an insufficient knowledge of 
the molecular mechanisms of disease, therefore discovery is hindered at the first hurdle. This 
thesis is aimed at the very first stages of the drug discovery process by development of new 
approaches to generate a hit compound for difficult, orphan targets. Orphan protein targets 
include those that are generally under-explored in academia and pharma industry and have 
no known inhibitors and are therefore considered difficult or undruggable. The PPI protein 
targets presented in thesis are detailed in chapters 2 and 4.The following sections describe the 
first two stages of the drug discovery pipeline. 
1.2 Target Selection and Validation 
The first step towards developing a drug is to identify the druggable genes at the root of 
disease. Most drugs currently on the market have a known target for interaction, and there 
are various methods of identifying (determining a drug target) and validating (demonstrating 
the effect of the interaction) the drug target. These two steps are closely associated and are 
generally considered together. Most drug targets are proteins, however, DNA and RNA can 
also be the focus of drug intervention. The advances in structural genomics and analysis of 












validation. However, the general principle of validation has to be considered throughout the 
entire drug discovery process and relies on: cell-based validation, validation in animal studies 
then proof-of-concept in humans (clinical trials). The methods towards target validation can 
be broadly split into two categories: biological and chemical, as illustrated in table 1.2. 
Biological validation generally adopts a functional in vivo assay (phenotypic observations) to 
determine target validity, whereas as chemical validation focusses on mechanistic studies of 
binding interactions in vitro. 
Biological (in vivo) Chemical (in vitro) 
 Gain of function: gene over-expression 
in cells or whole animals 
 Loss of function: gene knockout tests in 
model organism 
 Protein inhibition by small molecules, 
peptides, antibodies and aptamers in 
chemical assays (affinity determination). 
Table 1.2: This table gives an overview of the biological and chemical methods of target 
validation. 
1.2.1 Target Focus in Drug Discovery 
There are approximately 30,000 genes in the human genome, leading to the concept of the 
druggable genome.15 Hopkins and Groom (2002) carried out an extensive analysis of the 
number of molecular targets amenable to drug intervention.15 It was found that there were 130 
distinct protein families representative of known drug targets, however, nearly half of all 
targets fell into just six families: G-protein-coupled receptors (GPCRs), serine/threonine and 
tyrosine protein kinases, zinc metallopeptidases, serine proteases, nuclear hormone receptors 
and phosphodiesterases. A more recent class of therapeutic targets, which were deemed 
intractable twenty years ago, are protein-protein interactions, and these are discussed in the 
next section. 
1.2.2 Protein-Protein Interactions 
Many of the fundamental processes in cells are controlled by proteins interacting with one 
another. These are called protein-protein interactions (PPIs) and are critical in the regulation 
of biological systems and controlling signal transduction pathways. The dysregulation of this 
vast interactome in the development of disease is widely recognised. However, inhibitors of 
these PPIs are relatively scarce, as these are generally considered difficult, or undruggable, 
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targets. Peptide inhibitors are often used to target PPIs due to their native affinity for proteins, 
however, as described previously, they are hindered by their inferior stability and 
bioavailability to small molecules. Despite this, recent work has emerged demonstrating that 
certain PPIs are amenable to small molecule inhibition by a similar mode of action to peptides, 
by binding into pockets on the surface of proteins and disrupting the interaction. Further 
mechanisms of small molecule inhibition of PPIs include: allosteric mechanisms or binding at 
a catalytic site. High resolution structures, gleaned from X-ray crystallography or NMR, has 
shown that PPI interfaces are generally flat and large (1,000 – 2,000 Å2)16, however, most 
inhibitors target PPIs where the essential binding interactions are concentrated in ‘hot-spots’. 
These hot-spots are the interactions responsible for driving the affinity of two proteins and are 
specific residues distributed across the surface of the proteins. PPIs can be generally classified 
by whether the interface consists of a primary protein sequence, a single region of secondary 
structure or multiple sequences containing tertiary structures, this is illustrated in figure 1.6. 
 
Figure 1.6: A diagram to show the decreasing druggability of a PPI according to the 
complexity of the epitope. Image taken directly from Arkin et al.17 
As described earlier (section 1.1.4), the alanine scanning technique was one of the leading 
methods that inspired confidence that PPIs could be modulated by small molecules. In the last 
decade, more than 40 PPIs have been targeted and there are several inhibitors currently in 
clinical trials, this makes it the fastest growing target class for drug inhibition.18 
1.2.3 Inhibitors of PPIs 
One of the first examples of a PPI inhibitor approved for clinical use is Tirofiban, an 
antiplatelet drug used to reduce the rate of thrombotic cardiovascular events. It is a small 
molecule designed to mimic the linear peptide RGD, which is the epitope of fibrinogen that 
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interacts with glycoprotein IIb/IIIa (figure 1.7). This is a good example of the design of a small 
molecule from a known peptide inhibitor using prior knowledge of the essential binding 
interactions. 
 
Figure 1.7: Chemical structure of Tirofiban and the mimicking peptide (RGD). 
Arguably the largest area of drug research is development for cancer therapies. Inhibitor of 
apoptosis proteins (IAPs), including XIAP (X-linked Inhibitor of Apoptosis), are regulators of 
apoptotic cell death. 
These IAPs have interaction domains called BIR domains that directly bind to an N-terminal 
tetrapeptide sequence on caspases and thereby prevent caspase-promoted cell death. An 
example of an endogenous inhibitor of IAPs is Smac (second mitochondrial activator of 
caspases), which competes with caspases to stimulate apoptosis. Therefore, small molecule 
inhibitors are designed to mimic the tetrapeptide binding motif on Smac and are called Smac 
mimetics. Several Smac mimetics have been developed that show anti-tumour activity, these 























Table 1.3: A table showing various SMAC mimetics (peptide-like inhibitors of primary 
epitope PPIs) currently in clinical trials. Adapted from Arkin et al.17 
1.3 Hit Discovery 
After a target has been selected and shown to have a relative capacity for intervention, the 
next stage is to find ligands for the target. This is generally done by application of screening 
campaigns in industry and there are two, distinct alternative approaches to hit discovery: high 
throughput screening (HTS) and fragment-based drug discovery (FBDD). These are 




Figure 1.8: A schematic diagram of the two approaches to hit discovery: HTS and FBDD. 
1.3.1 High Throughput Screening - HTS 
Originally, the pharmaceutical industry used high throughput screening to discover new lead 
molecules against a chosen target. This consisted of screening many thousands (50,000 – 
1,000,000) of large, complex, drug-like molecules for their ability to modify the biological 
activity of the chosen target.19 Companies have invested in complex hardware and robotic 
systems to test large numbers of compounds quickly and efficiently and provide a competitive 
advantage.20 The HTS method is frequently employed with analytical techniques such as X-
ray crystallography, NMR or coupled methods, e.g. LC-MS/MS. Also, biophysical techniques 
such as fluorescence spectroscopy and isothermal titration calorimetry have also been used to 
screen compound libraries. However, an important caveat of HTS is that it requires a robust 
assay specific to the target to minimise the effect of false positives.21 This is time-consuming 
to develop and requires detailed knowledge of the biological function of the target. This also 
requires the use of orthogonal techniques to validate the hit compound. 
Over the past two decades the discovery and development of new drug compounds has relied 
heavily on these HTS techniques. The pharmaceutical industry has invested heavily in HTS 
projects that have yielded fewer and fewer drug leads and clinical candidates particularly 
against difficult targets. Multimillion member compound libraries deliver poor hit rates or 
unsuitable compounds, therefore, there is a clear need to deliver alternative approaches to 
Traditional High Throughput Screening 





address these limitations. One approach that is becoming increasingly popular in industry 
and academia is fragment-based drug discovery (FBDD). 
1.3.2 Fragment Based Drug Discovery - FBDD 
“Great things are done by a series of small things brought together” – Vincent van Gogh. 
Fragment-based drug discovery (FBDD) is now a well-established approach in academia and 
the pharmaceutical industry for the discovery of ligands that bind to proteins and/or nucleic 
acid targets.22 This method is used extensively in the search for new drug compounds, with 
many already in clinical trials23, and with the first fragment-derived compound treating 
patients24.  
The concept of the FBDD approach is that large drug-like molecules are built up of two, or 
more, smaller, lower complexity components, i.e. fragments. These small fragments can 
sample a larger volume of the available chemical space. Chemical space is a rather abstract 
concept that describes the theoretical number of molecules that can be synthesised, numbers 
range from 1060 - 10100 molecules.25 Screening for the smaller fragments using low molecular 
mass, fewer compound libraries (in the range of hundreds to a few thousand) will yield a core 
structural starting point for hit-to-lead optimisation. Screening fewer compounds is also 
faster, less expensive and hit fragments have the potential to keep complexity and molecular 
mass low of lead compounds. However, detection and characterisation of such weak affinity 
compounds is problematic using many traditional biochemical HTS assays. Therefore, highly 
sensitive biophysical screening methods, such as NMR or X-ray crystallography are required 
to detect binding (see section 1.3.3). A crucial aspect to FBDD is in the design of the library 
and choosing suitable compounds for screening, this is discussed in further detail in chapter 
3. 
There are two options for hit development after fragment screening, these are illustrated in 
figure 1.8. Fragment linking is an attractive option to increase the potency of two hit fragments 
to a particular target, this was demonstrated in the ‘original’ SAR by NMR approach 
implemented by Fesik et al.26 Fragment growing requires extensive medicinal chemistry to 
optimise hit compounds in the hit-to-lead development stage. This is costly and time-
consuming however, generally, simpler chemical syntheses are required over complex hits 
obtained in HTS. The FBDD approach is also impacting significantly on hit discovery for  
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Table 1.4. This table compiles the most recent (2016) fragment-derived drugs currently in 
clinical development. Table adapted from Erlanson, 2016.28 
Status Drug Company Target 
Approved 
Vemurafenib Plexxikon B-Raf(V600E) 
Venetoclax AbbVie/Genentech Selective Bcl-2 
Phase III 
PLX3397 Plexxikon FMS, KIT, and FLT-3-ITD 
Verubecestat Merck BACE1 
AZD3293 AstraZeneca/Astex/Lilly BACE1 
Phase II 
AT7519 Astex CDK1,2,4,5,9 
AT9283 Astex Aurora, JAK2 
AZD5363 AstraZeneca/Astex/CR-UK AKT 
Erdafitinib J&J/Astex FGFR1-4 
Indeglitazar Plexxikon pan-PPAR agonist 
LY2886721 Lilly BACE1 
LY517717 Lilly/Protherics FXa 
Navitoclax (ABT-263) Abbott Bcl-2/Bcl-xL 
NVP-AUY922 Vernalis/Novartis HSP90 
Onalespib Astex HSP90 
Phase I 
ABL001 Novartis BCR-ABL 
ABT-518 Abbott MMP-2 & 9 
ABT-737 Abbott Bcl-2/Bcl-xL 
ASTX660 Astex XIAP/cIAP1 
AT13148 Astex AKT, p70S6K, ROCK 
AZD3839 AstraZeneca BACE1 
AZD5099 AstraZeneca Bacterial topoisomerase II 
BCL201 Vernalis/Servier/Roche BCL-2 
DG-051 deCODE LTA4H 
IC-776 Lilly/ICOS LFA-1 
LP-261 Locus Tubulin 
LY2811376 Lilly BACE1 
PF06650833 Pfizer IRAK4 
PLX5568 Plexxikon Kinase 
SGX-393 SGX BCR-ABL 
SGX-523 SGX Met 
SNS-314 Sunesis Aurora 
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challenging targets, such as protein-protein interactions (see section 1.3.2), where many HTS 
campaigns are unsuccessful.  
Currently, FBDD is practiced widely in academia and industry and a recent review, 2016, of 
fragment-based drug design includes an up-to-date list of fragment-derived drugs that are in 
clinical development, these are shown in table 1.4. Arguably one of the most eagerly 
anticipated drugs included on this list is the BACE-1 (Beta-secretase 1) inhibitor Verubecestat 
from Merck. The so-called ‘Amyloid hypothesis’ is a leading philosophy of neurodegeneration 
in Alzheimer’s disease. Its primary directive involves the accumulation and deposition of 
amyloid β-peptide (Aβ) as plaques in brain tissue.27 Key to the formation of these short, 
aggregating peptides is cleavage of the amyloid precursor protein (APP) by BACE-1, 
therefore, in theory, an inhibitor of this membrane protein would prevent build-up of Aβ and 
may slow or prevent Alzheimer’s disease. This shows that FBDD is a significant technique for 
the identification of new hit compounds for difficult, orphan targets and diseases. A summary 
of the advantages and disadvantages of HTS and FBDD is given in table 1.5. 
 Fragment Based Screening High Throughput Screening 
Advantages 
 High hit rates (3 – 10 %) 
 Fast 
 Cost effective 
 Hits are easier to 
optimise 
 Large numbers of compounds can be 
screened quickly 
 High affinity binders 
 Minimisation and low complexity of 
assay 
 Reduction in costs 
Disadvantages 
 Low affinity binders 
 Sensitive detection 
methods required 
 Extensive medicinal 
chemistry 
 Low hit rates (< 1%) 
 Complex medicinal chemistry 
 High attrition rates in lead 
development 
Table 1.5: A comparison of the advantages and disadvantages of HTS vs FBDD. 
1.3.3 Methods in Fragment Based Drug Discovery 
A fundamental aspect to FBDD is the chosen assay to screen the compound library. Fragments 
are inherently weak affinity binders, therefore highly sensitive methods are required. Among 
the classical, biophysical assays for fragment screening are NMR spectroscopy, X-ray 
crystallography and SPR. In a recent poll, 2016, on the popular drug discovery blog ‘Practical 
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Fragments’ the most popular technique used by respondents for FBDD was ligand-detected 
NMR (Figure 1.3.1), followed by SPR and X-ray crystallography.29 
 
Figure 1.9: A chart showing the most popular techniques used in FBDD. Adapted from 
Erlanson [23]. 




10 mM – 100 nM 
Can detect very weak binders however 
requires large amounts of protein. 




5 mM – 100 nM 
Requires isotopic labelling of the 
protein (size limit < 40 kDa). Affinity 
determination and binding site 
mapping can be determined. 
X-ray crystallography All affinites 
Crystal structure provides detailed 
description of binding site and essential 
interactions. Co-crystallisation can 
required different crystal conditions for 




500 μM lower limit 
Allows kinetics of binding to be 
measured and accurate Kd 
determination. Difficult to immobilise 
protein. 
























Arguably, the origin of FBDD began with the work of Fesik and co-workers in their paper 
entitled ‘SAR by NMR’, and the use of NMR in drug discovery projects has greatly increased. 
Table 1.6 summarises the classical methods utilised in FBDD. NMR is advantageous as it 
requires almost no assay development, all that is needed is a soluble target and i.e. there is no 
requirement for crystallisation, immobilisation or labelling of the target. The practical 
applications of NMR in FBDD are discussed in more detail in section 1.4. 
1.3.4 Fluorine in Medicinal Chemistry 
Fluorine chemistry is a large area of research, particularly in the pharmaceutical and 
biomedical industries. Advances in synthetic organic chemistry has made possible the 
production of a wide range of fluorine-containing analogues of many different biological 
compounds, e.g. nucleosides, amino acids, lipids and sugars. The role of fluorine in drug 
design is increasing and is now widely recognised for its unique properties. The inclusion of 
a fluorine atom in a drug compound can have advantageous effects on a molecule’s 
physiochemical properties, including:30–32 
 pKa: a fluorine atom is generally introduced to increase the acidity of acids and 
decrease the basicity of bases. 
 Lipophilicity: is also usually increased if a fluorine atom is placed in the vicinity of 
basic nitrogens or introduced to aromatic rings. Lipophilicity is particularly increased 
by the introduction of trifluoromethyl or trifluoromethoxy (CF3 or OCF3 respectively) 
containing groups, whereas a single F atom (CF) may alter it in either direction. 
 Membrane permeability: can be increased by introduction of an F atom at a specific 
site of a molecule due to intramolecular hydrogen bonding 
 Metabolic stability: a fluorine atom is frequently used to replace a H atom in a lead 
compound where metabolism is likely to occur. The higher dissociation energy of a 
C–F bond, compared to a C–H bond 
 Binding affinity: a single fluorine atom in a molecule can also have a large effect on 
the binding affinity of the compound to the target. This is due to the different van der 
Waals radius’ and stereoelectronic effects of fluorine and hydrogen and their specific 




Historically, Fludrocortisone was the first example of a fluorinated drug compound to be 
developed (Figure 1.10) and many of the currently available market leading pharmaceuticals 
now contain fluorine atoms,33 as shown in table 1.7. 
 
Figure 1.10: Chemical structure of Fludrocortisone, the first fluorinated pharmaceutical to be 
developed. 














Table 1.7: Structures of some fluorine-containing drugs and their uses. 
This thesis focusses on the use of fluorine containing compounds for screening by fluorine 
NMR methods. A comprehensive review and approach to fluorinated peptides and fluorine 
fragment library design is described in chapters 2 and 3, respectively. 
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1.4 Applications of NMR Spectroscopy in Drug 
Discovery 
Nuclear magnetic resonance (NMR) has found many applications in FBDD. NMR can be used 
for screening large libraries and is an important alternative to X-ray crystallography in 
determining high resolution structures. Over the years, several NMR methods have been 
developed towards fragment-based screening and these techniques can be categorised into 
two groups: ligand-observed NMR and protein-observed (target-based) NMR, these are 
discussed in the following section. 
 
Figure 1.11: NMR properties of proteins and small molecules. Fragments adopt the properties 
of the target protein upon binding due to the increase in the effective molecular mass. From 
Klages et al.34 
1.4.1 Protein-observed Screening Methods 
Almost exclusively, protein-observed NMR methods measure chemical shift perturbations 
(CSPs) to detect ligand binding. The chemical shifts of certain protein residues in the binding 
site will change upon the addition of ligand due to changes in the local environment. The most 
common protein-observed NMR technique used is the 2D heteronuclear single quantum 
coherence (HSQC) experiment. The isotopic labelling with 13C or 15N allows for the 
identification of residues involved in the binding interaction which can then be used for 
affinity determination or binding site mapping. Again, the original ‘SAR by NMR’ approach 
adopted by Fesik et al observed CSPs of 15N-HSQC NMR spectra of However, isotopic 
labelling is relatively expensive and protein expression typically produces poor yields. Also, 
2D spectra take much longer to acquire than 1D and a relatively high concentration of protein 
is required to obtain a practical signal to noise (S/N) ratio. A further limitation of protein-
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observed NMR is the effective size of the protein. For large macromolecules, the number of 
signals increases and they become broader due to slower molecular tumbling. This results in 
spectral overlap which can complicate spectral analysis. A 1H-15N correlation is a molecular 
fingerprint of the protein and is a good measure of whether the protein is folded or 
aggregated.  
1.4.2 Ligand Observed Screening Methods 
Ligand-observed methods are based on the fact that small molecules adopt the properties of 
the protein upon binding (Figure 1.11). For example, proteins exhibit fast relaxation rates, 
positive NOE (Nuclear Overhauser Effect) cross correlation and slow diffusion coefficients, 
whereas small molecules have slow relaxation, negative NOEs and large diffusion coefficients. 
Ligand-observed methods generally measure a 1D spectrum and are therefore faster than 
protein-observed methods. Also, it is possible to screen large mixtures of ligands as the ligand 
is directly detected, therefore no deconvolution of the hit compound is required. Measuring 
the spectra in compound pools is faster and often requires lower amounts of protein. Another 
advantage of ligand-observed methods is there is no need to isotopically label the protein and 
often higher molecular weight proteins can be screened. The most common NMR method for 
ligand-observed screening is saturation transfer difference (STD) NMR. Mayer (1999) was the 
first to apply the STD technique to screening of protein-ligand interactions. The general 
principle involves subtracting two spectra, one recorded in which the protein was selectively 
saturated (on-resonance) from one recorded without protein saturation (off-resonance) 
(Figure 1.12). The on-resonance spectrum is obtained by irradiating at a region that contains 
only resonances of the protein target (typically -1 – 0 ppm; –CH3 methyl protons) which gives 
signal intensities ISAT. The off-resonance spectrum is obtained by irradiating at a frequency 
where no 1H signals occur, with signal intensities I0. During acquisition of the on-resonance 
spectrum, saturation is transferred through the protein via spin-diffusion and any bound 
ligands will also receive saturation. The two spectra are subtracted from one another and any 
bound ligands will be visible due to the difference in intensities, non-binding ligands have the 
same intensity in each spectrum and are therefore cancelled out. The advantages of STD NMR 
include: use of an excess of ligand which allows for low consumption of protein and no upper 




Figure 1.12: Scheme showing the two required spectra for the Saturation Transfer Difference-
NMR experiment. The selective saturation of protein resonances allows intermolecular 
transfer of magnetisation from the protein to any bound ligands. Adapted from Viegas et al.35 
However, there is a lower size limit (about 10 kDa) as small proteins are not as effectively 
saturated by spin diffusion. A recent example (2016) of fragment-based screening by STD 
NMR is by Mesleh et al who screened a library 5643 fragments against S. aureus DNA Gyrase 
B which yielded 304 hits.36 Fragment hits were initially classified based on the STD signal 
intensity and then further reduced based on fragment novelty and chemical tractability, 
yielding a total of 46 fragments for follow up.  
Another popular method for NMR screening, similar to STD, is water-ligand observation by 
gradient spectroscopy (WaterLOGSY). The difference between STD and WaterLOGSY is that 
magnetisation is transferred from bulk water molecules to the protein via two pathways: 1) 
transfer from water molecules in the binding pockets of the protein and 2) hydrogen exchange 
of chemically labile hydrogens on the protein. Water molecules are almost always found 
linking ligands to the protein via a network of intermolecular hydrogen bonds.37 Therefore, 
magnetisation is transferred to any bound ligands via the water molecules in the binding site. 
Understandably, magnetisation will also be transferred to non-bound ligands in solution 
however, bound and non-bound ligands can be distinguished due to the difference in sign of 
the NOE. The large, protein-ligand complex tumbles slowly and has a negative NOE, 
however, small molecules rotate fast in solution and have a positive NOE. Therefore, protein 
bound ligands show a positive signal and non-binding ligands show a negative signal in the 
difference spectrum. WaterLOGSY is a sensitive method and can be used for mixtures of 














Figure 1.13: A series of NMR WaterLOGSY experiments showing the binding of compound 6 
(IC50 30 μM) to BACE-1. A) No protein (negative peaks for unbound compound); B) Spectrum 
after addition of 1.8 μM BACE-1 (peaks are less negative). C) With 3.2 μM protein (compound 
signals are increasingly positive). D) Addition of high affinity ligand to displace compound 6 
(NMR signals are negative again). Adapted from Geschwindner et al.38 
1.4.3 Fluorine NMR Spectroscopy for Screening 
There are many advantages of using the fluorine nucleus as an NMR probe for investigating 
biological systems.39 The 19F nucleus has a nuclear spin of ½, a high gyromagnetic ratio, 100% 
natural abundance and a sensitivity that is 83% that of the proton and is therefore ideal for 
studying protein-ligand interactions by NMR spectroscopy.39 It is widely used to study 
protein-ligand interactions either through ligand or protein observation, or indirectly through 
a reporter molecule. In the context of drug discovery and screening of large compound 
libraries, ligand-observed NMR methods are usually preferred, although protein-observed 
methods are not uncommon.40,41 In contrast to 1H observed ligand methods, 19F-based 
experiments routinely measure chemical shift perturbations (CSPs). The chemical shift range 
is very large, compared to the proton, and is very sensitive to the local electronic environment 
and to the changes during a ligand binding event. Furthermore, due to the high chemical shift 








effects at slow molecular tumbling rates, for example during a ligand binding to a large 
protein.40 Thus, the fluorine nucleus is ideal for use as a sensor to detect protein-ligand 
interactions. 
19F NMR is a relatively new approach to fragment screening and there are various methods to 
detect fragment binding currently employed.42,43 Fluorine NMR spectra are much simpler than 
1H spectra since there are typically fewer signals and no signals from the protein. This allows 
for screening of large mixtures of compounds, compared to proton observed methods, which 
greatly reduces the measuring time.44 Typically, a few thousand molecules can be screened 
per day and only a small amount of unlabelled protein is required.45 The main concern 
regarding fluorine fragment-based screening is the available chemical space coverage of 
fluorine containing compounds, this is discussed in more detail in Chapter 3. An excellent 
review in Drug Discovery Today from Anna Vulpetti and Claudio Dalvit, describes the 
ubiquitous use of 19F methods in drug discovery.46 They propose a complete workflow of the 
various ways that fluorine can impact the hit discovery and validation stages. The main 
extension and utility of fluorine NMR-based methods described is in competition-based 
assays using 19F-containing reporter molecules.47 For example, screening of a rudimentary 19F-
based fragment library can lead to weak affinity ligands. These are then used as ‘spy’ 
molecules in a competition-based NMR experiment termed FAXS (Fluorine Anisotropy and 
Exchange for Screening).40,48 Further methods of 19F NMR-based screening and the practical 
aspects are discussed in more detail in chapter 4. 
1.5 Concluding Remarks 
In summary, drug discovery is a vast area of research and the identification of potential drug 
candidates can be achieved by a plethora of techniques. A crucial aspect to the success of a 
drug discovery campaign is in design of the library, whether it is peptides or small molecules, 
a review of library design strategies is given in chapter 3.  
NMR screening has become a powerful tool for the discovery and validation of drug 
candidates in the pharmaceutical industry. Advances in NMR technology has made screening 
applications involving NMR indispensable to modern drug discovery. NMR techniques for 
screening do not require prior knowledge of the protein’s function and can therefore be 
applied to targets for which no biochemical assay is available. This is ideal for efficient drug 
discovery against difficult target such as PPIs as described in this thesis. Also, NMR 
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techniques are solution-based methods, therefore are not compromised by crystallisation 
conditions or target immobilisation. The KD detection range is also very large and is in the 
ideal range for fragment-based screening where hits are likely to be around the μM to mM 
range. Also, NMR allows QC of fragments during setup and identification of poorly behaving 
compounds (i.e. aggregators) is straightforward. As described previously, the inclusion of a 
fluorine atom serves multiple purposes in drug discovery projects. The use of fluorine as a 
detection tool for ligand-observed NMR screening is rapidly gaining momentum for fast, 
efficient drug discovery. The aims of this thesis are to discover new, novel ligands for difficult, 
underexplored protein targets by 19F NMR-based screening and strategic design of peptide 






Peptides and Peptidomimetics 
This chapter contains the results of work performed on OBOC synthesis of peptide libraries 
and SPPS of fluorinated peptides for screening purposes. A short introduction covers the 
background to the experimental approach and also information on the protein targets for 
screening. The results and discussion section is split into two parts: 1) peptide tools for ATAD2 






2.1.1. Towards the use of Peptides as Screening Agents  
Over the last two decades, high throughput screening of large libraries of compounds against 
the most validated targets has been the method of choice for efficient drug discovery. One 
important aspect for success in the early drug discovery process relies on screening the right 
classes of chemical compounds for a specific target. Highly diverse small molecular libraries 
are extremely costly and logistically difficult to handle.49 While libraries of up to 5 million 
compounds (e.g. Pfizer) were successfully screened against enzymes and GPCRs, the success 
of finding chemical starting points for PPIs was very limited.50 Besides of the fragment 
screening approach covered in chapter 3 and 5 of this thesis, the second most successful and 
still promising chemical reagent class are peptides and peptidomimetics. To discover a novel 
lead compound, whether it is a small molecule or peptide, has led to considerable effort in 
developing alternative fast and flexible screening methods. Two different approaches for 
finding hit compounds for difficult targets are covered in the sections below; one of them, to 
our knowledge has not been applied before. 
Peptides are a central focus in biological, medicinal and pharmaceutical research; therefore 
methods of synthesis are a major focus in organic chemistry. Solid-phase synthesis of peptide 
chains was first reported by Merrifield in 1963, and for development of this technique he 
received the Nobel Prize in 1984.51 Merrifield’s work revolutionised the field of peptide 
chemistry, facilitating the production of high molecular weight polypeptides in high yield and 
purity thereby eliminating the need for purification. The initial Merryfield technique of 
peptide synthesis was developed further towards generating small peptide libraries of known 
sequences.52 Peptide libraries can be used as targeted and focused, or as a “random” screening 
library. One-bead one-compound (OBOC) library synthesis and screening by various methods 
in solution and on the solid surface, allows  efficient ligand discovery for many targets  and 
many applications, most importantly in drug discovery and molecular imaging.53 
2.1.2. One-Bead One-Compound (OBOC) Libraries 
In 1991, Lam et al developed a peptide screening approach named ‘one-bead one-compound’ 
(OBOC) synthesis.54 In the OBOC approach, compounds are prepared by solid-phase 
synthesis in a “split and mix” technique, resulting in the display of many copies of a 
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compound on one single micro bead (figure 2.1). Modern solid-phase combinatorial 
techniques have achieved efficient synthesis of compounds each containing ~100 pmol of a 
single compound per bead.55 This method can produce tens of thousands to millions of 
compounds within a single library at relatively low cost and short timescales.53  
 
Figure 2.1: Diagram illustrating the split and mix synthesis concept to generate a one-bead 
one-compound library (grey circles are micro beads). Here, 3 building blocks (blue, green and 
orange circles) are used to generate a didipeptide library which gives 32 = 9 compounds.56 
Post synthesis, there are two approaches to screening the libraries: solution-based or directly 
on-bead. The solution-based approach is most aptly demonstrated by Schreiber et al who 
demonstrated their ‘one-bead, one-stock solution’ technology platform.57 This approach 
involved synthesis of small molecules on macrobeads which delivered stock solutions of 
compound after cleavage and resuspension in assay well plates.58 These can then be screened 
in phenotypic microarray assays. The drawbacks associated with the solution based approach 
post-synthesis are difficulties with compound identification, small quantities of compounds, 
low purity of pooled compounds and the requirement for re-synthesis of hit compounds.59 
In the on-bead screening (OBS) approach, immobilised ligands are screened directly at the site 
of synthesis, this provides a number of advantages. For example, there is no need to purify 
compounds prior to screening, only hits need to be resynthesized and characterised. Also, 
identification of low affinity ligands, up to millimolar dissociation constants (KD) can be 






cells, and interacting compounds can be identified by appropriate reporter systems, such as 
fluorescence or colourimetric enzymatic assays.61 The primary method for on-bead screening 
in many academic groups, involves the use of a bead sorter (Union Biometrica, COPAS) and 
standard fluorescent microscope equipment. Hits are identified using a fluorescent target 
molecule and generally fluorescence imaging detects the signal over the entire bead volume. 
This introduces an issue with background fluorescence from the bead matrix and can lead to 
‘picking’ of false positive beads.62,63Another drawback is that calculated KD values from OBS 
were generally not reproducible in solution, and that unspecific binding was generally a 
concern. 
2.1.3. The CTB On-Bead Screening Platform 
The Auer lab (CTB) has extensive experience in on-bead screening methods for identifying 
new ligands from diverse one-bead one-compound (OBOC) chemical combinatorial 
libraries.62,55,65–67 To address the issues of the COPAS detection method with bead 
autofluorescence, the establishment of confocal nanoscanning (CONA) provided the 
technology to focus on the outer circumference of microbeads where most of the binding 
events occur, as proteins are generally too large to diffuse into the matrix. This approach 
allows one to differentiate between real binding events and bead autofluorescence, hence 
minimising false positives. Also, the libraries are generally synthesised on TentaGel™ resin, 
made of a crosslinked polystyrene matrix onto which poly-ethylene glycol (PEG) is attached. 
The PEG groups are functionalised with an amine group for initiating peptide synthesis using 
solid-phase peptide synthesis (SPPS). High quality amino acid building blocks are widely 
available and many modified derivative and non-natural amino acids are also commercially 
available. TentaGel™ resin also exhibits minimal autofluorescence and increased mechanical 
stability, opposed to polystyrene-based resins, therefore is a big advantage. The beads, 
exhibiting the library compounds, are incubated with a fluorescently labelled target protein. 
Screening is then performed using a scanning confocal microscope for the detection of the 
bound protein via its fluorescence. The imaged obtained is a cross section of the beads in 
which binding events can be detected as halos or “rings” around the beads. Beads are picked 
using a highly automated bead picking instrument, PickoScreen-02 (PS02), developed in 
collaboration with Perkin Elmer, Germany. For hit compound deconvolution and KD 
determination, a method for fluorescently labelling the active compound was devised, this 
was named post synthesis/post screening labelling (PS/PS). A small tagging group, is 
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incorporated into the structure of the screening compounds for attaching a dye following 
screening, this reduces the risk of non-specific interactions and provides a means for KD 
determination using techniques such as fluorescence correlation spectroscopy (FCS). The 
tagging group commonly used in the Auer group is a terminal alkyne containing amino acid 
(propargyl glycine) which can be labelled using the copper catalysed Huisgen 1,3-dipolar 
addition ‘click’ reaction between an alkyne and an azide functionalised dye before cleavage. 
The Pra residue is stable to the chemical conditions of peptide synthesis so is useful for 
biorthogonal chemistry. Azide functionalised tetramethylrhodamine (TMR) is the frequently 
employed dye used due to its excellent fluorescence properties and stability to peptide 
cleavage conditions (see figure 2.3). 
 
Figure 2.2: Scheme of click chemistry for single bead labelling. A terminal alkyne bearing 
amino acid (Pra) is incorporated into the library construct. After hit bead detection, copper 
catalysed cycloaddition allows labelling using an N3 functionalised dye, for example tetra-
methylrhodamine azide (TMR(N3)). 
The use of a cleavable linker is required for on bead screening for deconvolution of hit 
compounds after screening, the linker used in this project is a modified version of SCAL 
(Safety Catch Acid Labile) linker.68 Primarily, the linker is required to allow for orthogonal 
side chain deprotection, for screening, and subsequent peptide cleavage, this is illustrated in 
figure 2.3. Also, a space group is attached to increase the distance between the library 
compound and the label, minimising the effect of the label on the binding affinity. Finally, the 
peptide is built up by stepwise addition of Fmoc-protected amino acids, a schematic of the 




Figure 2.3: Top: Schematic of SCAL2 linker. The peptide is synthesised by standard SPPS 
methods using protected amino acids. The protection groups can then be cleaved by treatment 
with TFA, leaving the native peptide still attached to the bead and therefore available for 
screening. Reduction of the sulfoxide groups by treatment with TMSBr allows the native 
peptide to be released from the resin for solution binding studies. Bottom: Diagram of the 
components for solid-phase synthesis of peptide libraries. TentaGel™ beads (black circle), 
SCAL linker (blue), Pra (propargyl glycine, labelling site, red), Spacer (green), example of 
trimpeptide library building blocks (magenta, R1, R2, R3 are random amino acid side chains). 
Post screening, hit compounds are cleaved and usually deconvoluted by mass spectrometry 
for identification. This highly automatable and high throughput screening platform has been 
proven to work reliably in the synthesis of > 60 small molecule and peptidomimetic libraries 
for many PPI targets including: Mdm2, HuR, Importin-beta, LFA-1 and SAP, to name a 
few.65,67,69 
2.1.4. The Tripeptide Concept 
A popular metric used in drug discovery to narrow the search for lead compounds is ligand 
efficiency (LE). This is defined as the binding free energy of a ligand divided by its molecular 
size (i.e. number of heavy atoms (HA)).70 It is frequently presumed that there is a level of 
additivity between different functional groups of a given ligand. This assumes that the overall 
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affinity of a ligand is a linear combination of the affinities of the constituent pieces.71,72 
However, Reynolds et al re-examined the extensive amount of literature on protein-ligand 
binding affinities and show that up to a certain limit of heavy atoms (or molecular size) the 
maximal affinity is linear and then plateaus (this is illustrated in figure 2.4). The overall trend 
is that for a given number of HAs the change in affinity is not linear with size and is observed 
across a wide range of protein-ligand interactions. 
In theory, an OBOC peptide library can contain peptides of any length, however, synthesis 
beyond ~ 20 amino acids tends to generate problems. The concept behind the use of tripeptides 
for screening is that the smallest information for specific recognition events between amino 
acids in endogenous peptidic ligands and their native receptors are three amino acids. It has 
been shown repeatedly that tripeptides have important signalling roles in biology and are 
capable of various functions.73,74 For example, Rajasekhar et al have developed a 
multifunctional peptidomimetic inhibitor of amyloid beta (Aβ) aggregates, a hallmark of 
Alzheimer’s disease. This was based on conjugation of a natural, metal chelating tripeptide 
(GHK) and a peptidomimetic analogue of the core recognition unit (Sr-V-Sr-F-Sr, Sr: sarcosine) 
of Aβ fibrils.75 The modified peptide interacts with Aβ monomers and prevents formation of 
toxic Aβ oligomeric and fibrillar aggregates. This parallel peptide/peptidomimetic approach 
excellently demonstrates the use of natural peptides and peptidomimetic tripeptides as 
potential therapeutic agents. Also, one can apply the tripeptide concept to the ligand efficiency 
metric described by Reynolds. Figure 2.4 shows the average number of HAs in a single amino 
acid, a dipeptide and a tripeptide as red, yellow and green lines respectively. This shows that 
a tripeptide should theoretically be at the maximal affinity obtainable for ligand efficiency. 
Identification of a tripeptide or peptidomimetic would allow development of a tool 




Figure 2.4: The ‘maximum affinities’ of compounds (as measured by IC50) increases rapidly 
up to 20 heavy atoms (HA; non-hydrogen atoms), but plateaus beyond 25. For reference, the 
average number of heavy atoms in a single amino acid, dipeptide and tripeptide are shown as 
red, yellow and green lines respectively. Figure adapted from Reynolds et al.76 
2.1.5. Fluorinated Peptides and NMR Screening 
On-bead screening and solution-based screening can be very efficient, however, for short 
peptides which might further be converted into drug like molecules by medicinal chemistry, 
for example, tripeptides with the highest ligand binding efficiencies, a method is required 
which works with lower affinity to allow for higher μM KDs.  
NMR spectroscopy is a well-established, solution-based method for detecting ligand binding, 
however, literature is relatively scarce on the screening of peptide libraries. As described 
earlier (Chapter 1.4), NMR-based screening approaches are generally divided into two 
categories: ligand-observed and protein-observed. NMR screening of peptide libraries has 
generally been reserved to protein-observed methods owing to higher sensitivity at weaker 
affinities.77 However, the disadvantage is that hit compound deconvolution is difficult as the 
ligands are not observed, therefore compounds need to be individually retested. Ligand-
observed screening therefore offers a host of advantages. SPPS allows the incorporation of 
non-natural amino acids and using a fluorinated amino acid derivative in a peptide library 
alleviates the issue of compound deconvolution. This is because the 19F nucleus is highly 
sensitive and peptides constructed using a fluorinated amino acid will show a unique fluorine 
resonance. This is in contrast to 1H observed methods where, again, hit compound 
deconvolution is difficult due to spectral overlap of proton ligand resonances. Fluorine NMR 
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screening is described in detail in chapter 1. An example of the broad applicability of 
fluorinated peptides comes from Howard and co-workers who describe a combined approach 
of ligand-observe 19F and protein-observe 15N-HSQC NMR to study peptide binding to the 
human protein disulfide isomerase (hPDI). The peptide-ligand is a 14 mer (H2N-
AGSKNFFWKTFTSS-OH) that binds to hPDI with KD ~ 100 μM and stepwise mutations to the 
phenylalanine residues increased the KD until all binding was abolished. They also highlight 
the advantage that 19F offers a more accurate measure of KD due to higher spectrum 
resolution.78 
The generation of peptide libraries is generally limited by the stipulation for chemical or 
biological tags to allow easy identification. Similarly biological approaches to peptide library 
synthesis, for example, phage display rely on multiple rounds of biopanning and sequencing 
to identify the highest affinity peptides.79,80 Therefore, the use of 19F as a sensor for ligand 
binding detection in a library of fluorinated peptides would be a simple approach for low 
affinity binding detection and simple hit deconvolution. 
2.1.6. Target Selection and Motivation 
As described earlier (Chapter 1.2), target selection and validation is the first stage of the drug 
discovery pipeline. Moreover, the majority of the ~ 25,000 human genes have not been fully 
characterised for their implication in disease.81 The common definition of a validated drug 
target is that up- or down regulation and/or knockout models in vivo produces a disease 
relevant phenotype. However, generating a knockout model is time-consuming and 
upregulation is not always straightforward, this is biological target validation. Another 
method to identify a potential target, is to develop a known, low molecular weight ligand to 
use as a tool compound for studying molecular effects and concentration dependent 
modulation of inhibition. This is chemical validation and addresses the specific ligand binding 
sites and, hence, potential for inhibition. The target focus of this thesis are PPIs and discovery 
of inhibitors/modulators of these interactions for studying their therapeutic benefit. The 
following sections introduce two important target proteins used in this project. 
2.1.7. ATPase AAA Domain Containing 2 (ATAD2) 
The epigenome is a functional record of chemical modifications to the DNA and histone 
proteins that moderate gene regulation. Currently, there are over 16 major histone chemical 
modifications that determine the transcriptional status of a cell, including: methylation, 
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acetylation, phosphorylation and ubiquitination.82 Epigenetic regulators are the main proteins 
involved in histone remodelling/modifying and are involved in a myriad of PPIs governing 
cellular dynamics. Histone acetylation is one of the most studied histone modifications that 
implicates an open chromatin structure and hence involved in moderating DNA transcription. 
The acetylation of lysine residues within the N-terminal domain of histone tails is found across 
the entire epigenome. There are three main families of proteins dictating the levels of 
acetylation on histone tails, these are: histone acetyl transferases (HATs), histone deacetylases 
(HDACs) and bromodomains (BRDs). HATs catalyse the transfer of an acetyl group to the ε-
amino group of lysine side chain residues in the N-terminal chain of histone tails, whereas 
HDACs’ function is to remove it. BRDs are the primary protein modules that recognise the 
acetylated epigenetic mark.83 
BRDs are a family of evolutionarily conserved protein interaction modules and the human 
proteome encodes 61 BRDs present in 46 diverse nuclear and cytoplasmic proteins. Despite 
the surprisingly large sequence variations, BRDs share a conserved tertiary structure that 
comprises of 4 α-helices (αZ, αA, αB and αC) linked by diverse loop regions of variable length 
and charge. The acetyl lysine binding site is situated at one end of the helical bundle in a 
centrally located hydrophobic pocket (see figure 2.5).84 The acetyl lysine is recognised by a 
conserved asparagine residue mediated by hydrogen bonds from conserved water molecules. 
It has been shown that some BRD modules (i.e. BET subclass of proteins) simultaneously 
recognise two acetylated lysine histone marks on the same histone tail.  
 
Figure 2.5: Structure of the BRD of ATAD2 in complex with capped acetyllysine (PDB ID: 








by two diverse loop regions (ZA and BC). The acetyllysine binding site is located between the 
ZA and BC loops. 85 
ATAD2 (ATPase family AAA Domain containing 2), also called ANCCA (AAA Nuclear Co-
regulator Cancer Associated), is a transcriptional regulator that carries two AAA (ATPases 
Associated with diverse cellular Activites) domains and a single BRD. The overexpression of 
human ATAD2 has been associated with many cancer types and Zou et al have shown that 
ATAD2 is strongly induced by estrogen in human breast cancer and is required for estrogen 
induced cell proliferation.86 Several other reviews of this interesting protein have exposed its 
role as a genetic marker for poor prognosis of cancer suffering patients.87–91  
Due to the growing significance of transcriptional dysregulation in disease, BRDs have 
emerged as a potential target for pharmacological intervention. Knapp et al. have recently 
reported highly potent small molecule inhibitors of the BET (Bromodomain and Extra-
Terminal containing) family of proteins largely due to the hydrophobic nature of the acetyl 
lysine binding pocket.92 Current drug discovery efforts are focused largely on the BET family 
of bromodomain containing proteins, with a large volume of literature originating in this 
family of proteins.93–95 The proven druggability of bromodomains, together with their central 
role in tumorigenesis and disease, suggests an appealing target for drug intervention.96  
2.1.8. Ubiquitin Conjugating Enzyme L3 (UbE2L3) 
The ubiquitin proteasome system (UPS) is the principal network for protein catabolism which 
is central to the regulation of almost all cellular processes. Ubiquitination is a proprietary 
mechanism of the UPS through which transfer of a ubiquitin molecule to a substrate protein 
occurs via thioester transfer by way of an E1-E2-E3 enzymatic cascade (figure 2.6). The 
resultant mono- or poly-ubiquitinated substrate is then typically targeted for degradation by 
the 26S proteasome, although ubiquitination also plays a role in other cellular processes such 
as: cell signalling and regulation of DNA transcription.97,98 The prime interactor in this 
enzymatic cascade is the E2 conjugating enzyme which performs a variety of functional roles. 
The E2 is first charged with ubiquitin on its active site cysteine via an E1-catalysed ATP-
dependent thioesterification. The E2 is then responsible for a subsequent transfer of ubiquitin 
to nucleophilic reactive residues on substrate proteins via: transthiolation (transfer to Cys), 
esterification (transfer to Ser/Thr), amide formation (transfer to N-terminus) and isopeptide 
formation (transfer to Lys residues). The final step to substrate ubiquitination often occurs 




Figure 2.6: Scheme illustrating a typical ubiquitination reaction. The activation of ubiquitin 
occurs via an ATP dependent thioesterification transfer to an E1 enzyme. A transthiolation 
reaction transfers the ubiquitin to an E2 enzyme. There are then two mechanisms by which 
substrate ubiquitination can occur: 1) ubiquitin transfer occurs directly from E2 to substrate 
via a PPI mediated by an E3 enzyme or 2) ubiquitin is transferred via another transthiolation 
to the E3 which then directly ubiquitinates the substrate.99 
Due to the importance of UPS in regulating cellular processes, defects in this system can result 
in pathogenesis of several important human diseases, including: autoimmune diseases and 
Parkinson’s. Table 2.1 describes an overview of E2 implications in disease. 
Name and synonyms Cellular processes Disease association 
UbE2C;UbcH10 Cell cycle Cancer100 
UbE2D4; UbcH5d Apoptosis101  
UbE2E2  Diabetes, lung cancer102 
UbE2K;HIP2;UBC1; E2-25K Apoptosis, proliferation 
Parkinson’s, Alzheimer’s and 
Huntington’s diseases, 
cervical cancer103–106 
UbE2L3/UbcH7 Cell cycle 
Autoimmune diseases, 
Parkinson’s disease107,108 
UbE2L6/UbcH8 Immune response 
Cancer, obesity, Parkinson’s 
disease, viral infection109–111 
UbE2Q2 Cell cycle, apoptosis Cancer, renal pathologies112,113 
Table 2.1: A variety of E2 enzymes and their cellular processes with their implication in 
diseases. Adapted from Koszela.114 
Specifically, UbE2L3 is one of the 38 E2 enzymes encoded by the human genome. Several 
genome-wide association studies (GWAS) have identified various polymorphisms in the 
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genomic locus of UbE2L3 associated with autoimmune and neurodegenerative diseases.107 A 
revolutionary discovery identified it as one of the few E2s that only exhibits transfer activity 
towards cysteine residues on E3 ligases.115 Recognising its implication in disease lends itself 
as a potential target for drug intervention, and as of 2018 there are no known specific inhibitors 
of this particular E2. The multifunctional role of the E2 proteins in PPIs with E1, E3 and 
ubiquitin provide multiple opportunities for modification of E2 activity. That is, modification 
of activity can be addressed by targeting the E1 binding site or E3 binding sites, in addition to 
the conventional inhibition of the E2 catalytic site.  Also, allosteric moderators of this E2 
enzyme may interfere with the PPIs governing interactions with both E1 and E3 enzymes, for 
example the small molecule inhibitor CC0651 for UbE2R1.116An example of an E3 ligase 
associated with UbE2L3 activity is Parkin, of which mutations are associated with 
mitochondrial dysfunction leading to neuronal damage in Parkinson’s disease.108,117 Hence, 
direct binding site inhibition of this E2 will prevent the ubiquitination cascade and prevent 
premature neuronal cell death. 
2.1.9. Aims 
The aim of this part of the thesis work was to explore new concepts of how short peptides and 
peptidomimetics (mainly di- and tripeptides) could be screened against PPI targets. There are 
two approaches presented here for the use of peptides as screening agents.   
I. The first utilises the OBOC approach to synthesise a bromodomain-focussed 
tripeptide library that can be used for screening ATAD2. This BRD has a large, open 
hydrophobic binding pocket and it is hypothesised that using a non-natural lysine 
derivative at the central position of each tripeptide in the library will uncover a unique 
binding partner. Also, it was necessary to produce a positive control peptide for 
binding evaluation. Therefore, an additional aim was to synthesise a known peptide 
pentapeptide mimic of the histone H4 tail and evaluate it as a tool compound for 
binding against ATAD2 using various NMR methods.  
II. The second approach introduces an ‘on-protein peptide growing’ (OPPG) method by 
using fluorinated amino acids as chemical probes for binding detection. The 
hypothesis was that using a fluorinated amino acid in an initial dipeptide library 
would provide a sensitive probe to detect weak affinity dipeptides by 19F NMR. Hit 
dipeptides could then be extended, either C- or N-terminally with natural or non-
coding amino acids, to increase the binding affinity to the target protein. This idea is 
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outlined in figure 2.7. It was envisaged to perform a proof of concept study to 
determine the feasibility of the approach. For this we applied a known tetrapeptide 
peptidomimetic, which had been developed in the Auer lab, towards the inhibitor of 
apoptosis (IAP) related protein, survivin.118 The final, ratified OPPG approach was 
applied to the UbE2L3 protein target. 
 
Figure 2.7: Schematic of the ‘on-protein peptide growing’ approach using a fluorinated amino 
acid as a probe molecule for binding detection. The initial dipeptide library is screened by 19F 
NMR and hits can be deconvoluted based on changes in 19F resonance signals. A hit dipeptide 
can be extended to a tripeptide by amino acid addition at both the ‘N’ or ‘C’ terminus and 
binding measured again by 19F NMR.  R1 and R2 indicate randomised natural amino acid 
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2.2. Results and Discussion 
2.2.1. Peptide Tools for Studying ATAD2 
The Structural Genomics Consortium (SGC) is a public-private partnership with the core 
directive to determine 3D structures of human proteins of clinical importance to accelerate the 
drug discovery process. In collaboration the Knapp lab, at the SGC University of Oxford, 
supplied structural data for the ATAD2 BRD protein in complex with a pentapeptide, herein 
named H4K5. H4K5 is a peptide mimic of histone H4, with an acetylated (Ac) lysine residue 
at position K5 (figure 2.8).119 
1. H2N-MSGRGKGGKGLGKGGAKRHR…… 
2. H2N-MSGRGKGGKGLGKGGAKRHR…… 
Figure 2.8: The N-terminal sequence of histone-H4 (shown NC). 1. The highlighted region 
is the pentapeptide that was used for crystal soaking at the SGC. The protein sequence starts 
at M0, and the pentapeptide is R3 – G7. The lysine at position 5 was acetylated for the soaking 
experiments. 2. The highlighted region here is peptide H4 (figure 2.13), sequence from R3 – 
G13. 
Examining the structure of the H4K5 peptide in complex with ATAD2 (figure 2.9), it can be 
seen that the C-terminus is extended into space and does not appear to contribute any 
significant binding contacts. It was therefore hypothesised that addition of a fluorinated 
amino acid probe at the C-terminus separated by a small spacer would not hinder the binding 
effect and provide a useful probe for binding detection of by 19F NMR.  
 
Figure 2.9: Structure of the ATAD2 binding site in complex with peptide H4K5(Ac) (green) 











2.2.2. ATAD2 expression, purification and 15N labelling 
ATAD2 was successfully expressed in E. coli (expression strain Rosetta (DE3) pLysS) using 
traditional bacterial shake flask expression methods. The protein was purified by gravity flow 
using immobilized metal ion affinity chromatography on Ni-NTA agarose resin. The yield 
from a 1L bacterial cell culture was excellent: 19 mg.L-1 of culture and purity was measured at 
> 95% by analytical HPLC and SDS-PAGE. For 15N-HSQC NMR experiments, isotopic 
labelling with 15N was required. This was achieved by traditional bacterial shake flask 
expression in minimal media and 15N ammonium sulfate ((15NH4)2SO4) as the sole nitrogen 
source. Again, the protein was purified by gravity flow using immobilized metal ion affinity 
chromatography on Ni-NTA agarose resin. The yield from a 1L bacterial cell culture was good: 
4 mg.L-1 of culture and purity was measured at > 95% by analytical HPLC and SDS-PAGE 
(figure 2.10, see chapter 7.2.1 for full materials and methods and analysis). 
  
Figure 2.10: HPLC chromatogram of, left: ATAD2, tR 15.6 mins. Right: 15N-ATAD2 tR 14.0 mins. 
(N.B. gradient methods were different, hence different retention times, see Chapter 7 for 
details). 
2.2.3. Synthesis of Fmoc-acetyl lysine 
The acetylated lysine is the central amino acid for the H4K5 peptide. Fmoc protected acetyl 
lysine can be synthesised in the lab using available reagents (see figure 2.11). The materials 
and methods for synthesis of Fmoc-N-acetyl-lysine-OH are given in chapter 7. The final 
compound was analysed by HPLC and showed a purity > 95% and LCMS shows the correct 
ion peak: [M+H]+calc = 411.2, [M+H]+obs = 411.1. 1H and 13C NMR spectra were also acquired to 
determine correct structure. Figure 2.11 shows the HPLC chromatogram of the final 






















































Figure 2.11: Top: Scheme for synthesis of Fmoc acetyl lysine. The Boc protected ε-amino of 
Fmoc-Lysine(boc)-OH (2.1) is first deprotected to Fmoc-Lysine-OH (2.2). Then acetylated 
using acetic anhydride to generate Fmoc-N-acetyl-L-Lysine-OH (2.3). Bottom: HPLC 
chromatogram of Nα-Fmoc-Nε-acetyl-L-Lysine-OH. tR = 15.9 mins; purity > 95 % as measured 
by peak area. 
2.2.4. ATAD2 peptide synthesis and binding detection by 19F NMR 
The peptides synthesised for use in this section are illustrated in figures 2.12 and 2.13. All 
peptides were synthesised by Fmoc SPPS and identified by LCMS and purity measured by 































Figure 2.12: Top: chemical structure of peptide H4K5. Bottom: HPLC chromatogram and 
mass spectrum of peptide H4K5. HPLC: tR = 15.6 mins. Absorbance is measured at 254 nm, 
and purity is > 95% (as measured by peak area). LCMS mass spectrum of peptide H4K5 
(PRA-β(mCF3)F-DOA-G-G-Kac-G-R). [M+H]+calc 985.4; [M+H]+obs 985.6.  
 
  
Figure 2.13:  Top: chemical structure of peptide H4. Bottom: HPLC chromatogram and mass 
spectrum of peptide H4. HPLC H4. tR = 11.7 mins. Absorbance is measured at 210 nm, and 
purity is > 90% (as measured by peak area). LCMS mass spectrum of peptide H4: C59H102N20O18 












































































































Figure 2.14: A superposition of 19F NMR spectra of fluorinated peptide H4K5 (1.3 mM) in the 
absence (red) and presence (blue) of 200 μM ATAD2 (1:6.5 protein:ligand molar ratio). Top: 
full spectrum. Middle: expanded region of the peak at -75.3 ppm corresponding to TFA. 
Bottom: expanded region of the peak at -62 ppm corresponding to the fluorinated peptide. On 
the addition of protein there is no visible change in the chemical shift or line width of the 
fluorine resonance, indicating no binding between the ligand and protein. Spectra are 
analysed using MestReNova v10.0.2-15465 (see Chapter 7 for experimental details). 
The fluorinated peptide H4K5 was used in a 19F NMR binding assay against the ATAD2 
bromodomain. A 1D 19F NMR spectrum of the peptide was recorded in the presence and 
absence of protein (figure 2.14). The spectra are then easily analysed by superposition to 
identify spectral changes in the fluorine resonance. From figure 2.14, it can be seen that there 
is no distinct change in the fluorine resonance on addition of protein (blue spectrum). Peptide 
cleavage conditions require the use of TFA to remove peptides from the resin. The peptides 
are then precipitated in diethyl ether leaving the final peptide as a TFA salt. The TFA can 
therefore be seen in the 19F NMR spectrum as a single peak at -75 ppm. This is commonly used 
as a reference peak, as TFA is a small organic molecule, it is unlikely to bind to the protein, 
and therefore any changes in chemical shift from the peptide can be referenced to the TFA 
peak. Using 19F resonance as a sensor to detect binding is useful as there are no peaks from 
endogenous fluorine present in the buffer or from the protein, therefore, spectra are easily 
interpreted. However, there was no indication of the peptide binding to the protein in 
solution. This could be due to the addition of the spacer and/or fluorinated amino acid that 
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are sterically hindering the binding of the peptide. It could also just indicate that the fluorine 
nucleus is too far away in space to have a direct interaction with the protein. Although 
extremely sensitive to environmental changes, the fluorine nucleus may simply be only 
surrounded by solvent molecules and not directly interacting with the protein. 
2.2.5. 15N Labelling and Binding Studies of H4 Peptide Mimic to ATAD2 
The premise behind 15N isotopic labelling was to provide a higher sensitive method for 
binding detection of the native ligand. It was also hypothesised that a longer synthetic peptide 
mimicking the H4 histone tail would provide a higher binding affinity and, hence, a better 
chance of observing binding (structure of this peptide is given in figure 2.13). The peptide was 
also tri-acetylated according to information gleaned from the collaboration at the SGC. From 
herein this peptide is referred to as H4. This was aimed at developing a tool compound to 
study effects of inhibition, and provide a ligand for competition binding experiments. 
The 15N labelled ATAD2 bromodomain was initially analysed by 15N-HSQC NMR to 
determine the degree of labelling and the extent of folding. The 15N-HSQC experiment 
provides a fingerprint of the backbone and side-chain amides of the protein and a correctly 
folded protein will show good peak dispersion of amide resonances. However, the HSQC 
spectrum of the protein does not show many resonances in the amide region and we would 
expect the number of resonances to equal the number of amide groups in the backbone. For 
the ATAD2 protein there are 145 amino acids (excluding prolines) therefore one would expect 
roughly 145 peaks in the spectrum. However, there are approximately only 60 distinct 
resonances in the amide region of the HSQC spectrum. This could indicate a misfolded protein 
or aggregation in solution. The protein itself required a high amount of salt (NaCl - 500 mM) 
in the buffer to solubilise it. The drawback with high salt concentrations is two-fold: 1) high 
salt concentrations can lead to protein aggregation in solution and 2) a high ionic strength 
buffer lessens the benefit of the CryoProbe™ and, hence makes it less sensitive. This could 
indicate the low signal intensities and number of amide resonances. A solution would be to 
increase the number of increments and number of scans per increment of the experiment to 
increase the resolution and signal to noise ratio respectively. Additionally, however, high salt 
concentrations are sometimes beneficial because this can indicate that binding is not driven 
by general nonspecific ionic interactions. Another problem encountered was that was difficult 




The acetylated 11mer, H4 was used in a titration experiment with 15N labelled ATAD2 BRD. 
A superposition of titration points is shown in figure 2.15. On addition of peptide H4, there 
are no perturbations to the backbone amide resonances in the spectrum. The titration molar 
ratios ranged from 1:1 to 1:16. Even at the highest concentration of ligand there are no changes 
in the backbone amide resonances, figure 2.16 shows a superposition of the first and last 
titration points for clarity. What is evident is that some signals disappear on the addition of 
H4, however, this could be due to a reduction in protein concentration during the titration as 
the final protein concentration is reduced by approximately 10%. However, signal 
disappearance is more likely due to unfolding of the protein as it appeared to be particularly 
unstable after being left at room temperature. 
 
Figure 2.15: 15N HSQC titration of 15N-ATAD2 with peptide H4. From light to dark: 0, 50, 100, 
200, 400, 1000 μM peptide and the protein concentration was 60 μM. The 15N-HSQC 
experiments were performed on a Bruker Avance 800 MHz spectrometer in the School of 
Chemistry, University of Edinburgh. Each resonance signal corresponds to a backbone amide 
proton of the protein. However, some peaks are very weak and the resonance dispersion is 































Figure 2.16: 15N-HSQC titration of 15N ATAD2 with peptide H4. This diagram shows a 
superposition of the first and last titration points of peptide H4 and ATAD2 BRD. The red 
spectrum is protein only, and the blue spectrum is the final peptide concentration of 1 mM 



























Figure 2.17: 15N-HSQC titration of 15N-ATAD2 with peptide H4. A superposition of the first 
and last titration points of peptide H4 and ATAD2 BRD. The red spectrum is the protein 
without peptide, and the blue spectrum is the protein with a final peptide concentration of 1 
mM. The protein concentration is 60 μM (1:17 protein:ligand molar ratio). The green spectrum 
overlay also shows the 15N natural abundance spectrum of the free peptide. 
There are also some signals in the spectra that can be attributed to the natural abundance of 
15N in the H4 11mer peptide (figure 2.17). In summary, there is no evidence of ligand binding 
by 15N-HSQC experiments with the native H4 peptide to the bromodomain of ATAD2. 
2.2.6. OBOC Peptide Library Synthesis 
In parallel to peptide tool compound development, a ‘One Bead One Compound’ tripeptide 
library was synthesized for on-bead screening against ATAD2 in search of a novel tripeptide 
ligand. The hypothesis is that ATAD2 has a very large, open, hydrophobic binding pocket. 

























covalent binding interactions, for example, electrostatic interactions, hydrogen bonding and 
van der Waals (enthalpy driven binding). Furthermore, common to BRDs, is a conserved 
water molecule in the binding site that forms a water bridge between the acetyllysine and an 
arginine residue. Therefore, displacement of this conserved water molecule in the binding 
pocket would also contribute to increased binding affinity (entropy driven binding). The 
library consisted of 3072 unique compounds synthesized by the ‘split and mix’ method (see 
chapter 7.2.9 for full materials and methods). There are three points of diversity R1, R2, R3 
with 16 L-amino acids in position R1, 12 Lysine derivative amino acids in position R2 (lysine 
derivative structures are given in appendix 8.1.9) and 16 L-amino acids in position R3. This 
leads to 16 x 12 x 16 = 3072 compounds in 16 sub-libraries (see figure 2.18). A sub-library is 
defined by, after the final amino acid addition, the beads are not mixed, therefore the final 
amino acid in the sequence is known, and the R1, R2 amino acids are unknown. 
 
Figure 2.18: Schematic of the OBOC bromodomain focussed library. 
Although there are 20 natural L- amino acids available for synthesis, four out of 20 are not 
included in the final library, these are: isoleucine, glycine, cysteine and methionine. The thiol 
containing amino acids cysteine and methionine are not included as these are highly reactive 
and can cause side reactions and cross-linking. Glycine tends to be flexible and does not 
contribute significantly to the binding interactions therefore is not included. And isoleucine 
cannot be distinguished as a hit from leucine by mass spectrometry as they have identical 
masses. 
The first step in peptide synthesis requires the use of a cleavable linker for subsequent removal 
of hit peptides for deconvolution. The linker used for on-bead screening has to have 
orthogonal chemistry for the peptide to remain on-bead yet be capable of removing side chain 
protecting groups. The linker developed in the Auer lab is a modified version of the SCAL 
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(Safety Catch Amide Linker), SCAL2, which allows orthogonal deprotection of side chain 
residues whilst leaving the peptide attached to the resin.68 After SPPS each sub-library must 
be analysed for purity and loading capacity. From each sub-library, a small amount of resin 
(~ 1 mg) was used for quality analysis by fluorescent labelling with tetramethyl rhodamine 
carboxylic acid (6-TAMRA) on the N-terminus. Ten individual beads were then picked from 
each sub-library and cleaved from the resin. The cleavage solution was then analysed by 
HPLC, equipped with a fluorescent detector. Figure 2.19 shows an example HPLC of a single 
bead cleavage solution, the fluorescent trace is recorded at 555 nm and the purity is analysed 
by peak area. 
 
Figure 2.19: HPLC chromatogram of a TMR labelled peptide from a single microbead. The 
fluorescent trace is measured at 555 nm and purity is measured by peak area (75 % purity). 
Figure 2.20 shows a plot of the purity vs the loading capacity of single beads from each sub-
library. The information available from the HPLC is two-fold: 1) purity is assessed by the 
percentage area under the curve and 2) loading capacity is calculated using a standard curve 
of TMR fluorescence (shown in appendix 8.1.8). 
Analysing the purity data, it can be seen that there is an average loading capacity of 17 
pmol/bead and an average purity of 60 %. The loading capacity is significantly low, however, 
a lower compound concentration will inevitably lead to higher affinity peptide binders during 
screening. The purity is considered acceptable for a screening approach and the impurities 
may be due to bromination of the peptides under the cleavage conditions. Trimethylsilyl 




























be inefficient and various side products can occur.120 It is also shown that Trp and Tyr residues 
are the most problematic for bromination side reactions, as can be seen by the lower purity for 
these sublibraries (figure 2.20). However, it is generally accepted for QC analysis and for 
compound deconvolution by mass spectrometry post screening. The final library can also be 
stored on bead at room temperature in a desiccator for further screening. 
 
Figure 2.20: Loading capacity of beads in each of the 16 sub libraries plotted vs the purity of 
the library. Purity is determined by the peak area of the compound by fluorescence detection 
of the TMR dye (λex 555 nm; λam 575 nm) by HPLC. The loading capacity is also determined 
using a standard curve of TMR concentrations (see Chapter 7.2.9 and appendix 8.1.8).  
2.2.7. Fluorescent Labelling of ATAD2 
Maleimide functional groups are often used in the cross-linking of sulfhydryl groups present 
on cysteine side chains. The cross-linking occurs via conjugate addition into the maleimide 
which results in a stable thioether linkage. However, any disulfide bonds in the protein must 
be reduced in order to offer the free thiol for conjugation. Some common, thiol containing 
reducing agents, e.g. dithiothreitol (DTT), cannot be used in the protein buffer as these will 
react with the maleimide functionalised dye. Therefore, a different class of reducing agents 
must be used, such as TCEP (Tris(2-carboxyethyl)phosphine), which was included to prevent 















































for labelling with maleimide functionlised dyes. It was chosen to label these cysteines with a 
cyanine-5 functionalised maleimide, however, attempts to label these sites proved difficult. 
The labelling reaction is performed in excess of dye (molar ratio 1:7) on a 750 μg scale of 
protein and overnight at 4 °C. 
 
Figure 2.21: HPLC chromatogram overlay of fractions from Cy5 labelling purification. Black 
line: fraction 2 from the NAP-5 column. Red line: fraction 6 from the NAP-5 column. The 
protein elutes at ~15 minutes and the free dye elutes at ~10 minutes. The free dye is present in 
fraction 6, therefore this was not used for pooling. The intensity of absorption is measured at 
633 nm. 
After the labelling reaction, the protein is purified on a NAP-5 column and fractions are 
collected by gravity flow in ~50 μl aliquots (see Chapter 7.2.7 for full materials and methods). 
A NAP-5 exclusion chromatography column is prepacked with Sephadex G-25 for 
purification of small molecules from large, globular proteins. The free, small molecule dye is 
retained on the column and the large, labelled protein is separated by gravity flow. The 
fractions were then analysed by HPLC for presence of labelled protein and free dye. Fractions 
containing the labelled protein were pooled and concentration was measured by UV/Vis 
spectroscopy. However, typically, ATAD2 was prone to aggregation in solution, and 
precipitation at low salt concentrations. Although the labelling reaction appeared to be 
successful by HPLC analysis (figure 2.21), there was a significant amount of aggregation of 
the protein as shown by UV/Vis post labelling. This could be seen by stray light corrected 
concentration determination by UV/Vis analysis (see appendix 8.1.2). Absorption of proteins 









































(Tyr) and phenylalanine (Phe).121 It was not possible to determine the total amount of protein 
concentration as there is a large absorbance in the 330 nm range. Absorbance in this region is 
due to light scattering caused by protein aggregation. The calculated pI of ATAD2 protein 
(151 amino acids)  is 5.6 (ExPASY ProtParam), and the labelling reaction is most efficient 
between pH 7.0 – 7.5, so pH is unlikely to be an issue.  
Due to the difficulty in handling the fluorescently labelled ATAD2, it was not possible to 
screen the OBOC library using this method. Another popular labelling method is to use lysine 
residues and an N-hydroxysuccinimide ester (NHS) functionalised dye. However, labelling of 
the protein was most likely corrupted due to protein aggregation in solution therefore this 
would not likely resolve the issue. An alternative to fluorescent labelling, and detection of 
binding after target incubation with the OBOC library, would be to use an antibody specific 
for ATAD2. However, no antibodies exist directly for the bromodomain of ATAD2, therefore 
this approach is not feasible. However, this particular construct contains a hexa-his tag for 
purification, and there are a multitude of fluorescently labelled antibodies available specific 
for his-tag detection. Therefore, this approach would provide a means of detecting hit beads 
after incubation with the target protein. However, this approach is not pursued as part of this 
project. 
2.2.8. Discovery of small molecule ATAD2 bromodomain inhibitors 
Epigenetics is a popular topic and fragments have played a major role in finding lead 
compounds against several targets, particularly in the BET family of BRDs.122 At the start of 
this work there were no known inhibitors or ligands to the particular bromodomain of ATAD2 
reported in patent or academic literature. A paper from Fesik et al at Vanderbilt University, in 
2014 describes the use of SOFAST-HMQC (similar to 15N-HSQC) to screen a huge library of 
13800 compounds as mixtures of 12 (1150 individual experiments).123 This resulted in 65 active 
compounds with KDs ranging from 350 μM to > 2 mM (determined by HSQC titrations), and 
12 had affinities below 1 mM. This is a hit rate of < 0.1 % which is low for a fragment screen, 
although it would be in the normal hit range for a standard HTS. However, several novel 
chemotypes against this bromodomain were identified. This finding opened up the possibility 
that the ATAD2 bromodomain is indeed druggable, and almost simultaneously the SGC also 
published small molecule ligands, albeit with low affinities, for ATAD2.124 This prompted a 
surge of interest and in May 2015, two papers from GlaxoSmithKline offered potent inhibitors 
of ATAD2. The first paper introduced the target-to-lead effort based on the quinolone 
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fragment hit described in the Fesik paper. Using a time-resolved fluorescence resonance 
energy transfer (TR-FRET) labelled peptide displacement assay the GSK group screened 
various analogues of the quinolone fragment against the ATAD2 bromodomain.85 Then, 
through various rounds of medicinal chemistry, GSK optimised the series by synthesis of 
increasingly potent analogues. They also screened the best compounds against the BET family 






 R = Me R = OMe R = H R = Me 
ATAD2 peptide FRET 
pIC50/LE 
5.9(4)/0.31 5.9(4)/0.30 6.9 6.5 
ATAD2 SPR Kd/LE 2.5 μM/0.30 N/A 7.1 μM 6.7 μM 
BRD2  BD1/BD2 pIC50 5.2/4.7 5.4/4.7 4.5/< 4.5 <4.3/< 4.3 
BRD3  BD1/BD2 pIC50 5.1/4.7 5.2/4.7 <4.3/< 4.3 <4.3/< 4.3 
BRD4  BD1/BD2 pIC50 5.6/4.8 5.9/4.8 4.8/5.3 4.1/< 3.3 
BRDT  BD1/BD2 pIC50 5.1/4.5 5.2/4.6 4.5/< 4.3 <4.3/< 4.3 
Table 2.2: Properties of optimised ATAD2 inhibitor compounds. Chemical structures of most 
potent chemical analogue, the initial fragment is shown in blue. This shows the pIC50 values 
(μM) as calculated using the TR-FRET assay and the comparison to other BET family 
bromodomains. Reproduced from Demont and Bamborough respectively et al.85,125 
A follow-up paper built on this work used structure-based optimisation (X-ray 
crystallography) methods to develop this compound further into low nanomolar inhibitors 
with much greater selectivity profiles (2.5, table 2.2,).126 More recently, in 2017, the SGC 
reported on the development of a small molecule inhibitor based on a different chemical 
scaffold to the GSK inhibitors.127 Purporting to their remit this compound was developed 
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purely as a tool compound to study the effects of inhibition of ATAD2, and is available for 
purchase (2.6, figure 2.22). 
 
 
Figure2.22: Chemical structure of BAY-850 (2.6), developed at the SGC in conjunction with 
Bayer AG Pharmaceuticals. 
There are now 37 structures of ATAD2 bromodomain in complex with various ligands 
available in the PDB. The advent of these small molecule inhibitors of the ATAD2 
bromodomain, no observed binding with synthesised peptides and the difficulties 
encountered in handling the protein led to switching the target focus of this thesis to a separate 
class of PPI, the ubiquitin conjugating enzyme, UbE2L3. Targeting the family of ubiquitin 
conjugating enzymes (E2s) is an exciting area of research and, in particular, E2s are a class of 
enzymes the Auer group has experience in working with. 
2.2.9. Conclusions from ATAD2 Project 
In summary, ATAD2 was expressed and purified in good yield and purity both in unlabelled 
and 15N isotopic enrichment labelled form. Two known peptide ligands were synthesised by 
SPPS and used in 19F and 15N-HSQC NMR experiments, however no ligand binding was 
observed by chemical shift perturbation. It is possible the 19F probe nucleus was positioned 
too far away from the binding site and therefore did not interact with the protein, leading to 
failure of detection of binding. Screening by 19F NMR has advantages as lower protein 
concentrations can be used, reducing the propensity for precipitation. Also, the ATAD2 15N 
HSQC spectrum has not been assigned, therefore any residue shifts in the amide region are 
unidentifiable. The 15N signal loss on addition of high concentrations of peptide was also an 
issue, and the high salt concentrations required for protein solubility reduced the benefit of 
the CryoProbe technology. It was also considered difficult to fluorescently label the protein 
due to aggregation during the labelling reaction.  
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The OBOC library was synthesised in reasonable purity and remains available for screening. 
The objective behind the peptide library design was to deliver biologically active compounds 
against ATAD2. There are two main categories of screening libraries: random libraries and 
target focussed libraries. Random libraries are a collection of compounds that have a unique 
structure and no similarity between known biological actives. Targeted libraries, however, 
have a distinct similarity between compounds and known biologically active structures, i.e. 
contain a structural feature recognised by the molecular target, e.g. kinase focussed libraries. 
They may also contain a privileged scaffold, i.e. a structural motif that interacts with a 
molecular target. Consequently, this OBOC library with a central lysine derivative, can be 
thought of as a target focussed library. Essentially, all BRDs bind an acetylated lysine on 
histone tails, and specificity is only differentiated by the ZA and BC loop regions. Therefore, 
this library could be screened against any BRD for discovery of novel ligand scaffolds. 
2.3. On-protein peptide growing (OPPG) 
To continue with the peptide approach to discover novel ligands, a strategy to detect weak 
affinity binders using 19F NMR was devised. This would entail screening a library of 
synthesised dipeptides, each containing a fluorinated amino acid. The fluorinated amino acid 
is used as a sensor molecule to detect weakly binding dipeptides and the most active, i.e. the 
dipeptide indicating the biggest change in the fluorine resonance, is selected from this library. 
It was envisaged that a hit peptide could then be extended into a tripeptide by SPPS to increase 
the affinity (see figure 2.23). A fluorinated tripeptide library can then be screened analogously 
to identify higher affinity ligands, and so forth. To assess the feasibility of this approach and 
the potential for hit dipeptide detection, a known peptide ligand was synthesised. The chosen 
peptide was a modified version of a known tetrapeptide to the cancer-associated, inhibitor of 




Figure 2.23: Schematic of proof-of-concept peptide growing approach. Coloured circles 
indicate amino acids, with single amino acid letters. The initial dipeptide (1) is screened for 
binding activity against survivin. The hypothesis is that extension of the initial dipeptide to 
the tripeptide (2) and finally towards the known tetrapeptide (3) sequence can be monitored 
by changes in the 1D 19F NMR assay. The known tetrapeptide sequence is H2N-hoA-m(CF3)F-
E-R-OH. hoA: homoalanine (blue circle); m(CF3)F: meta-trifluoromethyl phenylalanine (green 
circle); E: glutamic acid (yellow circle); R: arginine (orange circle). 
2.3.1. Proof of Concept 
A collaboration between the Jeyaprakash and Auer groups has identified a non-natural 
tetrapeptide that binds to the cancer associated, inhibitor of apoptosis (IAP) protein survivin. 
The structural analysis of survivin complexed with N-terminus of histone H3, identified 
putative epitopes for other survivin-binding mitotic proteins, such as human Shugoshin 1 
(hSgo1). A peptidomimetic of the N-terminal sequence of hSgo1 (native sequence: Ala-Lys-
Glu-Arg (A-K-E-R)), was shown to bind to survivin with low micromolar affinity (KD ~5 μM, 
PDB ID: 4A0I).128  This was then modified using the proprietary iterative in silico design 
method, MorPH, (Shave-Auer personal communication) and the original sequence modified 
to a non-natural amino acid containing tetrapeptide of the form: homoAlanine-
carbamoylPhenylalanine-Glutamic acid-Arginine (hoA-cF-E-R; shown in figure 2.24). This 
peptidomimetic, hoA-cF-E-R, showed 50% increase in survivin binding affinity, compared to 
19 F 
hoA E 
H 2 N OH 
19 F 
hoA 
OH H 2 N 
Proof - of - concept 
19 F 
hoA E 







the natural peptide, whilst introducing potential proteolytic stability with a half-life in human 
plasma of ~ 20 hours.  
 
 
Figure 2.24: Peptide and crystal structures of survivin ligands and complexes. Panel A: X-ray 
co-crystal structure of peptide 2.8 in complex with survivin. Panel B: predicted binding mode 
model structure of peptide 2.9 in complex with survivin (Modelling performed by Dr Steven 
Shave). Panel C: chemical structure of native peptide (2.7) (AKER). Panel D: chemical structure 
of in silico designed tetrapeptide (2.8) (hoA-cF-E-R). Panel E: chemical structure of fluorinated 
tetrapeptide analogue (2.9) (hoA-m(CF3)F-E-R) proposed to bind to survivin. Single amino 
acid codes: A – alanine; K – lysine; E – glutamic acid; R – arginine; hoA – homoalanine; cF – 
carbamoyl phenylalanine; m(CF3)F – meta-trifluoromethyl phenylalanine. 
The homoalanine variant was proposed to increase affinity by extension of the sidechain into 
a known binding pocket on the surface. This binding pocket is known to be the main 
contributor to the peptide affinity. The carbamoyl-phenylalanine (carb-phe) replacement to 
lysine is a more rigid variant. The original lysine in the peptide contributes no definitive 
interactions with the protein, as shown by X-ray crystal structures (unpublished), therefore 
the more rigid carb-phe was proposed to essentially lay across the surface and create a more 
hydrophobic binding interaction.To utilise this medium-affinity peptide binder and inhibitor 
of survivin for a proof of concept study for the OPPG approach, designed in this thesis, it was 
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that introducing a trifluoromethyl group (CF3) at the meta position of the phenyl ring, as a 
replacement for the primary amide group, in the carbamoyl phenylalanine amino acid would 
maintain affinity whilst providing a sensitive probe for binding detection by 19F NMR. The 
position for including a CF3 probe was based on the crystal structure of the non-natural 
peptide derivative hoA-cF-E-R (provided by Jeyaprakash et al). This shows that the carbamoyl 
moiety is resting across the surface and does not incur any electrostatic interactions (figure 
2.24). The calculated model structure of the fluorinated amino acid replacement is illustrated 
in figure 2.24 (performed by Dr Steven Shave). This work is as yet unpublished, therefore 
confidentiality is required. The tetrapeptide, H2N-hoA-m(CF3)FER-CONH2 (3.2, figure 2.29), 
was synthesised by Fmoc SPPS in good yield and purity (> 95% purity, 11 mg, 85 % yield) (see 
Chapter 7.2.9 for materials and methods). Figure 2.25 shows the HPLC QC data for the 
tetrapeptide. See appendix 8.1.7 for mass spec analysis. The C-terminal, primary amide group 
of peptide 3.2, is a consequence of the cleavage conditions of Fmoc SPPS using the Rink linker. 
Under these conditions, cleavage with TFA yields a C-terminal primary amide group instead 
of a C-terminal carboxylic acid, as would be present in a native peptide. 
 
Figure 2.25: HPLC chromatogram of peptide hoA-m(CF3)F-E-R (3.2). tR = 12.1 mins, purity >  
95 %.  
The binding by 19F NMR was confirmed by spectral analysis of the fluorine resonance in the 
presence and absence of protein (figure 2.26). There are essentially two observable parameters 



























linewidth (coupled to change in intensity). As can be seen in figure 2.26, there is a significant 
line broadening effect observed in the presence of protein (blue spectrum). The line 
broadening is caused by a fast relaxation rate of the fluorine nucleus, which occurs due to slow 
molecular tumbling, this is the case when the ligand is in a bound complex with protein. 
Assuming a similar KD of ~ 10 μM of peptide 3.2, to the native peptide 2.8, would mean that ~ 
9% of the ligand is complexed with survivin under these experimental conditions. The 
sensitivity of 19F NMR to ligand binding events is nicely illustrated by the large line 
broadening effect (figure 2.26). To confirm the binding, and exemplify the sensitivity of 19F 
NMR to ligand binding events, a titration experiment was performed (figure 2.27). From these 
data, it can be appreciated that increasing the protein concentration, hence an increase in the 
fraction of bound ligand, shows an increase in the linewidth of the fluorine resonance (coupled 
with a decrease in intensity). A detailed description of 19F NMR binding kinetics is given in 
chapter 4.1.2.  
 
Figure 2.26: A superposition of 19F NMR spectra of peptide 3.2 acquired in the absence (red 
spectrum) and presence (blue spectrum) of 10 μM survivin. The peptide concentration was 
100 μM. Spectra were acquired on a Bruker Avance III 500 MHz NMR spectrometer equipped 
with Prodigy CryoProbe operating at a spectrometer frequency of 470.7 MHz with a spectral 
width of 236 ppm and number of scans 256. This yielded experiment time on the order of ~9 
minutes. 
The tetrapeptide (3.2) was shown to bind by 19F NMR, therefore it was hypothesised that the 
tri- and dipeptide truncates (see figure 2.29) of the primary sequence might also bind, albeit 




Figure 2.27: Line broadening effect of the fluorine resonance observed on increasing the 
survivin protein concentration. The peptide concentration is kept constant (100 μM) and 
protein is titrated in at: 1) 0 nM, 2) 100 nM, 3) 500 nM, 4) 1000 nM, 5) 5000 nM, 6) 10000 nM. 
The di- and tripeptide truncated sequences of the fluorinated peptide 3.2 were synthesised by 
SPPS in good yield and purity (figure 2.28; see Chapter 7.2.9 and appendix 8.1.7).  
  
H2N-hoA- m(CF3)F-OH (tR 13.5 mins) H2N-hoA- m(CF3)F-E-OH (tR 12 .2 mins) 
Figure 2.28: HPLC chromatograms of peptides 3.0 and 3.1.  
The di- and tripeptide truncates were then screened by 19F NMR against survivin under 




















































Figure 2.29: Chemical structures of the di-, tri- and tetrapeptide peptidomimetics. Sequences, 
dipeptide: H2N-hoA-pfF-CONH2; tripeptide: H2N-hoA-pfF-E-CONH2; tetrapeptide: H2N-
hoA-pfF-E-R-CONH2. Amino acid codes: hoA – homoalanine; pfF – para-fluoro phenylalanine; 
E – glutamic acid; R – arginine.  
The sole 19F resonance for each peptide has a unique chemical shift, and the change in chemical 
shift and linewidth indicates a binding event which is directly proportional to the binding 
affinity. Figure 2.30 shows a superposition of the chemical shift spectra for the di-, tri- and 
tetrapeptides in the presence and absence of protein. It can be seen that the free dipeptide 
(yellow, figure 2.30), shows a small change in chemical shift (Δδ 2.5 Hz) and reduction in 
intensity on addition of protein (green). This confirms the binding of the small dipeptide, 
albeit with low affinity. The free tripeptide (cyan, figure 2.30) shows a larger chemical shift 
change (Δδ 5.4 Hz) however, also a significant line broadening on addition of protein (dark 
blue). This confirms that more of the ligand is bound in the complex indicating a higher 
affinity. The final free tetrapeptide (red) shows extensive line broadening on addition of 
protein (magenta), almost disappearance of the signal which describes the increase in the 
binding affinity. Therefore, C-terminal extension of the initial dipeptide results in increased 





Parameter Dipeptide Tripeptide Tetrapeptide 
Δδ (chemical shift, Hz) 2.5 5.4 3.4 
ΔI0 (% decrease intensity ) 4 % 56 % 81 % 
ΔLW1/2 (peak width at half height, 
Hz) 
0.4 2.967 20.8 
Figure 2.30: Top: overlay of 19F NMR spectra of the fluorinated truncated peptides in the 
presence and absence of protein. The free dipeptide in yellow, and with protein in green. The 
free tripeptide in cyan, and with protein in dark blue. The free tetrapeptide in red, and with 
protein in magenta. Bottom: Table of changes in observable NMR parameters of the 19F 
resonance. The change in chemical shift is the difference between before and after the addition 
of protein. 
The aim of this proof-of-concept (PoC) study was to determine that the binding of a 
fluorinated dipeptide can be observed by 19F NMR and consequently observe increased 
affinity after successive, iterative extension. Based on this successful “reverse PoC study”, it 
was envisaged that screening a library of fluorinated dipeptides would result in a weak 
affinity hit which could be extended to a longer peptide with increased affinity. 
2.3.2. Application of ‘on-protein peptide growing’, OPPG, to UbE2L3 
The next step was to apply the OPPG method to the highly attractive E2 target UbE2L3 (see 
section 2.1.8) by generating a library of fluorinated dipeptides and screening against the 
protein in solution using 19F NMR. This required the synthesis of 16 individual dipeptides of 




from 1 – 16, with the prefix FDL (Fluorine Dipeptide Library), for example, FDL10 (figure 
2.32). 
 
Figure 2.31: Chemical structure of the dipeptide library with a fluorinated phenylalanine and 
all natural L amino acids at position R1. 
The fluorinated amino acid chosen for this library was para-fluoro-phenylalanine (pfF) due to 
wide availability and also, to assist in purification. The phenylalanine allows visualisation of 
the peptide by UV absorption in HPLC analysis and, hence, in determination of purity. Also, 
a single fluorine nucleus in the para-position is not thought to cause significant change in 
structure or electronic effects therefore it is close to the native form of the amino acid 
Additionally, although a single fluorine is less intense than a CF3 group, aryl fluorines (i.e. F 
atom connected to a ring system as in pfF) are more sensitive than aliphatic fluorines (CF3) to 
the change in environment. This gives rise to a larger chemical shift range and, hence, a more 
sensitive detection method. Solid-phase peptide synthesis traditionally constructs a peptide 
from the ‘C’ terminus to the ‘N’ terminus in a linear fashion. Using a solid support, such as 
Tentagel™ resin the 16 dipeptides were synthesised in good yield and purity (see chapter 7.2.9 
for materials and methods). Each peptide was quality checked by orthogonal, biophysical 
methods, including HPLC, LCMS and 19F NMR. The structures and QC data for each peptide 












HPLC: tR = 13.3 mins MS (ESI): [M+H]+calc 330.2; [M+H]+obs 330.0 
 
 
19F NMR (376 MHz, 10 % D2O) δ Hz -43795 Chemical Structure of FDL10 
Figure 2.32: Example quality control data (QC) for FDL10 (H2N-Phe-pfPhe-CONH2). 
2.3.3. UbE2L3 expression and purification 
The protein UbE2L3 was expressed and purified in good yield by traditional shake flash 
bacterial expression methods. The yield of protein was 2 mg.L-1 from 1 L of bacterial culture 
and 95 % purity as measured by HPLC. The protein was also analysed by SDS-PAGE for 
identification by molecular mass. All materials and methods are given in chapter 7.2.3 and QC 





















































Figure 2.33: HPLC chromatogram of UbE2L3. 10 μg was injected onto the column for analysis 
and the observed tR = 12.1 mins and > 95 purity as measured by peak area. 
2.3.4. 19F NMR screening of the fluorinated dipeptide library (FDL) 
The fluorinated dipeptides were pooled based on minimal overlap of 19F resonances. This was 
to minimise the amount of protein needed for the screen. At 10 μM protein concentration 
equates to 5 nmoles required per compound pool (volume 500 μl) which is 100 μg of UbE2L3 
(Mw 19.5 kDa). Figure 2.34 shows an example pool of the fluorinated dipeptides in the presence 
(blue) and absence (red) of protein. Due to the solid-phase cleavage conditions of peptides 
results in production of the compound as a TFA (trifluoroacetic acid) salt. TFA is observed in 
the 1D 19F NMR spectrum (figure 2.34, top left) however, this is useful as it can be used as an 
internal resonance reference shift. That is, in the superposition spectra the TFA peaks are 
overlayed so that any shift in the peptide resonances can be attributed to binding and not to 
minute changes in pH. The lower spectrum in figure 2.34 shows the fluorine resonances 
corresponding to the dipeptides. There are very slight changes in the resonance signal on 
addition of protein which could indicate a binding event. However, there are changes in each 
dipeptide which could also indicate nonspecific interactions of each peptide with the protein. 
Figure 2.35 shows a bar chart plot of the chemical shift difference of each dipeptide on addition 
of protein. The largest change in chemical shift was deconvoluted to the H2N-Val-pfF-CONH2 
dipeptide (FDL16) with Δδ 1.4 Hz. This is a very weak change in chemical shift and is likely a 
> 1 mM affinity ligand. Somewhat interestingly, the next highest observed chemical shift 






























Leucine and valine are both classed as branched-chain amino acids with aliphatic side chains. 
This could indicate, a hydrophobic interaction with a small pocket or a non-specific interaction 
with the surface of the protein. 
 
Figure 2.34: 19F NMR screening of the fluorinated dipeptide library vs UbE2L3. Top left: 
Superposition of compound pool (100 μM each) in absence (red) and presence (blue) of 10 μM 
UbE2L3. The peak at -75 ppm is TFA used as a reference peak. The cluster of peaks at ~115 
ppm are the peptide peaks. Top right: close up of the superposition of the TFA peak in the 
compound pool. This peak shows precise overlap in signal indicating no binding of TFA to 
the protein, this is then used as a reference for the compound peaks. Bottom: 4 fluorinated 
dipeptide compounds (100 μM each) in absence (red) and presence (blue) of 10 μM UbE2L3. 




Figure 2.35: A bar chart plot of the 19F resonance shift (blue bars) and corresponding line 
broadening (red bars) of each fluorinated dipeptide (FDL) in the presence of 10 μM UbE2L3. 
The shifts are weak indicating a low affinity.  
To validate the observed binding effect, the experiment was repeated with FDL16 and 
independently measured in the presence and absence of protein. Again, in this experiment a 
similar Δδ 1.5 Hz chemical shift change was revealed (figure 2.36). This shift is comparable to 
the chemical shift expected, as the proof-of-concept dipeptide (compound 3.0, figure 2.29), 
upon binding to survivin, showed a chemical shift change (Δδ) of 2.5 Hz. FDL16 was then 
taken forward for chemical extension at the C- and N-termini by SPPS. 
 
Figure 2.36: Stacked spectra of fluorinated dipeptide H2N-Val-pfF-OH in the absence (bottom) 
and presence (top) of 10 μM UbE2L3. Peptide concentration was 100 μM. There is a slight 
change in chemical shift (Δδ 1.4 Hz, ΔLW1/2 0.28) and decrease in intensity on addition of 
protein indicating a likely binding event. The dashed line indicates the downfield shift in 




























2.3.5. 19F NMR screening of the fluorinated tripeptide libraries 
The fluorinated dipeptide, FDL16, was then used as a scaffold for extension in an N and C 
direction (see figure 2.37). Using Fmoc SPPS a library of 32 fluorinated tripeptides were 
synthesised in good yield and purity (see chapter 7 for materials and methods). Figure 2.38 
shows the chemical structure C-FTL10 and corresponding QC data as an example (see 
appendix 8.1.11 and 8.1.12 for QC data of all synthesised tripeptides). The tripeptides were 
then pooled again based on minimal overlap of 19F NMR signals (see appendix 8.1.14 and 
8.1.15 for all peptide pools). The peptides are sorted based on their fluorine resonance, the first 
peptide is placed into pool 1, the second into pool 2 and so forth until the desired number of 
pools is reached. From herein, the N- and C-terminal extended tripeptides are referred to as 
N-FTL and C-FTL respectively (i.e. N-terminal Fluorine Tripeptide Library). 
 
Figure 2.37: Chemical structures of the N- and C-terminally extended tripeptide libraries (N-
FTL and C-FTL respectively highlighted in red). R2 is the position of the 16 natural L amino 
acids. 
Again, the peptides were screened against UbE2L3 under identical conditions, 100 μM ligand 
and 10 μM protein, as used in the dipeptide screen, and analysed for chemical shift changes 
or line broadening effects. However, changes in the fluorine resonances were not as significant 
as the dipeptide library pools, i.e. extension at either the N or C terminus did not contribute 
to an increase in binding affinity. The largest change in chemical shift occurred via N-terminal 
extension with a tryptophan residue (compound N-FTL14) with Δδ 0.9 Hz. However, this is a 
smaller change than the original dipeptide, and there were no line broadening effects 
observed. Figure 2.39 shows a bar chart illustrating the chemical shift changes for the N-FTL 
and C-FTL peptide libraries. This leads to the conclusion that both N- and C-terminal 
extension hinders ligand binding. This could indicate a rather small binding pocket, such that 
a small trimeric ligand is too large for the binding site. The E2 enzymes are generally classed 
as difficult, or undruggable targets due to the overall globular structure and absence of a well-




HPLC: tR 14.2 mins; > 95 % purity MS (ESI): [M+H]+calc 429.2; [M+H]+obs 429.2 
 
 
19F NMR (376 MHz, 10 % D2O) δ ppm  
-116.08 
Chemical Structure of C-FTL10 
Figure 2.38: Example quality control data (QC) for C-FTL10 (H2N-Val-pfPhe-Phe-CONH2). 
The result indicating that the N-terminal or C-terminal extension of the weakly binding 
peptidomimetic dipeptide with 16 natural amino acids did not lead to increased, but to 
decreased binding affinity was surprising. Taking the best of the binding tripeptides and 
replacing the natural amino acids with non-natural amino acids appears to be a possible step 
forward. Also, the effect of capping, and replacement of amino acid side chains with 
bioisosteres is a further option. Although of low affinity, it might be useful to test the best 
identified binders in a 15N-HSQC experiment to identify a binding site on UbE2L3. This would 


























































Figure 2.39: Chemical shift change for fluorinated tripeptide libraries. Top: A plot of the 
resonance shift of each fluorinated tripeptide (present at 100 μM) from the N-terminal 
extension library (N-FTL) in the presence of 10 μM UbE2L3. Bottom: A plot of the resonance 
shift of each fluorinated tripeptide (present at 100 μM) from the C-terminal extension library 
(C-FTL) in the presence of 10 μM UbE2L3. The shifts are very weak (< 1 Hz) indicating a very 
low affinity. 
There are a number of small molecules targeting E2 enzymes which classes this family of 
enzymes as druggable (see chapter 4.1.3.1). There is also one compound that has a broad 
spectrum activity on E2 conjugating enzymes. The small molecule compound BAY 11-7082 
inhibits the formation of E2-ubiquitin conjugates by direct covalent interaction in the binding 





































this compound on multiple members, not limited to E2 enzymes, of the UPS. Specifically, it 
has been found to have target activity against deubiquitinases and multiple other proteins.131 
 
Figure 2.40: Chemical structure of compound BAY 11-7082. This covalently attaches to the 
active site cysteine in E2 enzymes. 
The average molecular mass of a dipeptide is ~ 300 Da, which is also ‘fragment’ sized 
(described in chapter 3 onwards). Therefore, in the future the OPPG technique will be further 
explored in the context of 19F fragment based screening (FBS). The focus of this thesis from 
herein switches to fragments and screening of low molecular weight compounds for ligand 
discovery. The UbE2L3 protein is the target focus for fragment screening presented in the 
following chapters. 
2.4. Conclusions and future work 
A successful proof-of-concept study was achieved with detection of a weak affinity dipeptide 
peptidomimetic to survivin by 19F NMR. It was also shown that increased affinity towards 
survivin could be observed using 19F NMR by extension of the dipeptide to the corresponding 
tripeptide and tetrapeptide. The medium affinity tetrapeptide is a very useful probe molecule 
for future studies, and the use of 19F NMR is a simple yet sensitive detection method. For 
future work, this fluorinated peptide could be used in a FAXS approach (described in chapter 
4.1.1) for competition binding experiments in a fragment-based screen.  
The aim was to use the knowledge acquired via the proof-of-concept peptidomimetic study 
on survivin to develop a fluorinated dipeptide library using the UbE2L3 target in an initial 
approach. Using solid-phase peptide synthesis (SPPS) a 16 member fluorinated dipeptide 
library was synthesised for 19F ligand-observed NMR screening. A fluorinated amino acid, a 
para-fluoro-L-phenylalanine (pfF), was used as the fluorine containing moiety and these were 
screened against the UbE2L3 protein. However, initial hit dipeptides showed very low 
binding affinity and maybe binding unspecifically. The most active hit dipeptide was taken 
forward and a library of 32 C- and N-terminal extended tripeptides were synthesised by SPPS. 
These were screened for activity against UbE2L3 by 19F NMR however, binding was even 
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weaker than the dipeptide. This confirms that UbE2L3 protein is a difficult target for ligand 
discovery. 
To develop the OPPG approach further, other E2 enzymes could be screened with the initial 
fluorine dipeptide library. This would provide a measure of the druggability of this family of 
proteins and offer vital information for the pharma industry. Also, this approach can be 
extended to using different fluorinated amino acids as the chemical probe and non-natural 
amino acids in the ‘N’ and ‘C’ positions. For example, there are multiple fluorinated isomers 
of tryptophan that are commercially available which could be used as the fluorinated amino 
acid probe. Again, this is scope for creating a PPI target focussed library, for example, Bogan 
and Thorn (1998) compiled a database of 2325 alanine mutant proteins, for which the change 
in free energy of binding in the PPI has been measured.132 They describe the free energy of 
binding is not evenly distributed across the PPI interface, and binding is made up of hotspots. 
The amino acid residue most likely to occur in a hotspot is tryptophan,133 therefore using this 
amino acid as the probe molecule might increase the chances of finding a novel ligand. 
This novel approach to ‘on-protein peptide growing’ OPPG, can theoretically be used against 
any target. The simplicity of peptide synthesis, coupled with the assay sensitivity and ease of 







Fragment Library Design 
This chapter describes the approaches used to generate fragment libraries for use in NMR-
based screening. An introduction to library design principles and strategies is given along 
with some examples from Pharmaceutical and academic groups. A short analysis of the 
properties of available commercial libraries is also presented. Following this, three strategies 
which were successfully applied to design and generate fragment libraries for purchasing 
unique compound collections are described. 
I would like to acknowledge Dr Steven Shave for the huge contribution to the cheminformatics 
work described here. Where stated the programming, indexing and analysing of 
computational data is completed by Dr Steven Shave. I would like to thank him for his 
generous help and insight to produce these fragment libraries which provided an essential 





The fundamental tenet behind fragment-based screening is that small fragments can more 
effectively probe chemical space.134 A range of biophysical methods can be used to screen for 
hits, as described previously (Chapter 1.3), and, as a consequence, the library must be 
designed in such a way to limit certain physiochemical properties of fragments whilst 
maintaining a maximal level of diversity.25 According to the Hann model of molecular 
complexity, there is an increased chance of detecting binding when screening small, low 
complex fragments with a high sensitivity than large compounds with low sensitivity.135  As 
molecules become larger and more complex, they are more likely to have a single binding 
mode. This is shown by Schuffenhauer, in an analysis of the Novartis HTS data, where an 
increased hit rate is observed for screening low-complex fragments with higher sensitivity.136 
Fragment library design is extensively covered in the literature134,137 and the most important 
principles are discussed in section 3.1.1. 
3.1.1. Library Design Principles 
The success of a FBDD campaign is greatly dependent on the design of the library, i.e. the 
quality of the library dictates the quality of the hits found.138 The fragment quality, for 
example, can be defined by the capacity for chemical follow up into lead compounds. Another 
important consideration is the specific technology to be used for screening, that is, the design 
must ensure fragments are amenable to the type of assay that will be used. For example, many 
assays prove unsuitable for screening, with false positives a result of compound aggregation 
at the high fragment concentrations required. Additional considerations that must be taken 
into account in the overall library design include: the desired physicochemical properties of 
fragments to be included, the aqueous solubility and purity, an assessment of molecular 
diversity, the chemical tractability of the fragments for follow-up, which chemical 
functionalities are disallowed, the drug-likeness of the fragments and sampling of privileged 
medicinal chemistry scaffolds. Another aspect to library design is the debate over the optimal 
size, number and shape of fragments to be screened which, in particular, arouses 
controversy.139 Although all these factors must be taken into account when designing a 
fragment library, there are three main aspects to qualitative library design that are universally 
accepted, these are:  chemical space coverage, chemical tractability and few reactive moieties. 
Each of these parameters are discussed below. 
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3.1.2. Chemical Space and Rule of Three 
Chemical space is a concept that encompasses all possible molecules and chemical compounds 
that adhere to physical construction principles. Theoretically, there are 1060 – 10100 small 
molecule compounds available that populate this huge chemical space,140,141 and it is therefore 
impossible to methodically search for the optimal molecule. A fundamental advantage of FBS 
is that a better exploration of chemical space is available with smaller ligands as a result of 
lower molecular complexity and lower inherent selectivity. Fragment libraries are therefore 
commonly designed to maximise chemical diversity, whilst limiting certain physical 
properties of compounds. Ultimately, many of the library design strategies use similar 
property filters to ensure the quality of fragments and to maximise diversity. Lipinski’s Rule 
of Five, were the original guidelines for the development of a bioavailable drug compound. 
These parameters have been developed over time to include rotational bonds and polar 
surface area. With the advent of fragment-based screening, researchers at Astex observed that 
hits identified in screening campaigns appeared to obey a ‘Rule of Three’ (Ro3). The Ro3 states 
that a fragment has: 
 < 300 Da molecular mass 
 ≤ 3 cLogP (partition coefficient) 
 ≤ 3 hydrogen bond acceptors 
 ≤ 3 hydrogen bond donors 
 ≤ 3 rotational bonds (NROT) 
 ≤ 60 Å2 polar surface area (PSA) 
These parameters are widely considered as rough guidelines,142 however, academia and 
pharmaceutical companies tend to follow them in design of their in house libraries. Often the 
number of hydrogen bond donor and acceptor pairs are higher. However, it is shown that a 
minimum molecular mass of 150 Da is required to minimise the effect of reorientation of the 
fragment during hit development.143 The Ro3 has had a major impact in drug discovery 
however, recently has come in for some criticism. Köster et al designed a fragment library of 
364 compounds without strict conformation to the Ro3.144 They screened the library against 
endothiapepsin and eleven crystal structures were determined covering fragments with 
diverse binding modes. They noted that only 4 of the 11 fragments are consistent with the Ro3, 
therefore restrictions to this rule are limiting the pharmacophoric variety of chemical hits. In 
general, the average molecular weight of libraries is falling however, it is the physiochemical 
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properties, e.g. solubility and stability, and the potential for development that drive library 
design. 
3.1.3. Chemical Tractability 
Fragment libraries require additional constraints in design methods owing to the high 
aqueous concentrations needed for biophysical binding detection and the need for chemical 
tractability of hit compounds. Chemical tractability describes the capacity of fragment-like 
compounds to be developed into drug-like molecules. This is an important consideration in 
the design of fragment libraries as rapid development of hit compounds is paramount in a 
competitive field. One challenge in FBS is that polar moieties (such as amines or acids) in low 
molecular mass fragments often provide the key interaction, therefore any synthetic change 
to this group (for example amide formation) could eliminate the binding interaction. 
3.1.4. Reactive, Toxic and PAINs Compounds 
Compounds containing specific chemical functionalities may react covalently with biological 
targets. There are examples of this in certain drugs, however, usually these molecules are 
excluded from screening libraries. In a review by Rishton, the chemical groups illustrated in 
Figure 3.1 were reported to be potentially reactive.145 Although the functionalities in Figure 
3.1 are generally avoided, some chemical groups have been found to be frequent hitters in 
high throughput screens. In 2010, Baell and Holloway introduced the term Pan-Assay 
Interference Compounds (PAINs) to describe a number of substructural features that appear 
to hit multiple targets, these are illustrated in Figure 3.2. 
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Figure 3.1: Chemical structure of potentially reactive chemical moieties. These functionalities 
are potentially reactive and are usually avoided in fragment libraries. Reproduced from 
Rishton.145  
A common feature among many PAINs moieties is that they contain a Michael acceptor, which 
can react with nucleophilic residues in proteins, for example, rhodanines. Rhodanines are the 
archetypal example of the nature of the problem. A search of the literature reveals 2,132 
rhodanines that reportedly have biological activity in 410 papers, from 290 organisations, of 
which 24 are commercial companies.146 It is shown that these types of compound can undergo 
light-induced reactions that irreversibly modify proteins. They can bind either reversibly or 
irreversibly, however, the tendency to form covalent adducts make them unsuitable for drugs 
or probe molecules. They have since been reported to be active in other assays and are 
frequently missed in reactivity filters. Therefore, since its inception, PAINs filters have become 
a common implementation in fragment library design. It is important to note, however, that 
the structural features in PAINs compounds were identified using only one biochemical assay. 
The inclusion of PAINs filters are facing increasing criticism with over 80 small molecule FDA-
approved drugs contain PAIN structures.147 
The design principles described above are generally adopted by academic groups and the 
Pharma industry for fragment-based screening campaigns. Applying these considerations in 
the final library design offers the highest chance of identifying fragment hits. A summary of 
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library design approaches adopted by various academic and pharmaceutical companies is 
given in the following section (3.1.5). 
 
Figure 3.2: Chemical structures of pan-assay interference compounds (PAINs). These moieties 
are identified as frequent hitters in HTS campaigns and are generally excluded in the design 
of the final fragment library. Adapted from Baell and Holloway.148 
3.1.5. Fragment Library Design Approaches 
Many academic and pharmaceutical companies are intent on keeping library design methods, 
and indeed library content, undisclosed to maintain intellectual property. Therefore, it is 
difficult to compare the various strategies used between pharmaceutical groups. The only 
parameter that is generally published is the reported hit rate of the library. However, most 
libraries developed in Pharma are constructed in house by cheminformatics approaches by 
analysing a representative set for diversity, PAINs and solubility. The following sections 
summarise a few examples of library design strategies used by pharmaceutical and academic 






3.1.5.1. Cheminformatics Filtering 
The most published methods of fragment library design involve filtering of available 
compounds for desired physiochemical properties, the Ro3, diversity analysis and a subjective 
input from a medicinal chemist. For example, pharmaceutical company GlaxoSmithKline 
(GSK) routinely use fragment screening in their drug discovery projects. The fragment 
screening set they employ was developed by taking a large set of available in-house 
compounds and applied a set of 2D substructure and property filters to identify compounds 
(heavy atoms < 22, rotatable bonds < 6, donors < 3, acceptors < 8, cLogP < 2.2). A synthetic 
handle was also included to allow medicinal chemists to easily follow up on hits. Diversity 
analysis was also used to select a subset based on 3D pharmacophores to create a second 
fragment library.149 Another example comes from researchers at Pfizer who describe the 
design of their Global Fragment Initiative (GFI), a 2,885 member fragment library that is, 
supposedly, broadly applicable to any target using any screening method, i.e. NMR, X-ray, 
SPR, MS and biochemical assays.150 Compounds in this library were subject to rigorous filters 
including: reactive moieties, solubility at 1 mM in aqueous buffer and chemical complexity. 
Most of the fragments came from commercial sources, however 293 were synthesised 
specifically for the library. Interestingly, a large number of charged molecules were included 
(cationic and anionic) based on the observation that many approved drugs are charged. The 
fragments were also investigated for their 2D and 3D similarity in order to maximise diversity 
and ensure commercial availability of hit analogues 
3.1.5.2. Target Focussed Fragment Libraries 
Recently, smaller fragment libraries, directed at a specific target class have emerged as useful 
fragment sets for screening. One of the fastest growing target classes for drug intervention are 
epigenetic classes of protein, including: bromodomains, histone deacteylases and histone 
methyltransferases. As described in Chapter 1, these proven druggable families have led to 
companies, for example Enamine, creating focussed fragment libraries. In particular, 
Enamine, has created a PPI focussed fragment library to enrich for active molecules containing 
privileged core structures. This library contains compounds with similar core structures used 






Molecular mass 200 – 400 Da 
cLogP 0 – 4 
Hydrogen bond acceptors 0 – 5 
Hydrogen bond donors 0 – 4 
Rotational bonds 0 – 5 
Table 3.1: Table describing the criteria used for selection of PPI fragments in the Enamine PPI 
fragment collection. Adapted from Enamine.151 
Protein kinases are another example of an important drug target class for therapeutic 
intervention. An in-depth analysis of kinase inhibitors by Akritopulou-Zanze and Hadjuk led 
to the design of new kinase focussed libraries. The authors developed a scaffold-based 
approach that identified a novel class of low molecular mass compounds with kinase activity. 
This analysis of known kinase inhibitors would allow academics and pharmaceutical 
companies to design novel fragment collections to either increase intellectual property 
freedom or increase chemical space coverage.152  
3.1.5.3. Fluorine Fragment Libraries 
As described previously (Chapter 1.4.3), 19F ligand-observed NMR screening is currently one 
of the most popular methods of screening fragment libraries. 19F NMR spectra are much 
simpler than 1H spectra as there are no background signals from endogenous protein signals. 
However, a caveat of 19F NMR screening is that it requires fluorinated fragments in the library. 
This introduces a significant bias in the design of the library owing to constraints of the assay 
conditions. The main concern with this restriction is the limiting of chemical space to 
fluorinated fragments. Jordan et al carried out a comprehensive analysis of the coverage of 
fragment space of fluorine containing molecules. Using a total of 67,000 reference compounds 
and selection filters, diversity analysis of 19F fragment space was assessed. Figure 3.3 shows a 
graphical representation of the coverage of fragment space by fluorine containing molecules. 
The data is analysed by principal component analysis (PCA) using the selection filters that 
were applied to define the fragment space. PCA is a method to reduce the number of 
dimensions in a dataset, such that the variation in the lower dimensional data is maximised. 
The authors conclude that the overall coverage of fragment space with fluorine containing 
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molecules is approximately 30%, however, the diversity is sufficient enough to be used for 
screening. 
 
Figure 3.3: A graphical representation of fragment space coverage by 19F compounds. Red dots 
represent compounds contained in fragment space, while black dots represent compounds in 
the fluorine fragment library. Green squares are hit compounds from a screen β-secretase 
described in the paper.153 PCA_PC1 and PCA_PC2 are the principal components that describe 
each compound in the reference library. 
A novel fluorine library for NMR screening is described by Dalvit et al who generates a library 
of fluorine containing fragments based on the local environment around the fluorine 
nucleus.154 Fluorine atoms with different electronic charge distributions (i.e. different chemical 
shifts) will interact differently with the receptor, they call this the ‘Local Environment of 
Fluorine’ (LEF) library. In-house and commercial compounds were clustered according to a 
new fluorine fingerprint that clusters fragments based on LEF. They were also clustered using 
the whole molecular structure, using FCFP4 fingerprints (described in section 3.1.6.3), the two 
criteria give very different results as illustrated in table 3.2. This approach to library design 
represents a strategy directed towards the identification of fluorophilic protein environments.  
Overall, the general approach to library design often depends on available resources and the 
intended fragment screening method. The methods described in this thesis focus on ligand-
observed 19F NMR as the preferred biophysical screening method. As shown previously, using 
fluorine containing compounds limits the chemical space coverage, however the high 
sensitivity of NMR is considered to supersede this limitation. 
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The following sections addresses the issues of fluorine fragment library design and the 
strategies employed in this thesis towards designing an in house fluorinated fragment library. 
 
Clustered according to FCFP_4 Fingerprints 
A 
  
   
F-cluster 230 2 31 31 31 
Global 
cluster 
205 205 205 205 205 
Clustered according to LEF 
B 
 
   
 
 
F-cluster 230 230 230 230 230 
Global 
cluster 
205 126 126 77 58 
Table 3.2: Fluorine fragments clustered by two different descriptions. A) The five molecules 
belong to the same global cluster, 205, but to different F-clusters generated using the LEF 
fingerprint. B) The five molecules belong to the same F-cluster, 230, but to different global 
clusters. Adapted from Dalvit et al.154 
3.1.6. Cheminformatics 
The library design strategies described above were adapted and employed here to design an 
in house fluorinated fragment library. This chapter relies on a range of cheminformatics 
methods, here I introduce the basic methods and terminology used to handle the data. 
Cheminformatics was a term coined by Dr. Frank Brown in 1998 who described it as: “… the 
mixing of those information resources to transform data into information and information into 
knowledge for the intended purpose of making better decisions faster in the area of drug lead 
identification and optimization.” The main focus of cheminformatics is the handling of data 
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related to storage, indexing and searching of chemical compounds. Here, it is a term used to 
describe the range of methods used in designing fragment libraries. The main aspects of 
cheminformatics, with regards to fragment library design, include representing chemical 
structures and the calculation of molecular properties. 
3.1.6.1. Representation of 2D Structures 
There are various ways to computationally represent and handle chemical structures and their 
molecular properties. For example, the cancer drug 5-Fluorouracil can be illustrated in an 
image file (Figure 3.4, 1) or described by its IUPAC name (International Union of Pure and 
Applied Chemistry) (Figure 3.4, 4).  
 
Figure 3.4. Chemical representation of 5-Fluorouracil (5-FU). The molecule 5-FU is 
represented as: 1. Chemical structure image file; 2. Systematic name; 3. SMILES; 4. IUPAC 
name; 5. InChI. 
However, to perform computational analyses, such as molecular property prediction and 
substructure searches, these notations are impractical. A popular method for describing the 
connections of atoms in a molecule is the use of SMILES (Simplified Molecular Line Entry 
System) which constitutes a linear notation system (Figure 3.4, 3). To express a molecule as a 
string of atomic connections, SMILES has various rules including: atoms are represented as 
their atomic symbol, several symbols represent bonds and their character (e.g. = stands for 
double bond), branches are indicated with brackets and upper and lower case letters express 
aliphatic and aromatic atoms respectively. InChI (International Chemical Identifier) is also 
another method of representation in which every structure is described by a unique string 
composed of layers of information. These layers encode information pertaining to atom 
connectivity, tautomeric information, charge and stereochemistry.155 Figure 3.4, 5). For the 
following work, SMILES strings are used as the predominant molecular descriptor for 
property prediction and database searching. 
3.1.6.2. Pipeline Pilot Program 
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Pipeline Pilot is a cheminformatics workflow tool that offers an array of scripts for creating 
and analysing large, complex data sets, including cheminformatics, sequence analysis and 
modelling. It automates data analysis processes to allow fast, efficient work flows for 
analysing and reporting data. There are many opportunities to create custom protocols for 
specific functions and therefore adapt the scripts to allow focus on innovation. The following 
method for fragment library design utilises a clustering algorithm implemented with the 
program Pipeline Pilot from Accelrys. 
3.1.6.3. Clustering 
Clustering, or cluster analysis, is a method used to group a set of objects, based on some 
definition of similarity and pertaining to a defined threshold. It works by placing members of 
a dataset so that the distance (defined by some similarity metric) between members is 
minimised. Objects contained within the same group (cluster) are therefore more similar to 
each other, than those contained in another cluster. Clustering, itself, is widely used across an 
array of disciplines including cheminformatics, machine learning and image analysis. There 
are many different models used to define clusters, which in turn use specific algorithms that 
differ significantly in their definition of clusters and how to efficiently find them. The 
approach used by the program Pipeline Pilot uses a non-hierarchical method to cluster data 
sets. A set of compounds, from an input library, is divided into smaller sub-sets based on the 
maximum dissimilarity between compounds. The similarity score is determined using the 2D 
fingerprints ‘FCFP4’ (functional connectivity fingerprints of radius 4). This is a fingerprint of 
the molecule designed specifically for similarity searching.156 For instance, a random molecule 
is chosen as the first cluster centre, then the most distant molecule to this one is the next cluster 
centre. This is repeated until there are sufficient cluster centres described. The remaining 
molecules from the dataset are then distributed between these cluster centres to create the 
final cluster. 
3.1.6.4. Molecular Property Prediction - cLogS 
The molecular solubility is a critical property of a drug compound as this affects the 
distribution across the human body. The drug needs to be water soluble enough to be 
transported throughout the body, yet hydrophobic enough to pass through cell membranes. 
A common measure of a molecule’s solubility is the LogP, which is a measure of the 
distribution between octanol and water and gives information on the compounds 
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lipophilicity. However, the aqueous solubility, LogS, affects the overall bioavailability i.e. 
uptake and distribution, of the compound in their effective active site. For FBS we are 
interested in the aqueous solubility of fragments for screening as this is critical to the assay 
conditions. Therefore, predicting the molecular properties, such as logP/S/D, pKa and 
analytical spectra (NMR, mass spectrometry etc.) of compounds is a powerful tool to the 
computational chemist. There are currently a large number of scientific algorithms available 
to tackle this problem, however, these are usually developed using multiple computer 
languages and are difficult to transfer between different laboratories.157 The virtual 
computational chemistry laboratory (VCC) is a multi-platform, online data analysis tool that 
allows one to perform a series of comprehensive molecular property predictions online.158 The 
specific software package described here is the ALOGPS 2.1 Java applet used to predict the 
aqueous solubility of compound fragments needed for library design and screening. 
Compounds can be uploaded easily in SMILES format and the output is very fast and efficient. 
Fragment based screening is in widespread use, hence fragment library design is a major topic. 
Many review articles exist on the ways and means of fragment library design that share 
knowledge on the importance of the principles described here. The following aims are 
intended to build on these strategies for application in the following chapters.  
3.1.7. Aims of this chapter 
The aim of this chapter is to use three different approaches to design low-cost, fluorine-based 
fragment libraries that can be used for screening by 19F ligand-observed NMR. A fluorine 
fragment library using the cheminformatics methods and design principles described will be 
generated and compounds purchased to include in the screening collection. The libraries will 
be profiled and screened for novel, selective binders against a number of validated targets 
considered important in the Auer group. The three approaches encompass different strategies 
towards library design, and it is hypothesised that using these different strategies in parallel 
will provide a greater chance of success.  
In the first approach fragments are selected from the ChEMBL input database of known active 
compounds. Active compounds are filtered according to desired physiochemical properties 
and selected fragment sets are further reduced according to cost. It is hypothesised that known 
active compounds may provide a useful starting point for development into a selective ligand. 
Owing to the small size of fragments, selectivity is generally an issue therefore optimisation 
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of fragments is possible. This set is referred to as the ‘Recognised Active Fragment Library’ 
(RAFL).  
The second approach uses a conventional method to cluster fragments based on their 2D 
similarity. The input library of compounds is the online database of commercially available 
compounds eMolecules. This large, online database is filtered for desired fragment properties 
then clustered using the Pipeline Pilot clustering algorithm FCFP4. Fragments from clusters 
are chosen to maximise diversity, reduce reactivity and reduce the final cost, to follow the 
remit of a low-cost fragment library. This set is referred to as the ‘Clustered Fragment Library’ 
(CFL). 
The third approach introduces a new measure of diversity to identify a fragment set that gains 
the maximal diversity within that set. Due to the availability, good quality and diversity of 
fluorinated compounds, Fluorochem was chosen as the optimal vendor for purchasing 
fragments The input library of fragments is filtered according to the desired properties of the 
fragment library. A new measure of diversity is introduced that allows one to cherry pick a 
set of compounds to maximise the diversity. This follows again the objective of this project to 
gain a highly diverse, yet low-cost fragment set that will provide hits to our protein targets. 
This set is referred to as the ‘Directed Diversity Fragment Library’ (DDFL). 
Also, a short analysis of the physiochemical properties and diversity of commercially available 
fragment libraries is presented. 
3.2. Results and Discussion 
3.2.1. A Commercial Library Analysis 
There is an ever increasing number of commercial companies offering fragment collections for 
screening purposes. As one might anticipate, this would lead to a significant overlap of 
chemical space coverage between various libraries. A disadvantage of using commercial 
fragment libraries, and sourcing compounds from commercial vendors, is that direct 
competition results from sampling the same chemical space. Compound libraries were 
provided by commercial vendors and were supplied as structure-data file (SDF) files, allowing 
fast and easy similarity searches and molecular property prediction. We were able to obtain 
SDF files for 13 commercial vendors, listed in table 3.3, and apply common Ro3 filters to 
ascertain the quality of the library. Again, this is a rather subjective view, as the Ro3 is known 
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to be a rough guideline, however, it allows us to realise which vendor is selling the highest 
quality library for our requirements.  
3.2.1.1. Classifying Fragments 
The main aim here was to determine the quality of commercial fragment libraries, and how 
applicable they would be to an NMR screening approach. Firstly, we defined some simple 
filters to check how each library conforms to a reasonable fragment set. These were: removal 
of PAINs compounds, a molecular mass less than 300 Da and an aqueous solubility of greater 
than 100 μM (cLogS > -4). Solubility was calculated using the ALOGPS 2.1 cheminformatics 
lab described in section 3.1.6.4. Immediately from table 3.3 it was evident that the Maybridge 
(part of Thermofisher) library loses over 70% of fragments that do not conform to simple 
filters. Particularly alarming is the aqueous solubility filter which accounted for 41% of loss of 
fragments. This library would not be useful for NMR solution screening owing to the high 
solubility requirements for detection (> 100 μM). Figure 3.5 illustrates the distribution of 














Analyticon 30 - -2 -1 27 10 
Asinex 2,284 -70 - -396 1,818 20.4 
Bionet 1,952 -50 -6 -285 1,611 17.5 
ChemDIV 380 -4 -2 -32 342 10 
Enamine 6,842 -20 - -1336 5,486 19.8 
Life Chemicals 2,253 -1 - -621 1,631 27.6 
Life Chemicals 
Pooled 
1,010 - - -238 772 23.6 
Maybridge 5,244 -194 -2420 -1090 1,540 70.6 
Otava 1,217 -22 -8 -169 1,018 16.4 
Prestwick 99 -3 - - 64 35.4 
TimTec 91 -3 - -28 60 34.1 
Vitas-M 2,298 -113 - -721 1,464 36.3 
Table 3.3: Commercial library analysis. Table showing the percentage loss of each commercial 
library when filters are applied. The extraction of information and cheminformatics 
processing illustrated in this table was performed by Dr Steven Shave. 






Figure 3.5. Maybridge fragment screening collection statistics. Top Left: Plot showing the 
frequency distribution of the molecular mass of fragments present in the library.  Top Right: 
the frequency distribution of the aqueous solubility of fragments present in the library. 
Bottom: A 2D plot of aqueous solubility (cLogS) vs molecular mass of fragments in the 
Maybridge collection. Applying simple, common filters to the Maybridge collection reveals 
that it is not Ro3 compliant and would not be very suitable for NMR-based screening 
Before deciding on which library to purchase, another aspect to consider was the coverage of 
fragment space. One might expect a significant overlap of coverage space between commercial 
libraries owing to the small volume of fragment space and the large numbers of compounds 
available in libraries. However, the fragment crossover between libraries was surprisingly low 
as illustrated in table 3.4. This was done by using each library as a ‘query’ and cross-
referencing compounds to every other library. For example, there are 10.86% of fragments 


















































crossover was 2.6 % which implies that there are a lot of unique fragments present in each set. 
This is an advantage for consumers as this reduces competition if hits from screening are 
identified.  
An important objective from designing our in-house libraries was to reduce the cost as much 
as possible, whilst maintaining a maximal level of diversity. The aim is to investigate different 
strategies to increase diversity as a function of compound number. Commercial libraries 
containing > 1000 compounds are on average $7 (£5) per compound, however, a usually a 
minimum order of > 1200 compounds (£6000), this data is taken directly from company 
websites. Usually, ordering more compounds reduces the price per compound. Also, a 
disadvantage of commercial libraries is a general trend of vendors is to supply compounds as 
1 – 10 mM DMSO stocks or 1 mg powder in micro-well plate form. This is unsuitable for an 





Table 3.4: Fragment library crossover table. This table illustrates the percentage of the query library (left column) that is present within the criteria 
adherent candidate library (top row). The crossover is given as a percentage of the query library present in the candidate library. The analysis and 































100.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Asinex 
(2284) 
0.00 100.00 2.58 1.01 5.34 3.77 2.41 1.84 4.73 0.22 0.48 13.84 
Bionet 
(1952) 
0.00 2.97 100.00 0.10 5.89 1.95 1.54 10.86 4.25 0.87 0.20 4.71 
Chem DIV 
(380) 
0.00 6.05 0.53 100.00 0.26 1.84 1.32 0.26 1.58 0.26 0.26 3.16 
Enamine 
(6842) 









0.00 5.45 2.97 0.50 4.36 81.78 100.00 1.19 4.65 0.00 0.10 2.67 
Maybridge 
(5244) 
0.00 0.80 4.04 0.02 1.72 0.51 0.23 100.00 1.37 0.38 0.08 1.95 
Otava 
(1217) 
0.00 9.04 6.57 0.49 10.93 8.22 3.86 5.92 100.00 0.49 0.16 12.00 
Prestwick 
(99) 
0.00 5.05 17.17 1.01 6.06 1.01 0.00 20.20 6.06 100.00 1.01 6.06 
TimTec (91) 0.00 10.99 4.40 1.10 2.20 1.10 1.10 4.40 2.20 1.10 100.00 7.69 
Vitas-M 
(2298) 




3.2.2. Defining Physiochemical Property Filters 
To design our own, in-house fluorinated fragment libraries it was necessary to define the 
physiochemical properties that are required for NMR screening. Figure 3.6 illustrates the 
desirable properties for fragments in our library to possess. 
 
Figure 3.6: Pipeline of desirable physiochemical properties to be used as filters to define in-
house CTB fragment sets. The input library of compounds was filtered according to each box 
in the workflow. The input libraries are described in the main text for the different design 
approaches.  
The Ro3 states a molecular mass less than 300 Da should be used as a guideline for fragments. 
As illustrated in table 3.2.1, most of the libraries conform to this rule with the exception of the 
Maybridge library. This was chosen as the molecular mass cut off for CTB fragments. Aqueous 
solubility is a critical parameter for NMR fragment-based screening. A solubility threshold is 
a good selection filter as this tends to remove many compounds and is dependent on the type 
of assay to be applied for screening. An aqueous solubility of 100 μM is required for detection 
of 19F in NMR (see chapter 4.2.2), this equates to a cLogS of > - 4, therefore this parameter was 
also selected as a filter. As described previously (Section 3.1.4) primary screening hits must be 
scrutinised for possible artefacts, i.e. it is necessary to confirm that their activity is dependent 
on a specific interaction. Pan-assay interference compounds (PAINs) are defined as 
compounds that contain specific chemical structures that show activity across a range of 
assays and against a range of proteins. Therefore, including a PAINs filter in development of 
the libraries was necessary to remove any potentially promiscuous compounds. Hydrogen 
bond donor and acceptor pairs and number of rotational bonds were used as additional filters 
to reduce the size of fragments returned during the search of chemical space. 
The most important filter used in the pipeline workflow is the fluorine atom filter. The fluorine 
atom needs to be included in each fragment for ligand binding detection in the NMR screening 
assay. The benefit of fluorine NMR screening is that compounds with a single CF or CF3 group 
will have a single peak in the NMR spectrum, i.e. one singlet resonance per compound. This 
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with multiple magnetically distinct fluorine atoms, therefore, for the purposes of screening,  it 
is desirable to keep fluorine nuclei to a minimum Also, it has been shown that CF3 or OCF3 
moieties always reduce the aqueous solubility, whereas single CF groups can alter it in either 
direction.159 . The single F or CF3 filter was therefore applied to make spectral analysis 
straightforward.  
Other requirements in the selection of compounds include removing salt forms of fragments 
that are prone to precipitation after multiple freeze thaw cycles. Also, a rather subjective 
medicinal chemistry viewpoint on desirable chemical functionalities and ‘interesting’ looking 
compounds was used to select fragments. The following sections describe the results of library 
generation by each of the three methods of library design. 
3.2.3. Recognised Active Fragment Library (RAFL) (Performed with Dr Steven Shave). 
The first approach to constructing a fragment library was built on the hypothesis that known 
active fragments in the literature, that hit more than one target, may be a useful starting point 
for lead generation. These recognised actives may have alleged promiscuous activity, 
however, at such low molecular weight, optimisation into selective compounds is not 
uncommon. ChEMBL is an online database containing known, bioactive, small molecules. As 
of May 2017, there were 1,735,442 active compounds (of which 1,727,112 have .mol files). The 
data is curated from the available scientific literature and it covers parameters including: 2D 
structure, LogP, molecular weight, binding constants, pharmacology and ADMET data. 
Using the parameters described in section 3.2.2 to define the CTB fragment set, the fragments 
according to these filters were extracted from the ChEMBL database. This resulted in 30 
known fragment actives that had: Mw < 300 Da, cLogS > 4, 1F or CF3 containing moiety 
(example fragment in figure 3.7). This is only 3% of the available ‘fragment space’ included in 
ChEMBL; that is 960 fragments were extracted without the ‘fluorine atom’ filter (Figure 3.8). 
Also, 29 of 30 compounds only occurred once in ChEMBL, i.e. they were only active against 
one target. This could infer some selectivity, however, many of these compounds were found 
as part of the SAR exploration series and not part of a fragment screen. Therefore, their activity 
against one target is perhaps not surprising. For example, compound RAFL08 (figure 3.7) was 




Figure 3.7: Chemical structure of fragment RAFL08. 
 
Figure 3.8: A plot illustrating the ChEMBL fragment space in two dimensions: molecular mass 
and aqueous solubility. The red circles represent non-Fluorine containing compounds 
extracted from ChEMBL The blue squares represent the fluorine containing compounds.  
Also, pertaining to our objective of producing a quality, diverse library as a function of total 
cost, each compound was priced from the cheapest vendor, for 30 compounds the price was 
£3197. This was deemed out of budget, therefore a price per compound cut-off filter of £120 
was applied. This reduced the number of compounds to 22 and a final library value of £992, 
an average of £45.10 per compound. As many companies require a minimum weight order for 
custom syntheses, the benefit is that this provided enough material of each compound (~ 1 g) 
for chemical follow up of any hits. The disadvantage of ‘cherry picking’ compounds is that it 
is more expensive. These compounds were purchased and their structure and quality check 
data is presented in appendix 8.2 and 8.3 respectively.  
3.2.4. Clustered Fragment Library (CFL) 
The second method of library generation used a popular clustering method, as described in 
section 3.1.6, using the Pipeline Pilot algorithm. The input library of fragment compounds was 
eMolecules (September 2016), which is an online chemical database containing over 8 million 
compounds that are purchasable from commercial suppliers. Applying the filter sets 
illustrated in figure 3.6, reduced the number of compounds to 2625 unique fragments. Pipeline 
Pilot uses FCFP4 (Functional Connectivity Fingerprints of radius 4, see section 3.1.6.3), to 

















defined the number of clusters to 200 cluster centres, and fragments were placed into each 
cluster based on their FCFP4 score. In selecting compounds from clusters, the goal is to cover 
as much chemical space as possible, i.e. ideally one compound from each cluster. The output 
is a list of clusters containing compounds with the centroid as the first compound in the list, 
therefore priority was given to this compound (example: circled compound in figure 3.9). This 
ensures that the final selection has the highest diversity. However, this was not always 
possible with the goal of producing a low cost library as there were several compounds more 
expensive compared to the threshold of price per compound. Therefore, the compounds 
priced within the CTB threshold, from as many clusters as possible were priced to gain 
maximum diversity and minimum cost. Also, as compounds were taken from a commercial 
database, there were also salt forms of compounds present. These are undesirable as they may 
be unstable after storage in solution. This resulted in 24 compounds being selected, however, 
4 of these were from the same cluster, skewing the diversity. The overall price for 24 
compounds was £607, which was deemed reasonable for the amount provided. 
It is often easier to purchase compounds than synthesise them, therefore choosing compounds 
from clusters containing more than one compound might represent an effective approach. 
This is because fragment analogues can be easily purchased from the same cluster to allow 
rapid screening and SAR analysis. 
 
Figure 3.9: An example cluster output from the clustering protocol implemented in Pipeline 
Pilot. The circled compound illustrates the centroid of the cluster. From left to right illustrates 
the compounds in order of decreasing similarity within the cluster. 
The final library contained 24 compounds, each with a single CF or CF3 group, molecular mass 
under 300 Da, H-bond D/A > 3 and 6 respectively. Pipeline pilot uses an in built algorithm to 
calculate aqueous solubility, however, purchased compounds were double checked with 
ALOGPS 2.1 (see section 3.1.6.4) and were also found to be inside the limit. Compound 




3.2.5. Directed Diversity Fragment Library (DDFL) 
3.2.5.1. Covering Fragment Space: A new measure of diversity 
The cheminformatics work described here was completed by Dr. Steven Shave. The programming and 
calculation of A2A distances was also performed by Steven Shave. The input from myself was to aid in 
design of the algorithm in which to select the best compounds. For example, defining desirable 
properties, chemical functional groups and sensible chemical structures of fragments in the final set for 
optimisation of the final library.  
In a model library, all commercially available fragments would be purchased and screened, 
i.e. this would cover the entire accessible chemical space. However, this is impractical, 
therefore it is necessary to create a set of fragments to gain maximum diversity over the largest 
volume of fragment space. Hence, it is also necessary to be able to measure and quantify the 
diversity of a given fragment set. To do this, compounds can be represented by their 3D shape, 
a fundamental property that is directly observed in electron density maps. Assuming that 
shape complementarity is a requirement for ligand binding, it follows that a molecule with a 
similar shape could have similar binding modes and affinities. Ultrafast Shape Recognition 
(USR) is a moment-based virtual method that uses the relative positions of bonded atoms to 
describe the 3D molecular shape.162 Essentially, the molecular shape is encoded by a set of 
distributions (in this case 12 USR descriptors) that is unique to a set of spatial coordinates. 
This means that for each compound, these moments only need to be calculated once and can 
be stored easily in a database. USRCAT (Ultrafast Shape Recognition with CREDO Atom 
Types) is an extension that includes the pharmacophoric features with atom types in encoding 
compounds using a total of 60 USR descriptors. A pharmacophore is a description of the 
topological features of a molecule that contribute to the recognition of that molecule by a 
biological receptor. Including this information greatly enhances the power of the molecular 
similarity technique, pairing not only shape, but electrostatics. The similarity between 
compounds can therefore easily be calculated by taking the sum of squared differences 
between two molecules and their descriptors. This allows one to describe a simple model of 
diversity by a new parameter called the ‘All to All Distance’ (A2A). This measures the distance 
of every molecule in a library to every other molecule described by 60 descriptors, and hence, 




Figure 3.10: Compounds (red circles) represented as nodes with two descriptors (x and y 
coordinates on a 2D plane). The solid black lines indicate the distance measured from 
compound 1 to each other compound in the set. Dashed blue lines represent the distance 
measured from compound 2 to each other compound in the set. This is repeated for every 
compound included in the input fragment set. From this, an all-to-all distance can be 
calculated, measuring the diversity, or distance present between points. 
This diversity analysis was then applied to the commercial libraries to calculate the diversity 
within these fragment collections, this is shown in table 3.5. Here, the greater the A2A score, 
the more diverse the library is, and therefore it is evident that we want to optimise the A2A 
score. To do this, we take the most remote compound from the input library population, and 
move it to our selected library population (Figure 3.11). Whilst the selected library population 
remains below the desired number of compounds (N), we can select from the input library to 
maximise the A2A score. However, this is what is known as a ‘greedy algorithm’ and does not 
always find the most optimum solution.163  
 
Figure 3.11: This diagram illustrates how compounds are chosen based on maximising the 
A2A score. The most remote of the population is taken from the input set and placed into the 
‘selected’ library population. Whilst the ‘selected’ size contains less than the required number 
of compounds, the compound which maximises the A2A score is ‘picked’ from the input 
library and moved to the ‘selected’ fragment set. This is repeated until the desired number of 








































A2A distance A2A/(N*(N-1)) 
Analyticon 27 15339.3 21.85 
Asinex 1818 77110000 23.34 
Bionet 1611 44938100 17.33 
ChemDIV 342 2573070 22.06 
Enamine 5486 5.98E+08 19.88 
Life Chemicals 1631 65181800 24.52 
Life Chemicals 
Pooled 
772 14715300 24.72 
Maybridge 1540 46744700 19.72 
Otava 1018 21354400 20.63 
Prestwick 64 75777.1 18.79 
TimTec 60 62489 17.65 
Vitas-M 1464 47417200 22.14 
Vichem F-lib 335 3546450 31.70 
Table 3.5: The diversity scores of each commercially available library by its A2A metric.  
Analysing the commercial library A2A scores, if we define > 20 as a good score, is it possible 
to select compounds to generate a more diverse set by using all commercially available 
fragments. The input library was eMolecules, and a set of property filters were applied to get 
the best set of compounds to pick from. The filters prioritised were: Mw < 300 Da, cLogS > - 4, 
and single CF or CF3 group which returned 211192 fragments (Table 3.6). The best 100 
fragments were selected using the algorithm described above that maximised the A2A score. 
Immediately, the score appeared easy to improve upon, (Table 3.6), however this is clear as 
diversity must reduce with number of compounds, N. These compounds represent the 100 
best to select from commercial fragment space. However, many of these compounds contain 
unusual functionalities and are expensive to purchase. We therefore filtered the commercial 
chemical space to a single supplier, Fluorochem. This company was chosen for its relatively 








A2A distance A2A/(N*(N-1)) 
eMolecules 211192 8.94E+11 20.05 
Best 100 100 6.47E+05 65.39 
Table 3.6: The A2A scores of the eMolecules commercial fragment space and the best 100 
compounds from this input library that maximise the A2A score. 
The property filters (Mw < 300 Da, cLogS > - 4, and single CF or CF3) were applied to the 
Fluorochem compounds and this returned 4934 fragments. This was reduced to 3242 after the 
addition of a rotational bond filter (< 3). Again, the best compounds were selected to maximise 
the diversity score and these are shown for different number of compounds, N, in Table 3.7. 
The output is a list of compounds in order of generating maximum diversity. Based on 





A2A distance A2A/(N*(N-1)) 
Fluorochem 4934 3.81E+08 15.64 
Fluorochem-best-100 100 3.11E+05 31.41 
Fluorochem – filtered 3242 1.52E+08 14.43 
Fluorochem – filtered 50 6.35E+04 25.92 
Fluorochem – filtered 100 2.32E+05 23.42 
Fluorochem – filtered 200 8.41E+05 21.12 
Table 3.7: A2A scores of the fluorochem fragment set. An additional filter was included to 
reduce the total number of compounds; this was a rotational bond filter (NROT < 3) and 
removes 1692 compounds. The A2A scores from this reduced filtered set for the best 50, 100 
and 200 compounds is shown in the last column. 
Using this new measure of diversity, we were able to obtain the most diverse set of fragments 
at the lowest cost. Although fragment space coverage is very low, the diversity within our 
fragment set is high, giving the best chance of finding a hit compound. The details of all 
compound structures and quality data are given in appendix 8.2. 
3.2.6. Evaluating Fragment Libraries 
In summary, three libraries were designed to obtain the most diverse set of compounds at a 
reasonable cost. An overview of the three CTB proprietary fragment libraries is presented in 
table 3.8. The libraries are designed for screening with 19F NMR-based methods and this is 
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described in chapter 4. The fragment libraries can be screened against the PPI target focus of 
the Auer group and 2 proteins are presented in this thesis, UbE2L3 (Chapter 4) and 
NusE/NusB (Chapter 5). The average molecular weights and solubility conform to the Ro3 
parameter sets and the DDFL library A2A score was shown to be comparable to the 
commercially available libraries. This exemplifies it as a simple metric for measuring diversity 









Cost (£) A2A 
RAFL 22 189.2 -2.57 992 15.57 
CFL 24 181.3 -1.79 607 16.21 
DDFL 63 221.5 -2.93 4967 19.74 
Total 109 197.3 -2.43 6566  
Table 3.8: Overview of the designed, in-house CTB fluorinated fragment libraries. The 
number of compounds in each library (before QC) and the average Mw and cLogS are given 
to show Ro3 compliance. The cost of each library is also shown. 
Full details of compound structures and quality data are given in appendix 8.2. Quality check 
of compounds and pooling of the compound libraries is discussed in chapter 4. 
3.3. Concluding Remarks 
In conclusion, three separate methods of fragment library design were implemented in 
parallel to maximise the quality and diversity of selected fragment sets.  The first approach 
was to select fragments based on the knowledge that they were active in previous biochemical 
assays. Fragments extracted from the ChEMBL database conforming to a set of criteria were 
purchased and used to construct the RAFL set of compounds. 
The second approach, used a common clustering algorithm to explore the entire commercial 
fragment space. Fragment criteria were defined and these filters were applied to the 
eMolecules database of commercially available compounds. Fragments that conformed to the 
selected criteria were clustered according to their 2D molecular similarity. A subjective set of 
compounds were purchased from cluster sets to maximally represent the fragment space. One 
of the first steps after hit discovery is to test close analogues or larger compounds that contain 
the core of the fragment hit. It is always easier to purchase compounds than to synthesis them, 
therefore using the commercial chemical space as an input library is a useful approach. This 
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is sometimes referred to as a ‘SAR by catalogue’ approach and can rapidly increase the success 
of ligand discovery through easy access to commercially available, similar compounds.164  
The third approach was introduced to increase the chances of finding a hit compound during 
screening. A short analysis of the available commercial fragment libraries allowed one to focus 
on producing a high quality, diverse set of fragments at minimum cost. The libraries were 
designed for primary screening by 19F NMR methods. This limited the total chemical space 
coverage, however, a metric to ensure maximal diversity when selecting fragments was 
formulated. This was called the A2A score and was used to measure the diversity within 
commercial and selected fragment sets. This was the core principal of the DDFL library and 
led to the purchase of fragments that maintained high quality and diversity as a function of 
cost. This simple metric can also be used by academic groups looking to put together 
affordable, high quality and diverse libraries. 
The CTB libraries are also more amenable to a wide variety of assays as the high average, 
aqueous solubility allows for testing at much higher concentrations of ligand. Also, the 
relatively low, average molecular weight of each set means that hit rates are likely to be higher, 
conforming to the arguments proposed by Hann et al.135 The inclusion of the F atom, also 
means that 19F NMR can be used as a secondary binding confirmation method, if primary 
screening is achieved by another technique. 
The relatively small library sizes described here were created using established methods and 
shown to be far less expensive than a commercially available library. A well-established 
library is less challenging to work with and uses far less material throughout the course of 
screening.  Cherry picking, i.e. selecting the best or most desirable compounds, allowed us to 
gain enough material for multiple assays and for chemical follow up. Although a subjective 
chemical view towards ‘attractive’ fragments introduces a selection bias, this does ensure that 
hit compounds have the capacity for chemical evolution. 
The designed CTB libraries will be evaluated in the following chapters and were used for 






NMR Assay Development and 
Evaluation of Fragment Libraries 
 
This chapter contains the development of the NMR fragment screening experimental methods 
and parameters. An introduction to 19F ligand-observed NMR screening techniques and 
relevant NMR binding kinetics are discussed. NMR screening conditions are achieved by 
utilising a known fluorinated ligand to human serum albumin and compound handling and 
pooling conditions are described. The results of the 19F NMR fragment screen against UbE2L3 





4.1.1. Fluorine NMR Spectroscopy for Compound Screening 
NMR spectroscopy has been the predominant method used for screening fragments since its 
inception by Fesik and co-workers. There are a multitude of NMR methods that are capable 
of detecting binding events of small molecular ligands over a very broad affinity range. Rapid 
technological advances in cryoprobe technologies and high-field spectrometers has led to 
extensive applications of NMR spectroscopy to study protein-ligand interactions within a 
pharmaceutical perspective. 
Ligand-observed screening is ideal for NMR, advantages of this method include: small 
amount of protein required (nM – 10 μM), small amount of ligand required (excess ligand up 
to 250 μM, therefore solubility limits are good), no size limitation of protein and no isotopic 
labelling of protein required. Although, there are some drawbacks, namely ligands that have 
slow binding kinetics, i.e. high affinity (nM range), are difficult to detect. As described in 
chapter 1, STD, WaterLOGSY and relaxation-edited experiments are frequently used to detect 
ligand binding in fragment screening. The output of these experiments are 1D 1H NMR spectra 
in which changes in intensity or sign of the respective 1H signals of ligands are monitored.165–
168  
Fragment screening approaches based on 19F NMR have been extensively reviewed in recent 
literature.169 Fragment hits are identified by inspecting the 1D 19F NMR spectrum recorded in 
the presence and absence of the macromolecular target. During a ligand binding event, the 
fluorine nucleus experiences a change in the electric fields, short range contacts and even 
hydrogen-bonding effects which can cause a change in intensity (line broadening) or change 
in the chemical shift (chemical shift perturbation, CSP) of the fluorine nucleus. The fluorine 
nucleus offers several advantages, for example: 
 100 % natural abundance 
 Good sensitivity (0.83 % of the 1H) 
 Large chemical shift range 
 No endogenous background signals (i.e. from buffers or proteins) 
The final point above is particularly interesting as this offers possibilities to screen fragments 
in vivo. Another interesting view of 19F incorporation into drug molecules is their propensity 
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to form hydrogen bonds. A review by Bissantz shows that interactions between CF and polar 
hydrogen atoms frequently occur in the PDB.170 Another study also observed a thrombin 
inhibitor change its binding mode upon fluorination such that a CF---HN interaction is 
formed.171  
A good example of the broad range of applicability of 19F NMR methods is that of Dalvit et al 
who describe a screening method termed 3-FABS (3 Fluorine Atoms for Biochemical 
Screening). This method is based on the change in chemical shift of a trifluoromethylated (CF3 
containing) substrate when it is converted into a product by an enzyme. If a compound is 
present that inhibits the enzyme, the substrate will be converted less rapidly and the fluorine 
chemical shift changes will also decrease. Clearly the leader in the application of 19F NMR for 
screening, Claudio Dalvit and co-workers also pioneered another technique, called FAXS 
(Fluorine chemical shift Anisotropy and Exchange for Screening) which relies on the use of a 
weak-medium affinity fluorinated spy molecule. The relaxation of the fluorinated molecule is 
monitored in the absence and presence of protein and non-fluorinated screening compounds. 
It is based on a competition assay, where a hit is detected if the fluorinated spy molecule has 
a reduction in binding. Screening compounds are then deconvoluted by individually 
measuring compounds from the hit pool.  
19F NMR can also be used for protein-observed screening approaches. Protein-observed 
approaches require the incorporation of a fluorinated amino acid into the primary sequence. 
Gee et al describe the small molecule screening of the CREB binding protein (CBP) (CBP/p300, 
KIX) PPI through protein-observed 19F NMR spectroscopy (PrOF NMR). They replace native 
tyrosine residues with 3-fluorotyrosine and monitor the chemical shift of the fluorine 
resonance in the presence of screening fragments. This yielded seven final fragment hits 
deemed suitable after deconvolution. In this instance, a disadvantage of PrOF NMR is that 
deconvolution of hit fragments requires repetition and analysis of individual fragments. 
In this chapter the applied experimental aspects of NMR-based fragment screening and 
considerations for optimum assay set up are described. In the following section the 
considerations for determining the ligand – protein dissociation constant, KD, by NMR 





4.1.2. Ligand Binding at Thermodynamic Equilibrium and Relevance to NMR 
Spectroscopy 
NMR is a powerful technique to study the binding interactions of proteins and ligands. The 
characterisation of the binding properties by several NMR spectroscopic methods has been 
extensively reviewed.172 Here, I will discuss the binding of the theoretically correct 
mathematical treatment of complexation reactions relevant to the NMR spectroscopy 
techniques applied in this thesis. 
A simple advantage of NMR for fragment screening is that it can detect binding using 
compound concentrations well below the KD of the interaction. Using low concentrations of 
compound is advantageous as this lowers the risk of nonspecific binding (false positives)  by 
reducing aggregation.173 When a small molecule ([L]) binds to a larger macromolecule ([P]) to 

















Where, [P]f, [L]f and [PL] are the concentrations of free protein, free ligand and protein-ligand 
complex respectively.174 The rate constants, koff and kon describe the rate of chemical exchange 
between the free and bound states of the protein-ligand complex. Assuming a diffusion 
controlled on rate, where kon is approximately 107 s-1.M-1, the koff can be estimated according to 
table 4.1. 
KD koff (s-1) 
1 mM 10000 
1 μM 10 
1 nM 0.01 
Table 4.1: Relationship between KD and koff. Approximate off rates (koff) according to KD 
assuming a diffusion controlled on rate (kon of 107 s-1.M-1). 
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Estimates of koff are important when interpreting NMR binding experiments and there are 
three possible conditions under which ligand binding occurs175: 
1) Fast exchange: here the koff is greater than the difference in chemical shift between the 
free and bound states, i.e. a high KD (low affinity). For a system in fast exchange, the 
observed NMR signal is then a weighted average of the free and bound states and one 
will observe a smooth transition of the signal from the free state to the bound state.  
2) Intermediate exchange: koff is approximately equal to the difference in chemical shift 
between the two states. This results in severe line broadening effects or even complete 
disappearance of the signal. 
3) Slow exchange: where koff is less than the difference in chemical shift on the NMR 
timescale. This results in two separate signals being observed, one corresponding to 
the free state, the other to the bound state. 
Chemical exchange refers to the exchange between free and bound states of the ligand-protein 
complex. If the populations between free and bound states are unequal, then the chemical shift 
(δobs) observed during the fast exchange limit is a weighted average172: 
𝛿𝑜𝑏𝑠 = 𝛿𝑓𝑝𝑓 + 𝛿𝑏𝑝𝑏 
Equation 4.3 
Where δf and δb are the chemical shifts in the free and bound states respectively, and pf and pb 
are the fractions in the free and bound states respectively. Any differences between δobs and δf 
therefore indicate a hit in a NMR screen. In setting up NMR experiments it is important to 
estimate the fractions of each component present in solution, using equation 4.2 this can be 
expressed as a quadratic equation with the solution: 
[𝑃𝐿] =





Where [L]0, [P]0 and [PL] are total concentrations of ligand, protein and complex respectively. 








Equation 4.5 and 4.6 
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Where, pLb is the fraction of ligand bound and pPb is the fraction of protein bound, these are 
simulated in figure 4.1 at varying dissociation constants. 
 
 
Figure 4.1: Graphical simulations of equation 4.4 to represent percentage mole fractions bound 
of ligand and protein at varying KD values. [P]0 is constant at 10 μM. Top: The percentage of 
protein bound vs ligand concentration at KD 100 μM (black curve), 500 μM (blue curve) and 1 
mM (red curve). Bottom: The percentage of ligand bound vs ligand concentration at KD 100 
μM (black curve), 500 μM (blue curve) and 1 mM (red curve). Simulations were performed 
using equation 4.4 and plotted in Microsoft Excel. 
In the slow exchange limit, i.e. when koff is slower than the chemical shift difference between 
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appears at a different chemical shift. This makes KD determination difficult using titration 
experiments. Feeney et al. have studied the effects of intermediate exchange processes on NMR 
observed binding curves.176 They describe that where the fast exchange limit is commonly 
assumed (equation 4.3), this can result in considerable error of up to two orders of magnitude 
in KD. They acknowledge that it is essential to use ligand concentrations of the order of the 
protein concentration to obtain accurate KD results. However, usually ligand-observed 
methods are performed in the presence of an excess of ligand. Therefore, the fraction of ligand 
bound is important to estimate the effect of the observed NMR parameter (e.g. chemical shift, 
linewidths and/or intensities) in ligand-observed NMR. The optimal concentrations to use in 
the screen to maximise the response is discussed in section 4.2.4. The following sections 
describe two methods for the determination of protein-ligand dissociation constants by NMR 
spectroscopy. 
4.1.2.1. Differential Chemical Shift Perturbation (dCSP) 
To quantify the protein-ligand interaction, the objective is to deconvolute the mole fractions 
of the bound and free species. Using 19F ligand-observed NMR as a reporter nucleus, Jordan 
et al introduce a method called differential chemical shift perturbation (dCSP) for the 
determination of dissociation constants. They describe the difference between the chemical 
shift as: 
𝜐𝑜𝑏𝑠 − 𝜐𝑓𝑟𝑒𝑒 = 𝑝𝐿𝑏 × Δ𝜐
𝑎𝑝𝑝 
Equation 4.7 
Where νobs and νfree are the frequency (in Hz) of the bound and free states, pLb is the fraction of 
ligand bound and Δνapp is a complex function of the nuclear and kinetic parameters. As the 
ligand is in vast excess over the protein concentration ([L]0 >> [P]0) then the fraction of ligand 






















This is an interesting, yet novel, approach to KD determination and the authors validated the 
method by comparison to SPR data in parallel45 (see appendix 8.3.2 for derivation). 
4.1.2.2. Equilibrium binding in HSQC-based NMR spectroscopy 
The more frequent methods of KD determination by NMR utilise changes in protein resonance 
on addition of ligand. In these experiments, ligand binding is monitored by perturbations in 
the 15N HSQC spectra of the target protein, this is implemented in Chapter 5. 
An important advantage of protein-observed NMR titrations, is that it is possible to observe 
the fully bound state, i.e. conditions under a fully saturated protein. This means that the 
maximum NMR observable parameter (e.g. chemical shift) can be measured directly. To 
analyse [1H, 15N]-HSQC spectra upon ligand binding requires one to weight the contributions 
of each nucleus to the binding event, this is defined by the average weighted chemical shift 
difference, Δδnorm: 
∆𝛿𝑛𝑜𝑟𝑚 = √(∆𝛿
1𝐻)2 + (0.1[∆𝛿15𝑁])2 
Equation 4.11 
This equation describes the contribution of each nucleus to the average distance moved by the 
resonance signal. The scaling factor, 0.1, in equation 4.11 has no theoretically justified value, 
and values have ranged from 0.1 – 0.45.177 A threshold value of Δδnorm = 0.04 ppm is considered 
to indicate that the corresponding amino acid residue is involved in the binding interaction.178 
According to Fesik et al the lower limit for detecting 1H/15N chemical shift changes is 20% 
occupation of the proteins binding sites.179 Analysing figure 4.1, it can be seen that for a KD of 
~1 mM (red curve), a ligand concentration of ~250 μM ([P]0 = 10 μM, 1:25 molar ratio) is 
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required to saturate 20% of the protein binding sites. In HSQC-based NMR screening, the total 
protein concentration, [P]0, is lowered to reduce detection of weak affinity (> 1 mM) binders. 
The dissociation constant is obtained by monitoring the chemical shift change of the backbone 
amide residues as a function of ligand concentration. Multiple binding curves can be 
determined for separate residues and the KD value averaged over all residues that shift in the 
spectrum. They are then fitted by non-linear regression analysis to: 
∆𝛿𝑛𝑜𝑟𝑚 = ∆𝛿𝑚𝑎𝑥





Where Δδnorm is the observed change in the chemical shift from the free state and Δδmax is the 
maximum chemical shift achieved at saturation (obtained during fitting). An extensive 
analysis has shown that the optimal protein concentration, [P]0 is 0.5 KD. The ligand should 
ideally reach a molar ratio of 10:1 (ligand:protein) to gain an accurate KD measurement.172,180,177 
The methods described in sections 4.1.2.1 and 4.1.2.2 are important for the analysis and 
interpretation of NMR data presented in chapter 5. 
4.1.3. Target Selection 
The protein target for screening is the ubiquitin conjugating enzyme, UbE2L3. Applying a 
parallel fragment approach (to the peptide building method, chapter 2) it is hypothesised to 
give a greater chance to discover novel ligands. The motive for targeting this protein has been 
described in Chapter 2.1.8. 
4.1.3.1. Small Molecule E2 Conjugating Enzyme Inhibitors 
The success of clinically developed proteasome inhibitors has driven awareness toward the 
discovery of inhibitors for the E1-E2-E3 pathways. Although small molecule inhibitors are 
scarce for the E2 class of enzymes, advances in screening techniques has led to the discovery 
of increasingly unique inhibitors of these enzymes. Table 4.2 shows a selection of E2 





Target E2 Name Structure Description 
UbE2R1 CC0651 
 
Discovered from HTS for 
in vitro ubiquitination of 
p27. Allosteric binding to 
UbE2R1 causes long 
range conformational 
changes and inhibits 







virtual screening of the 
ZINC database led to 
discovery of a triazine 
core moiety for chemical 






Selectively blocks the 
formation of E2-SUMO 
thioester by binding to 
UbE2I. Discovered using 
an in situ sumoylation 
assay.183 
Table 4.2: Examples of E2 enzyme inhibitors currently being developed for clinical use. 
4.1.4. Aims of this chapter 
The aim of the work reported in this chapter was to develop and optimise the NMR assay 
parameters to the 19F-FBS screening process and evaluate our fragment libraries against the 
ubiquitin conjugating enzyme UbE2L3. Whilst it is relatively simple to start screening 
fragments, ultimately there are practical considerations that must be taken into account to 
deliver success. These include: choosing the correct NMR experiment, fragment library design 
(see Chapter 3) and target selection. Also, experimental considerations of ligand-observed, 
fluorine fragment-based NMR screening include: how many compounds per pool, CF vs CF3 
group, protein:ligand ratios, DMSO concentration and quality control of fragments. The 




4.2. Results and Discussion 
4.2.1. Preparing Fragment Stocks 
The first consideration for beginning a fragment screen is to prepare suitable fragments stocks 
so that compounds can be easily stored and distributed into respective pools. Stock 
preparation is also a rudimentary measure of poorly behaving compounds, such as 
aggregators or insoluble compounds. The fragments were purchased from commercial 
vendors (see chapter 7.3.1) in sufficient amounts (mostly > 50 mg) to test solubility and to 
allow running of sufficient screens. The purchased amount would also provide enough 
material for any biochemical follow up of hit compounds. Also, compounds that were 
available as salts were avoided as these have a higher propensity to precipitate from DMSO 
after multiple freeze-thaw cycles.184 
Fragments were stored in 100 % DMSO at either 10 or 100 mM concentration depending on 
solubility (see chapter 7.3.1) and stored at -20 °C. Fragments are stored as individual 
compounds, and not as pools for screening, as this reduces the probability of fragments 
reacting over time. Fragment concentration was determined by weight and the calculated 
amount of non-deuterated DMSO was added. Solubility was measured by visual inspection 
and all compounds were soluble at these concentrations, even after multiple freeze-thaw 
cycles. The stock concentration was determined by the desired concentration in the fragment 
screen (100 μM, see section 4.22). For example, screening a mixture of 10 compounds at 100 
μM (500 μl volume), with a maximum of 1% DMSO concentration, requires individual 
compound stock concentrations of 100 mM. Fragment samples were also diluted to 100 μM in 
25% acetonitrile:water (ACN:H2O) for quality check (QC) of purity and identity by HPLC and 
LCMS (0.1% final DMSO concentration). Fragments were labelled according to the library they 
originated from and the ID within that library, for example, DDFL30: Directed Diversity 
Fragment Library, compound number 30. Figure 4.2 shows an example of QC analysis for 
compound DDFL30 which passed QC criteria and compound RAFL03 which failed and was 










HPLC: tR = 13.3 mins HPLC: tR = N/A 
 
N/A 
MS (ESI): C11H9F3N2O. [M+H]+calc 243.1; 
[M+H]+obs 242.9 
MS (ESI): no peak observable by LCMS 
Figure 4.2: An example of QC analysis for compound DDFL30 and RAFL03. Concentration of 
compound is 100 μM in 25% ACN/H2O (0.1% DMSO). Top: HPLC chromatogram, Rt = 13.3 
minutes, > 95% purity determined by peak area. Bottom: LC/MS spectrum, [M+H]+calc = 243.1. 
[M+H]+obs = 242.9. 
4.2.2. Reference NMR spectra and compound pooling 
As the NMR method used for screening is a fluorine ligand-observed method, 19F reference 
spectra of individual compounds were recorded. Ideally, the NMR screen is performed under 
the same buffer conditions that the target protein is stable in, therefore, reference spectra were 
collected in a common biological buffer: 20 mM HEPES (4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid), 100 mM NaCl, 10% D2O at pH 7.5. One dimensional 19F 











































































spectrometer equipped with a BBFO+ room temperature probe (Double Resonance Broad 
Band probe, 19F optimised) operating at a 19F frequency of 376.5 MHz using 1H decoupling, a 
spectral width of 111111 Hz (295 ppm), an acquisition time of 1.18 s, and 256 scans with a 
relaxation delay of 1.5 s. This yielded experiment times on the order of 11 minutes each and a 
60 position sample changer permitted high automation (see chapter 7.1.3.1). The sample 
diameter was 5 mm, and the minimum volume of the NMR tube is 500 μl. The 19F spectra are 
used to confirm purity (i.e. a single resonance) and examined for line broadening (which 
would indicate compound aggregation) (figure 4.3). 1H decoupling also drastically reduces 
the complexity of the spectrum and this allows a single resonance to be defined per compound 
and hence makes deconvolution of hit compounds easier. 
 
Figure 4.3: Left: 1D 19F NMR spectrum of compound DDFL30. 19F NMR (376 MHz, Buffer + 
10% D2O), δ -62.34 ppm. Right: 1D 19F NMR spectrum of compound RAFL03. 19F NMR (376 
MHz, Buffer + 10% D2O), δ -122.3. Compound RAFL03 shows severe line broadening of 
fluorine resonance and was not included in the final screen. See appendix 8.3.3-5 for QC 
analytics of all tested fragments. 
 
Pooling fragments is essentially a method to reduce the amount of protein needed per screen 
and reduce the overall time for data collection. Typically, 1H ligand-observed NMR methods 
use fewer than 5 compounds per pool.185 However, the use of the fluorine resonance 
dramatically reduces spectral complexity, therefore, it is possible to screen up to 30 fluorine 
compounds per pool.186 This is also dependent on the solubility of fragments and protein 
tolerance to organic solvents. It is necessary to design the pools in such a way as to minimise 
potential chemical reactions between compounds and maximise the difference between signal 
resonances of compounds. For example, fragments for pooling are sorted by chemical shift 
(lowest to highest), then the first fragment is added to pool 1, the second to pool 2, and so on, 
until the desired number of pools is achieved. This minimises the spectral overlap and hence, 
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any changes in chemical shift of fluorine resonances will be more easily identified (see figure 
4.5). Another aspect to consider when pooling fragments is the presence of CF (single fluorine) 
or CF3 (trifluoromethyl) containing moieties. Due to synthetic chemical methods for 
synthesising a fluorine containing fragment, it is usually more convenient to insert a 
trifluoromethyl (CF3) group than a single fluorine atom. This is advantageous as a CF3 group 
is much more sensitive and therefore a lower concentration of fragment can be used. The 
integral (in effect the intensity) of the resonance signal is proportional to the number of nuclei 
causing it, therefore a CF3 group is 3 times more intense than a CF group (figure 4.4). This led 
me to sort fragments into CF and CF3 containing pools in order to achieve a similar intensity 
of signals for ease of interpreting spectra. Also, many of the fluorinated compounds purchased 
are fluorinated aryl rings (i.e. Ph-CF3 or Ph-F: Ph = phenyl). This meant there was a very small 
range of chemical shifts present in some pools. The typical range for a Ph-F chemical shift is -
100 to -200 ppm, and for Ph-CF3 is -50 to -90 ppm. Since the DDFL library consisted mainly of 
Ph-CF3 containing groups, 10 compounds per pool was considered sufficient to minimise the 
spectral overlap. Also, 10 compounds per pool gives a final DMSO concentration of 1%, which 
is generally not detrimental to the protein being screened.  
 
Figure 4.4: Effect of F and CF3 on signal intensity. The CF3 containing compound (red 
spectrum) is essentially 3x the intensity of the CF containing compound (blue spectrum). This 





Figure 4.5: An example spectrum of a fragment pool containing 10 fragments (each present at 
100 μM) in NMR buffer. Each resonance signal corresponds to a single, CF3 containing 
compound. The spectrum was recorded on a Bruker AVA 400 MHz spectrometer in NMR 
buffer. 
After QC analysis by orthogonal analytical methods (HPLC, LCMS and 19F NMR), compounds 
were selected or removed based on the result (see appendix 8.3 for QC data). The threshold 
for QC analyses was > 95% purity by HPLC and a single 19F resonance. Compounds that did 
not pass QC checks were discarded and not included in the final screen (theses are highlighted 














RAFL 22 -7 15 3 5 
CFL 24 -3 21 5 4.2 
DDFL 63 -12 51 5 10.2 
Table 4.3: This table shows the final library compositions after QC analysis of fragment 
compounds and pooling strategies. Compounds that did not pass QC checks were discarded 
and not included in the final screen. 
This rigorous testing exemplifies how critical QC of fragments prior to use can be. This is also 
something not usually supplied with commercial fragment libraries. The fragment libraries 
were designed to use 19F NMR as the primary biophysical screening method (i.e. via 
incorporation of an F atom), therefore, to develop the 19F NMR screen requires optimisation 
of assay parameters. The practical considerations necessary are to maximise the signal and 
response from hit compounds. The NMR experimental parameters for fragment screening are 




4.2.3. Developing the 19F NMR Screening Parameters 
To optimise the screening parameters requires a compromise between the ability to detect 
low-affinity binders, and the need for high throughput capacity. To validate 19F NMR as an 
effective biophysical screening method the binding of a known fluorinated fragment to human 
serum albumin (HSA) was measured using a range of experimental conditions. HSA is widely 
used as a model system to study small molecule interactions as it binds to a wide range of 
ligands and is stable in many buffer solutions, therefore it is suited to a variety of assays. The 
medium affinity fragment (FBA, KD = 41 μM, figure 4.6)40 was used as a control molecule to 
determine optimum assay parameters for screening the fragments libraries. HSA was 
dissolved in the same assay buffer (20 mM HEPES, 100 mM NaCl, pH 7.5, 10% D2O) that the 
fragments were measured in. A series of experiments using this system was performed to 
determine the optimum assay conditions for setting up the spectrometer and for gaining the 
maximum observable signal (see chapter 7.3.2 for materials and methods). 
 
Figure 4.6: The single fluorine-containing control molecule (FBA) has a KD of 41 μM to HSA 
as cited in the literature.187 It also conforms to the fragment property filters described in 
chapter 3 (< 300 Da, cLogS > -4 ([-1.67]calc), one CF, NROT < 3, H-bond D/A < 3). 
19F NMR ligand-observed methods involve the detection of changes in the characteristics of 
the ligand spectrum. In this case, changes in the 1D 19F NMR spectrum will provide an 
indication of ligand binding, as described previously. There are several parameters that need 
to be optimised in order to obtain the best signal in the most efficient manner, including: 
ligand concentration and the number of scans in the NMR experiment. The optimum 
concentration for detection of a singly, fluorinated fragment (FBA) was determined to be 100 
μM with 256 scans (figure 4.7). This gave a measurement time of around 11 minutes which is 
reasonable for a screening campaign (table 4.4). Also, the signal/noise ratio (S/N) at 256 scans, 
which increases with the square-root of the number of scans (√𝑁𝑆), is also practical for ligand 
detection (table 4.4). 
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Figure 4.7: Optimisation of assay parameters. Left: The spectra show the increase in intensity 
of the signal on increasing the number of scans, the corresponding number of scans from 1 – 
5 were 2048, 1024, 512, 256, 128. Right: The spectrum shows the effect of increasing the number 
of scans on the S/N ratio (spectra are intensity normalised). 
No. No. of Scans Intensity Ratio S/N Ratio Experiment time 
1 2048 1.00 131.26 01:31:28 
2 1024 0.51 94.25 45:44 
3 512 0.27 70.56 22:54 
4 256 0.13 49.46 11:25 
5 128 0.06 32.09 5:42 
Table 4.4: Overview of the NS, S/N and experiment time. Calculated intensity ratios and 
signal/noise (S/N) ratios of a singly fluorinated compound (FBA) as a function of number of 
scans and the experiment time (see chapter 7.3.2 for materials and methods). The spectra were 
analysed with MestReNova NMR suite. 
4.2.4. Protein:Ligand Concentration Ratio 
A concentration series was measured for the FBA compound against HSA to determine the 
optimum protein:ligand ratio for the maximum response. FBA was shown to bind to HSA by 
a distinct line broadening of the signal in the bound state. The KD of FBA is 41 μM which is 
approximately in the intermediate chemical exchange rate range (~koff = 410 s-1), therefore line 
broadening is the predominant observed effect.  This experiment shows the sensitivity of the 




Figure 4.8: Line width broadening of control molecule FBA (KD = 41 μM). The plot shows the 
effect of increasing the HSA concentration on the fluorine linewidth. The compound 
concentration was 100 μM and the HSA concentration ranged from: 1) blank; 2) 100 nM; 3) 500 
nM; 4) 1 μM; 5) 2.5 μM; 6) 5 μM.  
It is clear that increasing the concentration of HSA increases the fraction of the bound ligand. 
Even with a small fraction of the bound ligand (table 4.5, spectrum 5, pb = 0.018) the sensitivity 
of the fluorine nucleus to changes in it’s electronic environment show are observable by an 
increase in linewidth and consequent decrease in intensity. Table 4.5 shows the absolute 














1 0 0 5.07 1 1.57 
2 0.1 0.7 4.97 0.98 1.75 
3 0.5 3.5 4.79 0.94 1.81 
4 1 7.1 3.98 0.78 2.02 
5 2.5 17.6 2.67 0.53 3.10 
6 5 35.1 1.45 0.29 5.48 
Table 4.5: The effect of line broadening and intensity changes on increasing the bound fraction 
of FBA. FBA was kept at a constant concentration (100 μM) and the protein (HSA) 
concentration was varied. The intensity ratio is defined as the ratio between the intensity of 
the protein containing sample and the non-protein containing sample. 
To gain the maximum signal after a binding event, is therefore a compromise between ligand 
and protein concentration, i.e. the maximum signal gained is with the largest fraction of ligand 
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bound (table 4.5). The volume of the NMR tube (5 mm sample diameter) requires 500 μl of 
solution, this influences the amount of protein needed to gain a sufficient ligand:protein 
concentration ratio whilst also limiting protein consumption. The maximum fraction of the 
ligand bound to the protein will give the greatest signal, however, we need to maintain an 
observable signal using the minimum amount of protein. For singly fluorinated compounds 
(CF), 100 μM is the minimum concentration for detection by 19F NMR (as stated by Bruker). 
From the analysis of FBA binding to HSA (table 4.5), a significant line-broadening effect is 
observed at pb[L] = 0.018 (figure 4.8, spectrum 5 and figure 4.9, yellow dashed line) and the 
signal intensity reduces by approximately 50%. This fraction of ligand bound (pb[L] = 0.018) is 
therefore the limit to reliably observe a ligand binding event. To determine the optimal 
ligand/protein ratio, a simulation of the fraction of ligand bound (at constant ligand 
concentration of 100 μM) vs KD at varying protein concentrations was performed (figure 4.9). 
 
Figure 4.9: Simulation of fraction of ligand bound vs dissociation constant, KD. The plot shows 
a simulation of the fraction of ligand bound vs the dissociation constant at different protein 
concentrations (ligand concentration is constant at 100 μM). The black curve is [P]0 = 50 μM, 
red curve is [P]0 = 25 μM and the blue curve is [P]0 = 10 μM. The yellow dashed line indicates 
the threshold value (0.018) for reliable detection of the bound species under these 
experimental conditions.  
A simulation using a constant protein concentration of 10 μM (blue curve, figure 4.9), shows 
an intersection at approximately 500 μM. This therefore implies that, under these conditions, 
we could reliably see compounds in the range of 500 μM KD and lower which is very good for 
a fragment-based screen. A 10 μM protein concentration equates to 5 nanomoles of material 
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to 50 – 150 μg of protein per pool. There are 13 pools covering all fragments in the library, this 
gives a range for amount of protein as 0.65 mg to 1.95 mg (10 – 30 kDa) per screen. Typically, 
the yield of protein from a 1 L bacterial expression culture is 1 – 10 mg which is sufficient for 
multiple screens and fragment hit validation. The final conditions for screening were 
determined to be [L]0 = 100 μM and [P]0 = 10 μM. This would give a practical sensitivity for 
the fluorine signal, a reasonable throughput for protein consumption and a quantifiable 
measure of the fraction of ligand bound.  
4.2.5. 19F NMR Screening of the Ubiquitin Conjugating Enzyme UbE2L3 
As described in chapter 2, the ubiquitin conjugating enzyme E2L3 (UbE2L3) is often referred 
to as “difficult” or “undruggable” target. Due to this target status, we expected that all possible 
chemical and biological matter might be needed to find access points into further drug 
discovery. In this work we applied the newly developed OPPG technique (see chapter 2.3) 
which, in a first round using the pF-Phe centred dipeptide library as starting point, turned out 
to only deliver very low affinity binders and in addition was not showing increased affinity 
with library length expansion. While a variation of fluorinated, non-natural amino acid 
centred dipeptide libraries might support the identification of new targetable binding pockets, 
we progress in this work with the screening of our in-house designed 19F-fragment libraries, 
see Chapter 2. The in-house, designed, fluorinated fragment libraries (Chapter 3) were 
evaluated against this protein to discover novel ligands. The protein was expressed and 
purified (described in Chapter 2.3.3) and dialysed into NMR assay buffer (excluding D2O: 20 
mM HEPES, 100 mM NaCl, pH 7.5) (see chapter 7.2.3 for materials and methods). 
4.2.5.1. Enzymatic Functional test of UbE2L3 (Carried out with Dr Joanna Koszela) 
The functional viability of the UbE2L3 enzyme was assessed to confirm the protein is active 
under the same conditions as applied for the NMR screen (i.e. buffer, temperature, pH and 
DMSO concentration). A simple, gel-based enzymatic assay was used to measure the activity 
of E2 conjugating enzymes. This involves incubating a mixture of the E2 enzyme, an E1 
enzyme, ubiquitin protein and ATP (see figure 4.10). The E2 protein is verified as active by a 






Figure 4.10: Schematic showing the initial steps of the ubiquitin proteasome cascade. The E2 
enzyme is ‘loaded’ with ubiquitin via a covalent thioester bond, and the change in molecular 
weight is detected by SDS-PAGE analysis. 
The fortunate characteristic of UbE2L3 is that it forms a covalent complex with only a single 
ubiquitin protein. Therefore, a single band at ~ 27 kDa (UbE2L3 + ubiquitin) is observed (L4, 
figure 4.11) corresponding to the E2-ubiquitin complex.  
 
Figure 4.11: SDS-PAGE gel for the UbE2L3 functional enzymatic assay. L1: molecular weight 
marker; L2: no ATP control; L3: no UbE2L3 control; L4: ubiquitin, ATP, E1 and UbE2L3; L5: 
DTT containing control (see chapter 7 for materials and methods). 
4.2.5.2. 19F NMR Screening of the UbE2L3 enzyme 
All 13 fragment pools from the 3 CTB libraries (RAFL, CFL, DDFL) were analysed for chemical 
shift changes and/or line broadening effects on the addition of 10 μM UbE2L3. However, there 
were no evident perturbations to the chemical shift on addition of protein. This indicates that 
there were no fragment hits in the fluorine fragment libraries. The 1D 19F NMR spectrum 
shown in figure 4.12 is an example superposition from the DDFL library containing 11 
fragments. The blue spectrum is compound only and the red spectrum contains 10 μM 
UbE2L3. There is no significant change in peak shape, intensity or chemical shift of any 























fragments in this pool. Therefore, it is considered that there are no binding interactions to the 
protein occurring. 
 
Figure 4.12: Superposition of no protein (red) and protein containing (blue) 1D 19F NMR 
spectra. It is an example pool of fragments from the DDFL library (11 fragments in the pool). 
There is a small decrease in intensity of some peaks on addition of protein, however, this was 
not considered as strong enough to induce a start of chemistry efforts for identification of 
promising hit compounds. 
Figure 4.13 shows a histogram of the observed chemical shift change (Δδ) for all compounds 
screened against UbE2L3. Using a threshold of 3 standard deviations from the baseline, the 
calculated threshold value is 1.2 Hz. This identifies 4 compounds with a chemical shift above 
this value (figure 4.13). The largest change in chemical shift is Δδ 1.50 Hz (deconvoluted to 
compound DDFL09). However, such a small change in chemical shift indicates a low affinity 
binder (> 1 mM) and it was therefore considered that considerable chemical effort would be 
needed to increase the Ube2L3 binding affinity of all the primary hit fragments. Also, gains in 
affinity resulting from SAR analysis would likely be minimal as each compound is structurally 
dissimilar. Therefore these fragments were not pursued further. This would also have 
prevented to follow up with the main goal of the thesis, namely to design, establish and 
explore new 19F-fragment libraries in the Auer lab. It was therefore decided to focus efforts 
towards a next PPI target of different origin and thereby experiment with possible binding 









Δδ 1.50 Hz 
DDFL39 
Δδ 1.47 Hz 
DDFL53 
Δδ 1.24 Hz 
RAFL14 
Δδ 1.17 Hz 
Figure 4.13: Top: Histogram of 19F NMR chemical shifts of each compound screened against 
UbE2L3. The compound concentration was 100 μM and protein concentration was 10 μM. The 
change in chemical shift (Δδ) was calculated by subtracting the resonance frequencies of the 
protein containing spectrum from the compound only spectrum. The solid orange line 
indicates a threshold value that is 3 standard deviations from the Δδ Hz. This was used as the 
cutoff for identification of possible ligands. The red bars are the RAFL library compounds; 
green: CFL library; blue: DDFL library. 
Target druggability is a term used in drug discovery to measure the likelihood that a 
molecular target will bind with high affinity to a small, drug-like molecule. A high 
druggability score is usually assigned based on the hit rates from HTS or FBDD campaigns, 
for example, Hajduk et al refer to fragment screens as a prediction of the success of FBDD.188 
The concept has gained attention in Pharma where a high probability for success is 
paramount, for example, AstraZeneca are now using target druggability as a measure on 
which targets to pursue.189 
To continue pursuit of this target may require extension to the chemical space coverage of the 



















3-FABS NMR screening approach could be applied here. This is an enzymatic reaction in 
which ubiquitin is covalently attached, via a thioester, to the E2 conjugating enzyme. Using a 
fluorinated amino acid at the N-terminus of ubiquitin would provide a useful probe for 
monitoring this reaction. Screening with non-fluorinated fragments (hence a greater chemical 
space coverage) would then be a possibility to discover novel ligands. Also, many fragment 
screening approaches based on 19F utilise a T2 relaxation based experiment as this parameter 
can be more sensitive.190 This is a more direct measure of binding and is discussed in more 
detail in chapter 5. 
4.3. Concluding Remarks 
In conclusion, the designed fluorine fragment libraries (RAFL, CFL and DDFL, chapter 3) were 
established for use in a 19F NMR-based screening approach, then quality checked by multiple, 
orthogonal biochemical methods (HPLC, LCMS and 19F NMR) to determine purity and 
identity. Compounds that did not pass these QC checks were discarded for use in the final 
screen. Compounds were also sorted by 19F chemical shifts and designated to specific pools to 
minimise spectral overlap. The optimum concentrations for 19F NMR screening parameters 
were a [L]0 of 100 μM and [P]0 of 10 μM. This gave a final molar ratio of 10:1 (ligand:protein) 
to provide a reasonable throughput for protein consumption and a visible binding response. 
A consideration for future screening conditions is to use a lower concentration of CF3 
containing fragments. The DDFL compounds all contain a CF3 moiety, therefore for future 
screening campaigns the fragment concentration can be reduced to maximise the complex 
concentration and, hence the fluorine signal response.  
It is also shown how important that rigorous QC of fragments be performed prior to screening. 
All compounds are checked for aqueous solubility, aggregation and purity to give the highest 
quality fragment libraries and fragments that did not pass QC checks were discarded. 
UbE2L3 was screened for hit fragments by 19F NMR, however this fragment screen yielded 
hits with high likelihood of mM affinity. Chemical expansion was considered too demanding 
to tackle in this thesis, and gains from SAR analysis were not thought to present a worthwhile 
advantage given the limited capacity. Screening of other PPIs is therefore necessary to assess 
the diversity and deliverability of the fragment libraries. Also, screening multiple targets with 
the same library can assess the quality of diversity and fragments. It is highly likely that 
screening multiple PPIs would not deliver the same success. 
127 
 
In summary, the collection and analysis of fluorinated fragments was carried out and an initial 
screen with UbE2L3 was performed. It was decided to exploit and analyse the fragment 









Fragment Based Screening of the 
Bacterial PPI NusE/NusB 
 
The work presented in this chapter describes the screening of the bacterial PPI target 
NusE/NusB by 19F NMR with the fluorinated fragment libraries described in Chapter 3. The 
introduction presents the target and elucidates the importance of this PPI in the context of a 
potential antibiotic development. In the results section the details of the fragment screen and 
follow up of confirmed hit compounds are presented. The chapter concludes with describing 






Due to antibiotic resistance, many bacterial infections have become impossible to treat,191 
particularly multidrug resistant strains for example the ESKAPE pathogens: Enterococcus 
faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas 
aeruginosa and Enterobacter. Therefore, the identification of new targets and resistance 
pathways is essential for developing next-generation antibiotics to combat this. An example 
of a recent success story that aims to target this issue is the identification of AZD5099 by 
AstraZeneca. AZD5099 was identified in a fragment-based screen that targeted the bacterial 
topoisomerase II enzyme.192 Multiple rounds of optimisation to compound AZD5099 resulted 
in it entering clinical trials for the treatment of bacterial infections caused by Gram-positive 
and some Gram-negative bacteria. As shown in figure 5.1, a pyrrolamide scaffold identified 
in the fragment-based screen was developed into a potent (< 100 nM IC50) inhibitor of bacterial 
topoisomerases. 
 
Figure 5.1: Initial fragment hit (5.1) against the bacterial topoisomerase II enzyme (left) and 
the final clinical candidate (5.2, AZD5099, right) that was developed through many rounds of 
medicinal chemistry and is currently in Phase I clinical trials. 
However, very few new drugs are in clinical development to treat bacterial resistant 
infections. As described previously, PPIs are an emerging class of drug target and there are 
now a large number of publications showing that small molecule inhibition of PPIs is a feasible 
approach.193,194 A mounting body of research is now investigating the bacterial interactome to 
identify essential PPIs involved in bacterial growth and resistance.195  
5.1.2. Introducing the Target – NusE/NusB Protein-Protein Interaction 
PPIs involved in transcription are an attractive option for pharmacological intervention.196 A 
host of regulatory proteins are involved in this complex pathway, and disruption of this 
process has been shown to be of therapeutic benefit.197,198 The transcription of the genome 
during RNA synthesis is a complex cycle consisting of three major stages: initiation, 
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elongation and termination. The enzyme at the core of this process is RNA polymerase 
(RNAP) and it is regulated by a host of N-utilisation substance (Nus) transcription factors 
(NusA, NusB, NusE and NusG). These factors interact directly and/or indirectly with the 
RNAP to moderate its function and to produce a stable elongation complex (EC). 
 
Figure 5.2: Schematic of the roles of the Nus factors in the transcription elongation complex. 
The NusE/NusB heterodimer binds ssRNA and is anchored to the RNAP through NusG 
interaction. NusA is a multidomain protein that binds close to the RNA exit channel on the 
RNAP. Figure adapted from Drögemüller.199 
NusA is one of the first proteins to bind the RNAP after initiation and binds near the RNA 
exit channel, where it most likely prevents reattachment of the αCTD of the RNAP to DNA, 
thereby preventing a stalled transcription complex.200 The NusG protein is a transcription 
regulator found across all prokaryotes, eukaryotes and archaea.200 It has a two domain 
structure connected via a flexible linker that infers it is able to interact with multiple proteins 
as a linker. 
NusE (also called ribosomal protein S10) is a small, 12 kDa, protein and, as described, forms a 
separate complex with NusB that is also involved in the antitermination process of prokaryotic 
cells. In addition to its role in transcription, NusE is involved in linking transcription and 
translation as a component of the 30S subunit of the ribosome. The 30S subunit is the smaller 
subunit of the 70S ribosome; it complexes with the larger 50S subunit to form the 70S 
prokaryotic ribosome. The 30S subunit is further formed of the 16S ribosomal RNA (rRNA) 
and 22 proteins. The 30S subunit is the protein target for tetracycline and the aminoglycoside 
class of antibiotics.  
NusB is also a small, 16 kDa, protein involved in bacterial transcription of rRNA. It is recruited 
to bind to the boxA RNA sequence and its affinity for the boxA sequence is greatly increased 











Antitermination is unique to prokaryotes and is the cell’s aid to fix premature termination of 
RNA synthesis during transcription is an interesting target for drug intervention. 
Transcription and translation in prokaryotes are directly coupled and transcription 
antitermination allows the cell to progress from early gene expression to delayed early gene 
expression. In the complete antitermination complex, the Nus factors interacts with the RNA 
polymerase (RNAP) and allows progressive transcription elongation through termination 
sites. This is essential for efficient transcription of bacterial ribosomal RNA operons.202,203–205 
One particular PPI of this complex governing the regulation of transcription is the interaction 
between transcription factors NusE and NusB (collectively known as NusE/NusB. This PPI is 
critical for the formation of the highly regulatory antitermination complex in prokaryotes and 
to allow stable RNA transcription. The importance of the NusE/NusB binding interaction was 
described separately by Robledo (1991), Court (1995) and later by Lou (2008).206–208 It was 
shown that by incorporating point mutations separately into NusE and NusB resulted in a 
reduced protein-protein binding affinity, which subsequently affected the formation of the 
antitermination complex. Furthermore, the mutations affected the ability of E. coli cells to 
efficiently transcribe the 16S and 23S ribosomal transcripts, therefore leading to a reduced 
number of new ribosomes and, hence, a decrease in cell growth.  
5.1.2.1. Structure of NusE/NusB interface 
The PPI surface area of the NusE/NusB complex is determined to be around 1600 Å2 and 
comprises a mixture of hydrophobic and hydrophilic interactions, arising from the α1-helix 
and β2-strand of NusE facing the helical bundles of NusB (figure 5.3).209 The key interactions 
have been studied extensively by X-ray crystallography and NMR spectroscopy and there are 
currently 7 structures of this complex (from various organisms) available in the Protein Data 




Figure 5.3: Crystal structure of the NusEΔ/NusB protein complex (PDB ID: 3D3B) from E. coli. 
NusEΔ is coloured pale, and NusB is coloured green. The red dashed box indicates the 
interface of the main protein-protein interaction between the helical bundle (α4-7 of NusB) 
and the α1 helix/β2 strand of NusE. The red spheres on NusEΔ denotes Ser46, which replaces 
the ribosome binding loop region (46-67) in this construct. This image was constructed in 
PyMol and adapted from Cossar et al.209 
The key electrostatic interactions derived from molecular structures are shown to be 
conserved across many, clinically relevant bacterial strains, including: Staphylococcus aureus, 
Streptococcus pneumoniae and Haemophilus influenza.210  
5.1.2.2. Inhibitors of NusE/NusB PPI 
At the start of this project, there were no known inhibitors of this bacterial PPI, however, in 
July 2017 a group (Cossar et al, University of Newcastle, Australia) published a series of 
compounds targeting the NusE/NusB PPI.209 To support the hypothesis, Cossar et al 
demonstrated the ability to inhibit the NusE/NusB PPI by screening a 9-mer peptide (HO- 
YDHRLLDQS-NH2), in a bacterial growth assay. This peptide replicates the α1-helix of NusE 
and returned an IC50 of 71 μM, which confirms the potential to inhibit this PPI. They then used 
a pharmacophore-based screening approach of the mini-Maybridge 56,000 compound library 
that yielded 25 preliminary hits, which was reduced to 5 after energy minimisations (figure 
5.4). This compound library was used in a classical HTS screening approach, as compounds 
are larger and more drug-like, which explains the poor hit rate (0.04%). Compounds were re-
synthesised and tested in a bacterial growth inhibition assay and 3 compounds inhibited the 











Figure 5.4: Chemical structures of compound hits identified from a pharmacophore-based 
screen of the Maybridge 56,000 compound library. Figure adapted from Cossar et al. 210 
These results validate the NusE/NusB PPI as a new and accessible target for pharmacological 
intervention. A fragment-based approach may provide a better starting point for chemical 
tractability and discovery of novel starting points. 
5.1.3. Aims of this work 
The aim of the work described in this chapter was to discover novel fragment hits against the 
NusE/NusB bacterial PPI. This PPI complex was screened against the fluorinated fragment 
libraries (Chapter 3) by 19F NMR chemical shift perturbation (CSP) analysis (see chapter 4). 
The protein was supplied by collaborators in the Department of Biopolymers at the University 
of Bayreuth, Germany, and prospective follow-up of hits was feasible using a ‘SAR by 
catalogue’ approach (see chapter 3).. Furthermore, access to more specific NMR experiments 





5.2. Results and Discussion 
The NusEΔ/NusB protein complex was supplied by collaborators at the University of 
Bayreuth, Germany. The delta, Δ, refers to a deletion of a 22 amino acid ribosome binding 
sequence of NusE to increase the stability of the overall complex. It was found that the loop 
region does not contribute to the overall transcription efficiency so does not impact on 
complex stability.208 Furthermore, in this format it is unknown what the KD of the complex is. 
The data referring to protein handling is described in the materials and methods section, 
chapter 7.4. 
5.2.1. Fragment Library Screening by 19F NMR of NusEΔ/NusB PPI 
The NusEΔ/NusB protein complex was screened in a 19F NMR assay on a Bruker Avance 400 
MHz spectrometer against the three designed fluorinated fragment libraries (RAFL, CFL and 
DDFL, see chapter 3). Using 19F NMR, the binding of a ligand to a component of the protein 
complex is detected, not necessarily the disruption or disassociation of the complex in 
solution. Fluorinated fragments were present at 100 μM and NusEΔ/NusB was added at 10 
μM for protein containing samples (see chapter 7.4.2 for materials and methods).  
 
Figure 5.5: Superposition of two 1D 19F NMR spectra from a compound pool containing 4 
fragments. The red spectrum is compound only, the blue spectrum is recorded in the presence 
of 10 μM NusEΔ/NusB. The two peaks at approximately -58 ppm and -62 ppm are 
significantly downfield shifted in the presence of protein, indicating a binding event. The peak 
at – 70.6 ppm shows no change in chemical shift on the addition of protein and is shown to 
demonstrate a non-binding fragment. 
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Figure 5.5 shows a superposition of the compound only spectrum (blue) and protein 
containing spectrum (red) of the fragment pool containing hits. There are 4 compounds in this 
pool and two of the compounds show a change in the chemical shift on addition of 10 μM 
NusEΔ/NusB. This indicates a change in the chemical environment of the fluorine atom and 
hence a binding event. Deconvolution of hit fragments is simple due to the single 19F NMR 
chemical shift signal. The compounds were part of the ‘Clustered Fragment Library’ 
collection, which therefore could be argued that this is the best method for library design. 
However, with such a small number of compounds, the diversity of each library is likely 
similar, therefore identifying compounds from the CFL library is most likely fortunate. From 
herein, compound hits are named by the library they originated from, e.g. CFL, and the ID 
within that library. The two initial fragment hits are thus named CFL02 and CFL17 (see figure 
5.7). Using the 19F NMR conditions described previously (see Chapter 4), figure 5.6 shows a 
bar chart of the observed chemical shift (Δδ in Hz) change for each compound contained 
within all libraries (87 compounds in total). The threshold for hit identification was set to 4 Hz 
(0.01 ppm). The entire screen was completed in around one week and two compounds were 
identified as hits and selected for follow up. 
 
Figure 5.6: Change in chemical shift for all fluorinated fragments screened vs the NusE/NusB 
PPI protein target. The red section is the RAFL library fragments, green is the CFL library 

















Figure 5.7: Chemical structures of fragment hits identified from 19F NMR screen of 
NusEΔ/NusB  
The most productive step after hit identification and deconvolution is to check that the binding 
is not a false positive. These can arise due to aggregation of compounds in solution, which is 
particularly problematic in fragment-based screening where high concentrations of ligand are 
used (up to 1 mM). However, there are other mechanisms giving rise to false positives, for 
example, Walden et al describe the analysis of a promising hit fragment to the UbE2T protein 
only to discover a contaminating zinc metal ion was solely responsible for the observed 
binding effect.211 Concerns arose after analysis of hit analogues appeared to be inactive and a 
co-crystal structure confirmed the binding of the metal to the active site cysteine. Another 
example of a false positive screening hit comes from Klebe et al who discovered a fragment hit 
(figure 5.8, 5.8) against the aspartic protease endothiapepsin. The compound was a hit in five 
out of six fragment screens including: TSA, biochemical assays and ITC.212 However, again, X-
ray crystallography revealed that the fragment underwent a self-reaction mechanism and 
rearrangement in solution to produce a larger isoform of the original hit (5.9, figure 5.8). 
 
Figure 5.8: Fragment rearrangement from screen of aspartic protease endothiapepsin. 
Reproduced from Klebe et al.212 
In both of these papers, X-ray crystallography is used as an orthogonal binding confirmation 
method, and validation of the hit fragments. These are two excellent examples of using 
separate biophysical detection methods for validating hit fragments. Without these rigorous 
tests for artefacts could result in pursuing an erroneous compound costing precious time and 
money. The next stage therefore was to validate the hits to determine that they are not artefacts 
and to obtain biophysical binding data, such as dissociation constants. 
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5.2.2. Fragment Hit Validation 
The 19F nucleus spans a large chemical shift range, ca. 800 ppm, and is very sensitive to changes 
in the local electronic environment. These changes can occur due to ligand binding, or minute 
differences in pH and DMSO concentration. To confirm the binding of fragments, and to 
determine that shift changes were not due to, changes in experimental conditions hit 
compounds were analysed individually by 19F CSP analysis (figure 5.10). The chemical shift 
changes of hit fragments was reproducible, when tested individually, giving confidence that 
these are real hits. Also, a second control compound, to reproduce the binding effect (figure 
5.9) was included. This compound did not show any binding in the initial fragment screen 
(figure 5.11) therefore it was used as a control molecule to reference the change in chemical 
shift of the hit fragment.  
 
Figure 5.9: A control molecule that did not show binding in the initial fragment screen. 
 
Figure 5.10: Superposition of 1D 19F NMR spectra. Changes in 19F chemical shift for the two 
hit fragments are demonstrated in the presence (blue spectra) and absence (red spectra) of 10 




Figure 5.11: A control molecule (figure 5.2.3) at -60.75 ppm was included in a 1:1 mixture with 
the fragment compound (100 μM) plus NusEΔ/NusB to show that the CSP of the CFL02 
fragment is reproducible. The control molecule is used as a reference to show the change in 
chemical shift of the hit fragment. Transverse Relaxation Experiments 
To validate the binding effect, and to recognise that the 19F chemical shift perturbation (CSP) 
represents true complex formation, a second NMR-based method was used. In this instance, 
validation of NusEΔ/NusB binding is necessary due to the sensitivity of CSP to changes in 
DMSO concentration and pH. Therefore, this hit validation experiment was performed to 
clarify any possibility of false positive interactions occurring. The resonance signals of 
molecules in ligand-observed NMR have been used to study protein-ligand complexes by 
exploiting differences in their relaxation and diffusion rates. Here, I describe the use of a 19F 
relaxation experiment to monitor ligand binding.  
5.2.2.1. T1ρ relaxation detected ligand binding - Theory 
T1ρ is the spin-lattice relaxation in the rotating frame and is the mechanism by which the 
magnetisation vector decays along the applied radiofrequency field, which is static in the 
rotating frame of reference. With this method one monitors the longitudinal relaxation 
(analogous to T1 decay constant) in the rotating frame by application of a spin-lock pulse 








Where I0 is the intensity, T1ρ is the decay constant in the rotating frame and τ is the spin-lock 
pulse length. The experiment is repeated with different values of τ and the resulting intensities 
used to find the value of T1ρ. This detection method is used to exploit the difference in the 
relaxation rate between the bound and free states of the fragment molecules. The 19F T1ρ filter 
is achieved with a composite pulse scheme applied before acquisition that attenuates signals 
of rapidly relaxing ligands. A fast tumbling molecule, for example a small molecule ligand, 
will experience a slow relaxation and gives rise to sharp peaks. A large, slow tumbling 
molecule, e.g. a protein macromolecule will experience a fast relaxation and gives rise to broad 
peaks. Any bound ligands will adopt the properties of the protein therefore binders show 
strong attenuation of the signal, i.e. T1ρ is directly dependent to the overall molecular 
rotational correlation time. The basic pulse sequence is-based on incorporation of a spin-echo 
period. Initially, a 90o pulse creates the transverse magnetisation; a train of 180o pulses 
determines the decay of the magnetisation and is repeated n times (L4, figure 5.12); acquisition 
is then performed as usual. The delay between pulses (D20) is a fixed period and the intensity 
of the signals will decrease when the spin-lock period is increased. 
 
Figure 5.12: A schematic of the T1ρ composite pulse sequence. D20 is the delay between 180o 
pulses (wide rectangle) and L4 is the number of repetitions. By definition the spin-lock (SL) 
time (in milliseconds) is therefore: 𝑆𝐿(𝑚𝑠) = 𝐿4 × (2 × 𝐷20 + 𝑝2). D20 is a fixed echo time, set 
to 10 ms, to allow elimination of diffusion and J-modulation effects. The triangle represents 
the FID for detection. 
5.2.2.2. Relaxation-detection of ligand binding 
Using the T1ρ approach described in section 5.2.2.1, fragment hits were validated by this 
method. Figure 5.13 shows the effect of increasing the SL time on the signal intensity. A plot 
of signal intensity as a function of the SL time will show a dependence with equation 5.1, this 
is displayed in figure 5.14. The calculated T1ρ decay constants from fitting equation 5.1 are 
displayed in table 5.1. 










Figure 5.13: Effect of increasing the spin-lock time on the signal intensity. A decrease in 
intensity of the fluorine resonance is observable on increasing the SL time with the CPMG 
sequence. The left spectrum was acquired without protein, and the right spectrum was the 
result of an experiment containing 5 μM protein (CFL02 compound concentration was 100 
μM). The corresponding SL times are: Red: 40 ms, Yellow: 80 ms, Green: 160 ms, Blue: 400 ms 
and Pink: 800 ms. 
Compound T1ρ (compound) (ms) T1ρ (with protein) (ms) 
CFL02 1680 493  
CFL17 1507 532 
Table 5.1: Calculated T1ρ decay constants for compounds (100 μM) in the presence and 
absence of 5 μM protein. 
To demonstrate the use of T1ρ relaxation NMR as a potential ligand-observed screening 
method, the fragment pool containing the hits was also screened via this method. Figure 5.13 
shows a superposition of the compound only and protein-containing pools acquired with a 
spin-lock filter incorporated. The length of the spin lock sequence was 400 ms and as can be 
seen from the spectra, there is a dramatic decrease in intensity of the two fragment hits (peaks 
1 and 2). The fragments, peaks 3 and 4, show no difference in intensity of the two spectra 
indicating no-binding. Although this filter is a very sensitive method applicable to screening, 
incorporating a spin-lock into the experiment extended the total time of acquisition to 45 
minutes per experiment. This is impractical for a high throughput, fragment screening 








Figure 5.14: Relationship of the spin lock time and the intensity of the fluorine resonance in 
the absence (blue curve) and presence (red curve) of 5 μM NusEΔ/NusB. Left plot: compound 
CFL02; right plot: compound CFL17. A single exponential was used to fit the intensity data 
and fitting was performed in Origin 9.0. It clearly shows a faster relaxation of the fluorine 
nucleus in the presence of protein indicating that the ligand is binding and that it adopts the 
properties of the protein. 
 
Figure 5.15: Superposition of two 1D 19F NMR spectra with a spin-lock filter incorporated into 
the pulse sequence before acquisition; the length of the SL time is 400 ms. The red spectrum 
was acquired in the absence of protein, and the blue spectrum was acquired with 5 μM 
NusEΔ/NusB. Peak 1: CFL17. Peak 2: CFL02. Peak 3: CFL18. Peak 4: CFL19. 
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5.2.3. KD determination by Differential Chemical Shift Perturbation (dCSP) 
Determining the dissociation constant of a target binding hit compound is a critical parameter 
for selection of compounds for cellular testing, for structural biology and for medicinal 
chemistry. The binding of a ligand to a macromolecule is an equilibrium condition between 
free and bound states. The equilibrium ligand binding activity is therefore usually expressed 
as an affinity, KD, of the ligand and protein to each other. NMR methods for the determination 
of dissociation constants are extensively covered in the literature. The use of ligand-observed 
NMR methods in drug discovery has led to much interest in binding affinity determination 
by NMR. The most traditional ligand-observed methods require that the ligand is in fast 
exchange (see Chapter 4) and in excess of the protein concentration, to satisfy the condition 
[L]0 >> [P]0 and, hence, [L]free = [L]0.172 The difficulty here is that the observable entity in the 
experiment is the ligand, therefore usually the protein would be kept at a constant 
concentration. However, due to the relatively high concentrations needed for ligand excess, 
the solubility of fragments becomes an issue.  
Jordan et al introduces a method for KD determination by 19F NMR which cannot be achieved 
with 1H-based methods.153 They call this ‘Differential Chemical Shift Perturbation’ (dCSP), 
which utilises the changes in the 19F chemical shifts at two different concentrations of ligand. 
This implies that the change in chemical shift is proportional to the fraction of the bound 
ligand (pb = [PL]/[L]0). Provided that the total ligand concentration is in excess of protein, the 






Where [L]1 and [L]2 are the concentrations of ligand and γ is the differential frequency shift 
(see chapter 4.1.2.1 for description). Samples were prepared with [L]1 and [L]2 of 100 and 200 
μM respectively (for each compound) and protein concentration was kept constant at 5 μM 
(20:1 and 40:1 molar ratios). The experiment was performed in duplicate and for CFL02, the γ 
constant was determined to be 1.17 from the ratio of the frequencies, therefore KD was 
estimated to be 463 ± 8 μM (this is shown in figure 5.16). For CFL17, the γ constant was 
determined to be 1.14, therefore the KD was calculated to be 591 ± 2 μM. The KDs are 





Figure 5.16: Change in Hz at two different ligand concentrations of CFL02. [L]1 = 100 μM (blue 
curve); [L]2 = 200 μM (green curve); γ = 1.17, therefore using equation 5.2.2, KD = 463 ± 8 μM. 
The red curve is the reference peak of CFL02 that contains no protein. 
5.2.4. Fragment development 
In the early drug discovery pipeline, the stage after hit discovery, confirmation and validation 
is the hit-to-lead phase. This is a period where hit fragments undergo optimisation into 
promising lead compounds.214 Following hit validation and testing for artefacts, optimisation 
can be carried out by testing analogues (hit expansion) to improve and/or maintain affinity of 
the original compound. Readily available fragments can generally be sourced from 
commercial vendors enabling “SAR by catalogue”.164 One approach is to use sub-structure 
searches, where a fragment `core` is defined and different chemical moieties are displayed 
around it.  
5.2.4.1. Fragment linking 
Advancing fragments in the absence of a structure is a major challenge. The early work 
involved in the development of the fragment-derived drug Venetoclax, for example, relied 
only on NMR structures. Similarly, X-ray crystallography was unsuccessful against MCL-1215, 
however, NMR-based models allowed efficient fragment advances. Also, in silico modelling 
continues to improve and has recently succeeded in linking fragments into a nanomolar 
inhibitor of Jumonji histone demethylases.216 There are few examples of advancing fragments 
without structural information217,218 however, it is worth noting that drug optimisation was 
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achieved without the benefit of structural information decades ago. Fragment linking is an 
appealing strategy that involves linking two, or more, low affinity binders to increase potency. 
This has been achieved several times, a notable example is fragment hits against Bcl-2, a 
regulator of apoptosis. The researchers identified 2 fragments with μM affinity from a protein-
detected NMR screen of 17,000 compounds.219 Structural NMR work showed the fragments 
bind simultaneously and linking them increased the affinity to the high nanomolar range 
(figure 5.17). 
 
Figure 5.17: Compounds 5.10 and 5.11 were identified from an NMR screen with modest 
affinities to Bcl-2. Fragment linking led to compound 5.12 with high nanomolar affinity.219 
Show in figure 5.17 is a good example of a fragment linking approach to increase both affinity 
and specificity towards a target protein. Therefore, it was hypothesised that if the fragments 
identified to NusE/NusB bind close enough in space, they may be amenable to a fragment 
linking approach. The Nuclear Overhauser Effect (NOE) is a physical phenomenon in which 
nuclear spin polarization is transferred between nuclei that are close in space, rather than 
through chemical bonds. This gives rise to cross correlation peaks in 2D NMR spectra and the 
rate of build-up of the NOE (i.e. the cross relaxation rate) is proportional to: 1/𝑟6, where r = 
the internuclear distance.220 It has recently been extended to observing protein-mediated 
interligand cross correlations.221 This technique, known as Inter-Ligand Overhauser Effect 
(ILOE) relies on the fact that if two ligands interact simultaneously with the protein in adjacent 
binding sites, then ILOEs will be observed.222 
The two compounds both contain a trifluoromethyl group, (CF3) it was therefore considered 
to explore them in 19F homonuclear NOESY experiments to decrease spectral complexity. 
Figure 5.18 illustrates a 19F-19F (1H-decoupled) NOESY experiment for the two CF3 containing 
fragments. However, no 19F-19F NOE cross-correlation was detected, indicating that either the 
compounds bind at different sites far apart (> 5 Å) or compete for the same binding site. This 
suggests that the compounds cannot be linked by this strategy. However, it was also 
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hypothesised that, no ILNOE (Inter Ligand Nuclear Overhauser Effect) was observed due to 
the distance between the CF3 groups, therefore a second 1NOESY experiment was acquired to 
observe the 1H-1H NOEs (figure 5.19). 
 
Figure 5.18: This figure shows a 2D homonuclear 19F-19F-NOESY spectrum of compounds 
CFL02 (-58 ppm) and CFL17 (-62 ppm) (compound concentration is 100 μM and protein 
concentration is 5 μM). 19F-19F ILNOESs are not observed between the two fragments. This 




Figure 5.19: 2D 1H-NOESY spectrum of a mix of two hit fragments (100 μM) in the presence 
of NusEΔ/NusB (10 μM). It shows the aromatic region of compounds and the cross correlation 
between aromatic protons. The blue square indicates an NOE between the two protons (B & 
C) of CFL02. The orange square indicates an NOE between the two protons (B & C) of CFL17. 
As shown in Figure 5.19, there are no intermolecular NOE cross correlation peaks between 
protons of both fragments. Again, this could indicate one of two possibilities: 1) that these 
fragments do not bind to NusEΔ/NusB close together in space (> 5 Å apart), 2) they bind at 
the same site to NusEΔ/NusB, which means that they are competitive binders. However, the 
NOESY spectrum also shows a positive cross relaxation peak between protons of compound 
CFL02, this indicates a negative relaxation rate. This situation is encountered in the slow-
tumbling or spin diffusion limit for large molecules, such as proteins. Therefore, it can be 
concluded that these fragments adopt the same, slow tumbling properties as the protein, 
which is another indication of ligand binding. 223 
In the following section the optimisation of the fragment hits by testing compound analogues 
to increase the binding affinity is described. 
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5.2.4.2. Fragment Optimisation by Bioisosteric Replacement 
Bioisosteres are chemical functional groups that share similar physical and chemical 
properties which produce a broadly similar biological effect of the molecules containing them. 
The rationale behind exchanging bioisosteres on molecules is to enhance the biological effect 
without drastically changing the chemical structure. The replacement bioisostere can modify 
the pharmacokinetic properties of the lead compound, reduce toxicity and alter the 
bioavailability. An example of some simple, frequent replacements are shown in table 5.2. 
Chemical Functional Group Replacement 
-H -D, or -F 
-CH3 -NH2, -OH, F, Cl 
-Br iPr, -CF3 
-CH2- -NH-, O, S 
C Si 
Table 5.2: Table illustrating common bioisosteric replacements for chemical functional 
groups. 
Compound CFL02 has two obvious chemical moieties for exploring changes in the biological 
activity, these are the nitro group and the morpholine group (figure 5.2.15). Nitro containing 
compounds are organic molecules that contain one or more nitro functionalities (-NO2). Nitro 
groups are generally avoided by medicinal chemists owing to their relative reactivity and 
potentially toxic metabolites. They are readily reduced in vivo to hydroxylamines and 
nitrosamines which are highly reactive and known carcinogens.224 
 
Figure 5.20. Chemical structure of fragment CFL02 with the nitro-functional group 
(highlighted in red) and the morpholine group (highlighted in blue). 
Although instances of nitro containing compounds are rare in nature, a well-known example 
of a naturally occurring nitro compound is chloramphenicol (Figure 5.21). Chloramphenicol 
is a broad spectrum antibiotic useful for treatment of a number of bacterial infections 
including: conjunctivitis, meningitis, plague, cholera and typhoid fever. It's mechanism of 
149 
 
action is by preventing the peptidyl transferase activity of the bacterial ribosome. It 
specifically binds A2451 and A2542 residues in 23S rRNA of the 50S ribosomal subunit, 
preventing peptide chain elongation.225 
 
Figure 5.21: Chemical structure of the broad-spectrum antibiotic chloramphenicol. 
Also, Zeng et al describe the development of a class of small molecules inhibiting the HIV-1 
Tat and coactivator PCAF in which a nitro group on an aniline ring is essential for the binding 
activity.226 An example of a nitro bioisostere replacement for drug discovery comes from 
Merck, who ran a HTS campaign against the ROM-K potassium ion channel.227 They found a 
single hit compound that contained two aryl nitro groups. However, they followed this lead 
up and identified several bioisosteric replacements for the nitro group (shown in figure 5.22). 
 
Figure 5.22: Chemical structures of the hit compound and several bioisosteric replacements as 
reported by Merck (2012). Figure adapted from [https://www.cambridgemedchem-
consulting.com/resources/]. 
To optimise the fragments, a bioisostere replacement approach was used to generate similar 
compounds with enhanced affinity. The SwissBioisostere database contains information on 
specific molecular replacements and their effect in biochemical assays.228 A query of the nitro 
group and morpholine groups in the database, and filtering for compounds with LogP < 0 (i.e. 
better aqueous solubility) returns a list of 254 and 377 possible replacements respectively. The 
top 4 from each query, ranked by frequency (i.e. number of times replacement occurs in 
database), are shown in table 5.3. This table also shows the percentage of biochemical assays 
in which the replacement was a “better” effector of the assay. For example, in 45% of assays 
where a nitro group was replaced with an amine or hydroxyl group, this resulted in a better 
‘output’ from the assay. A structure search in eMolecules for commercially available 
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fragments containing these replacements was performed and it was found that replacements 
1, 2 and 4 (of the nitro group) and number 4 (of the morpholine group) were available at a 
reasonable price. These compounds were purchased for testing against the NusEΔ/NusB 
protein complex (see sppendix 8.4.2). 
Query No. Replacement Frequency % of assays better 
 
1  1015 45 
2  792 27 








2  409 40 




Table 5.3: Result of a SwissBioisostere search query on the nitro and morpholine groups 
present in compound CFL02. The table is ranked by frequency. 
5.2.4.3. Structure Activity Relationship Analysis by 2D Chemical Structure 
A second approach to derive analogues for SAR screening was to use 2D structural similarity 
searches of the initial hit fragments. As described in chapter 3, similarity searching using the 
FCFP4 fingerprints was performed by Dr Steven Shave in the Auer group. Due to its highly 
decorated structure, few 3D similar compounds could be found for CFL02. Prioritised 
fragments are ranked on their USRCAT score (a measure of the 3D similarity) and shown in 
table 5.4 and 5.5. For CFL02, there were 4 compounds selected for purchasing, however, 
compounds 1 and 4 were prioritised for screening (table 5.4). These compounds tended to 
explore SAR around the morpholine moiety with complete removal of the nitro group. For 
CFL17, again 4 compounds were prioritised for purchasing, however, analogues of this 
compound was very expensive, therefore, only one fragment analogue was purchased for 
testing (compound 1, table 5.5). This compound contains a trifluoromethylthio group (-SCF3) 










USRCAT Score: 6.60 
3 
 
USRCAT Score: 7.04 
4 
 
USRCAT Score: 7.13 
Table 5.4: Ranking of fragment analogues to CFL02 prioritised for purchasing. The USRCAT 
score is a measure of 3D similarity, the lower the score, the more similar the compound is to 
the query. Compounds 1 and 4 were selected for purchasing. 
Number 2D Structure Information 
1 
 
USRCAT Score: 4.92 
2 
 
USRCAT Score: 8.43 
3 
 
USRCAT Score: 9.40 
4 
 
USRCAT Score: 14.11 
Table 5.5: Ranking of fragment analogues to CFL02 prioritised for purchasing. The USRCAT 
score is a measure of 3D similarity, the lower the score, the more similar the compound is to 
the query. Compound 1 was selected for purchasing. 
The fragment analogues were screened by 19F-NMR CSP as before, at 100 μM concentration in 
the absence and presence of 10 μM NusEΔ/NusB protein complex. The change in chemical 
shift of the fluorine resonances are given in figure 5.23. As the response of the fluorine 
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resonance is proportional to the fraction of bound ligand (pb = [PL]/[L]0) the largest change in 
fluorine resonance can indicate a tighter binding ligand. As can be seen from figure 5.23, 
analogues CFL02f and CFL17a (highlighted in green) both give larger resonance shifts than 
their corresponding initial hit compound. It can also be seen that changes to the morpholine 
moiety almost completely destroy the binding (CFL02c and CFL02d). This could indicate that 
this functional group is necessary for the binding effect. Replacement of the nitro moiety also 
has a detrimental effect on the binding interaction. Ranking the nitro bioisostere replacement 
by chemical shift results in: NO2 > CN > NH2 > COOH. Figure 5.24 shows the 1D 19F NMR 
spectra for each analogue fragment in the presence of the NusEΔ/NusB complex and the 
change in 19F chemical shift. 
   
CFL02 
Δδ 19F (Hz) 13.7 
CFL02a 
Δδ 19F (Hz) 3.4 
CFL02b 
Δδ 19F (Hz) 5.8 
   
CFL02c 
Δδ 19F (Hz) 2.6 
CFL02d 
Δδ 19F (Hz) 0.7 
CFL02e 




Δδ 19F (Hz) 16.0 
CFL17 
Δδ 19F (Hz) 8.2 
CFL17a 
Δδ 19F (Hz) 9.8 
 
Figure 5.23: Chemical structure of each analogue purchased designed to increase/maintain 
affinity. Also shown is the change in chemical shift of the fluorine resonance (Δδ 19F (Hz)) on 
addition of 10 μM NusEΔ/NusB. The highlighted fragments show a larger change in chemical 
shift on addition of protein than their corresponding initial hits (i.e. CFL02f > CFL02 and 




Figure 5.24: 1D 19F NMR spectra of CFL analogue series. The spectra illustrate the change in 
19F chemical shift (Δδ Hz) for each analogue fragment on addition of 10 μM NusEΔ/NusB. 
Trace 1 is the reference peak for each compound in the absence of protein. Left: CFL02 series, 
2 – 7: CFL02a – CFL02f. Right: CFL17 series, 2 – 3: CFL17 and CFL17a respectively. 
The next step was to confirm the binding interaction and measure the affinities of the fragment 
analogues by application of a secondary label-free affinity technique. 
5.2.5. Quantitative Equilibrium Microdialysis (qµD) 
5.2.5.1. Theory 
Equilibrium dialysis is well-established as a biochemical technique, and important for the 
characterisation of protein-ligand interactions. It is attractive due to its inherent physical 
simplicity and ability to work with non-labelled ligands and proteins (avoiding, e.g. 
fluorescence and radiolabelling). The general objective is to measure the affinity (dissociation 
constant, KD) of small molecule ligands to macromolecules. Typically, this is exemplified 
indirectly as in a mixture of ligand and protein, the free ligand concentration is difficult to 
determine. Therefore, the theory behind equilibrium microdialysis is that, if the free ligand 
can be dialysed through a semipermeable membrane, then the free ligand concentration can 






Figure 5.25: The theory behind the microdialysis experiment. A) A schematic of the 
microdialysis experiment. The red chamber volume (V1) is 100 μl and the white chamber 
volume (V2) is 300 μl. Blue circles represent protein molecules and green circles represent small 
molecule ligands. The yellow dashed line is a semi-permeable membrane with a MWCO of 8 
kDa. B) A time course of the compound concentrations in the red chamber (solid lines) and 
white chamber (dashed lines). The black lines represent a control experiment without target 
protein, and the concentration is equal in each chamber after 24 h (pc = 1). The orange lines 
illustrate the presence of target protein and after 24 h there is a difference in ligand 
concentration between the two chambers (pt > 1). Figure B reproduced from Weidemann.229 
As described by Weidemann et al the ratio of ligand in the two compartments, V1 and V2, can 
be used to detect protein binding in compartment V1.229 Under ideal conditions, in a system 
without protein (pc subscript c for control), the concentrations in each compartment will be 
equal (pc = 1, figure 5.25). The protein and ligand are added to compartment V1 (pt subscript t 
for target containing experiment) and if the ligand binds to the target protein a certain fraction 
of compound will be retained in the protein compartment (pt > 1). The free ligand 
concentration can then be measured in compartment V2 with high accuracy. Weidemann 
relates the KD to the partition coefficient (or ratio of ligand concentration in each compartment) 






Where cp is the total protein concentration in the red chamber (V1) and pt is the partition 
coefficient in the experiment with protein (i.e. ratio of ligand between the chambers, ro). 
However, this relationship is independent of the volume of each compartment, and it does 









the absence of protein (i.e. pc ≠ 1). In the Auer lab, Dr Steven Shave, has established a new 
binding equation to correct for the situation when pc ≠ 1 (shown in appendix 8.4.3). This 
establishes a new equilibrium for when the compound does not fully equilibrate.  
5.2.5.2. Microdialysis Results 
The objective here was to measure the dissociation constants of the initial hit fragments and 
the analogues with improved affinity. Using an orthogonal, biophysical assay to validate the 
NMR dCSP data, quantitative microdialysis (abbreviated qμD) was chosen as an effective 
method. The method utilised the high accuracy LCMS-Orbitrap mass analyser to detect and 
quantify the fragment compounds. A simulation of the experimental conditions is shown in 
Figure 5.26. From this figure it can be seen that as the KD of the interaction increases the 
concentration of ligand and protein in each chamber converges. Therefore low affinity binders 
are difficult to determine without high accuracy methods. Here it is important to note that the 
KD is essentially calculated by measuring the free concentration of ligand, as opposed to 
measuring saturation curves.  
A calibration curve for each compound was produced to calculate the limit of detection and 
the limit of linearity of the analyser (Figure 5.27) (see chapter 7.4.7 for materials and methods). 
This would aid in setting up the experiment to determine the optimum concentration of ligand 
and protein to gain the largest difference between the chambers. Compounds CFL02, CFL02f 
and CFL17 all produced excellent standard curves for concentration determination (appendix 
8.4.3). However, compound CFL17a did not produce a reproducible signal in the mass 




Figure 5.26: Simulation of the concentration of ligand present in each chamber for a given KD. 
The protein concentration in the red chamber (V1) is 40 μM. The ligand concentration over the 
whole system without protein is 10 μM (pc = 1). [c] red = concentration of ligand in red chamber 
(V1) and [c] white = concentration of ligand in white chamber (V2). 
  
Figure 5.27: An example calibration curve for compound CFL02f detected on the LTQ orbitrap 
mass analyser. The limit of linearity is between 0.5 pmoles and 10 pmoles. This  
The next step is to determine that compounds equilibrate sufficiently across the membrane. 
Initially, the hit fragments (CFL02 and CFL17) were tested for equilibration, however, these 
compounds did not give reproducible data and the calculated partition coefficient was 













































determination even with the adjusted KD method where pc ≠ 1. This could be attributed to the 
compounds “sticking” to the membrane or the plastic walls of the sample chamber, this would 
result in a lower concentration than expected. Also, pipetting is of great importance here as 
the technique is very sensitive to changes in concentration. Compound CFL02f was the only 
compound that dialysed adequately and with reproducible results, that is, the standard 





intensity V1 (106) 
Mean peak 





2.39 2.06 1.16 ± 0.33  
CFL02f 
 
6.06 6.15 0.99 ± 0.03 
CFL17 
 
3.52 4.26 0.83 
Table 5.6: The mean peak intensity detected for each compound in the red chamber (V1) and 
white chamber (V2) in control (protein free) microdialysis. The calculated partition coefficient 
(pc) of each compound is also given. 
The partition coefficient (pt) for compound CFL02f was then assayed in the presence of 
NusEΔ/NusB and was found to be considerably higher than the control experiment (pc), 
indicating protein binding (table 5.7). The pt values, protein concentration and ligand 
concentration were then used to determine the KD using both the Weidemann formula 
(equation 5.1) and the corrected S. Shave formula (appendix 8.4.3). Here, the KD value given 














CFL02f 7.26 5.98 Pt = 1.21 ± 0.04 190 ± 35 171 
Table 5.7: Results of the microdialysis equilibrium experiment with compounds CFL02f in the 
presence of NusEΔ/NusB. The peak intensities in the red chamber (V1) and white chamber (V2) 
following dialysis with protein are given as well the partition coefficient (pt). The resultant KD 
value using both formulas is also shown. 
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This assay proved uncomplicated for confirming the binding of one hit analogue identified in 
the 19F NMR screen. However, the disadvantage with assaying small molecule compounds is 
establishing a sufficient equilibrium across the dialysis membrane, this proved problematic 
for 3 out of 4 compounds. Also, another limitation is the duration required for the system to 
reach equilibrium so it would be unsuitable for potentially unstable proteins. However, it 
validates the use of this method as a secondary binding assay for confirmation of fragment 
hits. 
5.2.6. Bacterial Growth Inhibition Assay 
The increasing emergence of new antibiotic resistant bacteria in hospitals and the community 
has led to rapid growth in strategic antibacterial drug campaigns. The rate of antibacterial 
resistance has greatly superseded the rate of discovery of new, effective drugs hence new lead 
compounds are desperately needed to respond to this. As our target is a bacterial PPI, it was 
relevant to assess the activity of the hit fragments identified in the initial 19F NMR-based screen 
and the SAR analogues on bacterial E. coli cells. 
A plate-based growth inhibition assay was devised to observe the effect of different 
concentrations of compound on bacterial growth. Here, the growth of E. coli was monitored 
by measuring the OD600 (optical density at 600 nm) at regular intervals over approximately 16 
hours. Using 96-microwell plates and a compatible plate reader allowed for easy set-up and 
for testing several compounds and concentrations at once (see chapter 7.4.6 for materials and 
methods). The bacterial growth strain chosen was E. coli BL21(DE3), as this was readily 
available and has predictable growth properties. An initial test of growth conditions was 
performed to determine the initial optimum cell density. In addition, fragment stocks were 
stored in 100% DMSO therefore it was necessary to determine the effect of DMSO 
concentration on cell growth.  It was verified that DMSO concentration has a negligible effect 
on the growth rate of E. coli up to a final concentration of 4% (figure 5.28). However, decreasing 
the initial concentration of cells (OD600) increased the lag time of the growth curve as expected 
(see appendix 8.4.4). This was not an issue over ~16 hours, and the final parameters chosen 
were a starting OD600 of 0.001 and a final DMSO concentration of 1% (see chapter 7.4.6 for full 




Figure 5.28: Effect of DMSO concentration on cell growth in the plate-based assay. The starting 
OD was 0.001 and the OD at 600 nm was measured every 15 minutes over a 16 hour period. 
There is a slight decrease in the rate of growth on the addition of increasing amounts of DMSO, 
It is shown that the effect of increasing DMSO concentration is not especially detrimental to 
the rate of cell growth. 
A typical bacterial growth curve shows five distinct phases: lag phase, exponential growth, 
stationary phase, cell death and, finally, long-term stationary phase. Lag phase remains the 
most poorly understood growth phase, however, it is hypothesised that lag allows the 
adaptation of bacterial cells to exploit new environmental conditions.230 Examining the growth 
curves from the hit fragments and SAR analogues, two different effects are observed. The 
benzothiazole containing CFL17 fragment series (CFL17 and CFL17a) causes an elongation of 
the lag phase for several hours, however, the growth rate is eventually restored to the same as 
the control (figure 5.29). This could be described as a partial bacteriostatic effect. An increase 
in lag phase of several hours indicates a requirement of the cells to adapt to a new 
environment. Importantly, the lag time increase shows a concentration dependence, i.e. lag 
time increases with increasing compound concentration. This strongly indicates a compound 
effect, negatively affecting bacterial growth and forcing bacteria to adapt to a new 
environment. However, there is no direct indication that this effect is due to inhibition of the 
NusE/NusB interaction pathway. Such a small fragment would most likely interact with 
several proteins involved in cell growth. However, as the NusE/NusB factors are essential for 
cell growth206, knockdown of this pathway is not possible to test this hypothesis. An additional 
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The NusB protein is specifically a prokaryotic system involved in transcription, and NusE 
shares little homology with interfamily ribosomal proteins.210 Therefore, complete inhibition 
of this pathway would not be expected to incur an effect on a eukaryotic species. 
 
Figure 5.29: Effect of varying compound concentrations of CFL17 series on bacterial growth. 
Plot of the OD600 vs time (hours) in Microsoft Excel. Top: Initial fragment hit CFL17. Bottom: 
CFL17a (compound concentrations are indicated in figure legends). It can clearly be seen that 
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Figure 5.30: Effect of varying compound concentrations of CFL02 series on bacterial growth. 
Plot of the OD600 vs time (hours) in Microsoft Excel. Top: Initial fragment hit CFL02. Bottom: 
CFL02f (compound concentrations are indicated in figure legends). CFL02 shows little effect 
on bacterial cell growth.  
Interestingly, the initial hit compound CFL02 did not show any activity on E. coli cells (figure 
5.30, top) whereas the analogue CFL02f (figure 5.30, bottom) caused a dramatic decrease in 
cell growth at high (1 mM) concentration. This indicates the compound interacting with 
bacterial growth pathways. There is also a concentration dependence of each compound 
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Figure 5.31: Chemical structures of fragment hit CFL02 and analogue CFL02f showing the 
morpholine and piperazine structures highlighted in red. 
The only difference between the two fragments is replacement of the morpholine moiety (in 
CFL02) with a piperazine ring (in CFL02f) (figure 5.31). A morpholine group is commonly 
used in medicinal chemistry to increase the aqueous solubility and, hence, oral bioavailability 
of lead drug candidates.231 This could explain how, due to its lower lipophilicity, it is unable 
to cross the E. coli cell membrane and cause an effect. 
5.2.6.1. Identifying the active fragment core 
Interestingly, the fragment hits and SAR compounds to the NusEΔ/NusB complex contain 
recognised core structures that are present in many active pharmaceuticals. CFL02f contains 
a substituted phenylpiperazine structure (Figure 5.32; 1) which is a known moiety in several 
drug derivatives. These drugs have a number of targets for a range of pharmacologically 
relevant illnesses, including bacterial infections, shown in table 5.8. The hit compound CFL17, 
and the thioether analogue (CFL17a), both contain the central benzothiazole core (Figure 5.32; 
2). This particular core is a useful moiety in several drug compounds targeting the central 
nervous system,232 however it also finds use in antibacterial discovery.233,234 This fragment 
compound (CFL17), as selected via the clustering design method, is actually a known drug 
compound, riluzole (marketed as Rilutek and Teglutik). It is currently used to treat 
amyotrophic lateral sclerosis (ALS). It’s mechanism of action occurs through inhibition of 
TTX-sensitive sodium channels, which are associated with damaged neurons.235  
 
Figure 5.32. Chemical structures of the fragment cores possibly responsible for the antibiotic 





Drug Structure Pharmacology 
Ciprofloxacin 
 
Broad spectrum antibiotic of the 
fluoroquinolone class. It is Active 
against both Gram - positive and 
Gram-negative bacteria. The molecular 
target for this small molecule is DNA 




Used in the treatment of schizophrenia 
and as an adjunctive for depression. 
This small molecule is a partial agonist 
for the dopamine D2 receptor and is 





A broad spectrum antifungal agent, 
particularly against Aspergillus. It 
inhibits the fungal-mediated synthesis 





Used to treat amyotrophic lateral 
sclerosis. 
Table 5.8: A range of drug compounds containing the similar moieties found in the fragment 
hits. Table is adapted from Trevor et al.236 
Despite the low affinity of the hit fragment (590 μM, measured using NMR dCSP) against the 
NusEΔ/NusB PPI, CFL17 (riluzole) could, in theory, be modified and optimised to increase 
the potency against this difficult target. However, from a medicinal chemistry viewpoint it 
would be necessary to monitor side effects on the CNS. This is known as drug repurposing 
(also as drug repositioning) and purports the use of known drugs and compounds to treat 
alternative diseases. Two of the most famous examples of drug repurposing include: Pfizer’s 
Viagra, initially studied for use in hypertension and angina pectoris, is now used for erectile 
dysfunction and pulmonary arterial hypertension, and Celgene’s thalidomide, primarily 
described to alleviate morning sickness in pregnant women, it is now used as a first line 
treatment in multiple myeloma.  
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5.2.7. 2D HSQC NMR Experiments 
The 2D HSQC (Heteronuclear Single-Quantum Coherence) experiment allows one to obtain a 
2D heteronuclear chemical shift correlation map between directly bonded 1H and any X 
heteronuclei (notably 13C and 15N with respect to protein NMR). This is the most standard 
experiment for protein NMR and shows a fingerprint of the backbone amide correlations. It is 
widely used as it involves irradiation and detection of 1H spins, therefore offering high 
sensitivity and efficiency. It requires isotopic labelling of the protein with nitrogen-15 and 
involves the transfer of magnetisation from the backbone amide proton to the attached 15N via 
J-coupling. The chemical shift is then evolved on the nitrogen before magnetisation is 
transferred back to the hydrogen for detection. The HSQC experiments were performed in 
collaboration with the Department of Biopolymers at the University of Bayreuth at their world 
leading NMR facility on a Bruker Aeon 1 GHz NMR spectrometer. They kindly supplied the 
15N labelled NusEΔ/NusB complex for KD determination and chemical shift mapping. In this 
complex it is only the NusEΔ protein that is 15N-labelled. 
5.2.7.1. KD Determination 
The determination of binding affinity after hit generation is crucial for ranking compounds 
for selection and optimisation. For equilibrium ligand binding kinetics with respect to NMR 
spectroscopy, please see chapter 4.1.2.Using a 15N-labelled protein, ligand binding is detected 
by perturbations to the chemical shift of backbone amide resonances. Figure 5.33 illustrates 
the titration of compound CFL02f into a solution of 15N labelled NusEΔ/NusB. The CSPs of 
backbone amide resonances can clearly be seen for specific amino acids on increasing 
concentration of ligand. The amide resonances of NusEΔ have been previously assigned by 
the Biopolymer group.237 The six active fragments (CFL02, CFL02a, CFL02b, CFL02f, CFL17 
and CFL17a) in the 19F NMR screen were used in titrations against the 15N labelled 
NusEΔ/NusB protein for accurate KD determination (see Chapter 7 for full experimental 
details and appendix 8.4.5 for HSQC spectra). Monitoring of the CSPs in the protein backbone 
allows one to create multiple saturation curves for each compound. A control experiment in 
which DMSO was titrated into the protein was also performed. This allowed for correction of 
CSPs that were affected by DMSO concentration (this is shown in figure 5.34). Also, multiple 
spectra of protein in the presence of 10% DMSO were collected over 72 hours to determine the 
stability of the protein in the presence of DMSO. After 72 hours, no protein degradation was 





Figure 5.33: 2D 15N HSQC spectrum of a series of titration points with compound CFL02f and 
15N-labelled NusEΔ in the NusEΔ/NusB complex. From light to dark shows the change in 
chemical shift on increasing concentration of ligand. Top: Full spectrum of amide region. 
Bottom: Inset of residues L76 and A78. Concentration of ligand ([L]0) ranges from 0 μM to 1.9 






























































Figure 5.34: 2D 15N HSQC spectrum of NusEΔ/NusB with DMSO titrations. From light to dark 
is increasing concentration of DMSO to a maximum 10% (equivalent to the final titration point 
with compound). 
Figure 5.35 shows a titration curve for CFL02f. The normalised chemical shifts were calculated 
using equation 4.12 and the binding curve fitting analysis is described in Chapter 4. In theory, 
this analysis can be applied to each residue that changes over the course of the titration, 
therefore multiple curves can be acquired for each compound and the KD values averaged. 
This was done for compound CFL02f, the standard deviation was deemed suitable that the KD 
value from one residue gave an accurate representation of the dissociation constant. The 
calculated dissociation constants for multiple residues in the titration experiment with CFL02f 
are given in table 5.9. The fitting parameters and calculation of normalised chemical shifts are 
































Figure 5.35: A plot of the saturation curve for compound CFL02f. The normalised chemical 
shifts were calculated for the R73 amide residue according to equation 4.11. The curve was fit 
to equation 4.12 using GraFit 7.0. The KD from this curve is calculated to be 154.4 ± 2.7. 
Residue KD (μM) 
R73.HN 154 ± 3 
E32.HN 167 ± 4 
K35.HN 159 ± 4 
R36.HN 124 ± 10 
L76.HN 178 ± 3 
Average 156 
Table 5.9: Compound CFL02f KD values for different residues that shift in the 15N-HSQC 
spectrum. The .HN refers to the fact this is an amide nitrogen that is observed, i.e. R73.HN is 
the amide nitrogen of the arginine 73 residue. 
The calculated dissociation constants and titration curves for each compound are shown in 
figure 5.36. The curves are fit to equation 4.12 and the KD is given in μM.  
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Δmax (Hz) 122.6 ± 2.2 Δmax (Hz) 123.8 ± 2.0 
KD (μM) 206.6 ± 16.1 KD (μM) 455.3 ± 25.9 
    
  
CFL02b CFL02f 
Δmax (Hz) 221.2 ± 4.0 Δmax (Hz) 350.8 ± 1.4 
KD (μM) 323.9 ± 14.9 KD (μM) 154.4 ± 2.7 
    
  
CFL17 CFL17a 
Δmax (Hz) 111.9 ± 5.4 Δmax (Hz) 71.8 ± 5.5 
KD (μM) 487.8 ± 72.0 KD (μM) 277.7 ± 65.0 
    
Figure 5.36: Titration curves for all compounds screened against 15N NusEΔ/NusB. The Δmax 
and KD are used as a fitting parameters. Curves are fit using GraFit 7.0.  
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Compound Kd (μM) 
CFL02 206 ± 16 
CFL02a 455 ± 26 
CFL02b 323 ± 15 
CFL02f 156 ± 3 
CFL17 487 ± 72 
CFL17a 277 ± 65 
Table 5.10: Summary of calculated KD values by 2D 15N-HSQC NMR experiments. 
From table 5.10, it can be seen that all compounds are approximately in the same KD range, 
between 100 – 500 μM. This is not unusual for fragments, and can be considered reasonable 
starting points for medicinal chemistry. The highest affinity fragment (CFL02f, KD 154 μM) 
has a useful secondary amine for SAR exploration using medicinal chemistry. One of the most 
common reactions for fragment growing is amide bond formation, due to its simplicity and 
wide range of available fragments. However, usually, advancing fragments in this way 
requires detailed, high resolution structural knowledge to determine key interactions. 15N 
HSQC spectra of each compound titration are shown in appendix 8.4.5. 
5.2.7.2. Identification of Ligand Binding Sites by Chemical Shift Mapping 
Chemical shift mapping (CSM) is a term used to describe monitoring of chemical shift 
perturbations and using them to determine the binding site.238 CSPs are most commonly 
tracked in 13C and 15N HSQC spectra, however 15N labelling is comparatively cheaper. The 
most common way of mapping the binding site requires an assigned HSQC spectrum and a 
detailed structure. CSPs are then mapped to the protein surface by colour coding according to 
the significance of the chemical shift change. However, usually the entire amino acid is 
coloured this way, rather than just the backbone amide residue, which can lead to 
misinterpretation of the essential interactions.177  
Figure 5.37 shows a histogram illustrating the maximum backbone amide chemical shift 
changes at saturating amounts of CFL02f ligand. This was achieved for all 6 active fragments 
(CFL02, CFL02a, CFL02b, CFL02f, CFL17 and CFL17a). There are three thresholds to 
determine the significance of chemical shift changes: slightly affected (0.04 – 0.10 ppm), 




Figure 5.37: CFL02f CSPs per residue. This plot shows a histogram of normalised amide 
chemical shift changes per residue in the presence of saturating amounts of CFL02f (1.9 mM). 
Amide chemical shifts were normalised using the equation described in chapter 4. The black 
dashed line indicates the chemical shift threshold for the slightly affected residues; above the 
yellow dashed line are moderately affected residues and above the red dashed line are 
strongly affected residues. The significantly affected residues (yellow and above) are assigned 
to: E32, K35, R36, Q40, V41, R73, L76. Unassigned residues are not shown. The green boxes 
show clustering of amino acid residues which is indicative of specific binding. 
Using these thresholds, a crystal structure available in the PDB (PDB ID: 3D3B) was colour 
coded according to the CSPs (this is shown for compound CFL02f in figure 5.38). When a 
ligand binds to the protein, chemical shift changes can be observed directly at the binding site 
or by inducing a conformational change in the protein. This can be imagined as an allosteric 
effect of ligand binding. If a ligand binds to a single site, then any changes far from that 
location must be due to a conformational change in the backbone of the protein. An 
encouraging indication from figure 5.37, is that CSPs appear to occur in clusters, which infers 
a single binding site (green boxes). The yellow residues (figure 5.38) appear to cover a wide 
area of the protein surface, however, this could be attributed to broad conformational 
changes.239 Unfortunately, it is not possible to map all of the changes in chemical shift due to 
unassigned resonances in the HSQC spectrum. Also, a 180° rotation shows that the rear facing 
surface also exhibits chemical shift changes (figure 5.38). 
 











































Figure 5.38: Chemical shift map of CFL02f CSPs represented on NusEΔ (PDB 3D3B from E. 
coli). The location of each amino acid affected is colour coded. Slightly affected residues are in 
yellow, moderately affected residues are in orange and strongly affected residues are in red. 
All atoms of amino acids whose backbone amide group are affected are coloured.  
This process was repeated and a chemical shift map was created for each fragment analogue, 
these are shown in figure 5.40. Analysing the chemical shift maps for each compound it can 
be seen that there is a similar clustering of CSPs for each fragment analogue, indicating a 
similar binding mode. Figure 5.39 illustrates the PPI surface area of NusE/NusB and the 
affected residues induced by CFL02f. The region highlighted in the red square is the α1 helix 
of NusE, which appears mostly affected, this is at the PPI surface interface between NusE-
NusB, this is a promising result for potential inhibition of this PPI. 
 
Figure 5.39: NusE-NusB interface. NusB is coloured green and NusE is colour coded according 
to affected residues (by CFL02f). The red box indicates the most affected region of the α1 helix 
loop of NusE at the interface with NusB. Yellow residues: slightly affected. Orange residues: 
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Figure 5.40: Chemical shift mapping of affected residues on NusEΔ (PDB 3D3B) for each 
compound. Structures were colour coded according to the thresholds: slightly affected 
residues are in yellow, moderately affected residues are in orange and strongly affected 




Figure 5.41: CFL17a CSPs per residue. This plot shows a bar chart of normalised amide 
chemical shift changes per residue in the presence of saturating amounts of CFL02f (1.9 mM). 
Amide chemical shifts were normalised using the equation described in chapter 4. The black 
dashed line indicates the chemical shift threshold for the slightly affected residues and above 
the yellow dashed line are moderately affected residues. 
The opposite face of NusE (to NusB) is the PPI surface for the transcription factor NusG (figure 
5.42). NusG has been shown to form a complex with NusE and is involved in linking 
transcription and translation.240 The ligand binding allosteric effects may therefore also affect 
the NusG binding capability. 
 
Figure 5.42: The NusE-NusG protein complex (PDB ID NusE: 3D3B alignment with PDB ID 
NusG: 2KVQ). NusE colour coded with affected residues by CFL02f and NusG in magenta. 
The affected residues show conformational changes that may affect the NusG binding 
capability. The PPI contacts of the loop regions on NusG (indicated by the green arrows) are 
directly affected by the fragment ligand binding. 












































5.3. Conclusions and future work 
In conclusion, two fragments that bind the NusEΔ/NusB PPI were identified from a 19F NMR-
based fragment screen. The hit fragments were validated separately and by orthogonal 19F 
NMR T2 relaxation experiments. A “SAR by catalogue” approach was used to purchase close 
analogue fragments and two analogues were found to bind with increased affinity (CFL02f 
and CFL17a). Microdialysis was adopted as a secondary binding assay to validate the hit 
compounds from the 19F NMR screen, however, only one compound, CFL02f, was shown to 
be amenable to this method. The method was validated for determining CFL02f compound 
affinity for the NusEΔ/NusB protein complex.  
Compound Microdialysis (μM) dCSP (μM) 15N HSQC NMR 
CFL02 - 471 206 ± 16 
CFL02a - - 455 ± 26 
CFL02b - - 323 ± 15 
CFL02f 171 229 μM 154 ± 3 μM 
CFL17 - 590 487 ± 72 
CFL17a - 161 277 ± 65 
Table 5.11: A summary of KD comparison of techniques applied to each compound. 
The fragment series for CFL02 and CFL17 were analysed by protein-observed NMR HSQC 
titration methods for chemical shift mapping and KD determination. The clustered amide 
resonances that showed chemical shift changes prove that there is a distinct binding site for 
each of these fragments. The extension to this work herein is to use CSP-guided docking 
techniques, such as the HADDOCK approach, to determine the binding mode of fragments 
and to establish the key interactions.241,242 Docking studies to identify the binding site would 
also determine the potential for inhibiting the NusE-NusG interaction pathway.  
The dCSP method of KD determination gives an approximation of the binding affinity and can 
be a useful method for a preliminary measurement. The KD from microdialysis for compound 
CFL02f was in excellent agreement with the 15N-HSQC measured KD value (table 5.11). The 
fragments identified here show a promising starting point for development. The most potent 
fragment, CFL02f, certainly has potential for medicinal chemistry to produce a lead 
compound. The identified fragments also prove that this PPI is a druggable target and small 
molecule intervention is certainly a possibility.  
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To extend this work further, the highest affinity compounds could be used in competition 
binding assays, such as the FAXS approach (see chapter 4), for further optimisation. These 
medium affinity ligands are useful as probe molecules and a competition with non-fluorinated 
analogues is a feasibility. The detailed SAR analysis and cheminformatics capabilities will 
facilitate in optimising the compounds further. Such small molecular ligands of this novel PPI 
target will help validate this target as a potential therapeutic strategy. 
In summary, the designed in-house CTB libraries produced two novel fragment hits for an 
under-explored PPI target. This is a hit rate of 2.3 % (Hit rate = (2/87)*100) for the fluorine 














6.1. Conclusions and future work 
The origin of disease tends to lie in a complex network of cellular processes mediated by many 
thousands of biological interactions. Recent technological advances, such as proteomics 
approaches, to identify these networks has led to the establishment of many PPIs with 
therapeutic potential.243 They have long been considered as challenging drug targets due to 
the large and flat nature of interfaces and also the absence of pockets available for ligand 
binding. However, the number of successful drugs targeting these interactions is rapidly 
increasing.15  
The main aim of the work presented in this thesis was to discover new, novel ligands to 
difficult, under-explored PPI targets. Owing to the challenges posed by inhibiting this novel 
class of target new technologies and strategies must be implemented to discover safe and 
efficacious drug compounds. This was achieved by strategic design and evaluation of peptide 
and fragment-based libraries for screening by 19F NMR. 
6.1.1. Peptides and peptidomimetics 
Short peptides are natural ligands involved in PPIs in the cell and therefore the peptide 
strategy for ligand discovery is well founded. In this project, two parallel approaches to 
peptide and peptidomimetic ligand discovery were explored, one established and matured by 
the Auer lab, the other one invented in this work. In the first approach an OBOC peptide 
library targeted at ATAD2 ligand discovery was successfully designed and synthesised by 
solid-phase peptide synthesis. This is an example of a target focussed library that can 
theoretically be used for generic bromodomain ligand discovery. The peptidic tool compound 
development to investigate the bromodomain containing protein ATAD2, namely H4K5 and 
H4, were synthesised and modified for detection by NMR spectroscopic methods. However, 
difficult protein handling conditions and coinciding publication of high affinity small 
molecules against ATAD2 was a misfortune resulting in abandonment of the project.  
The second approach, utilising peptides as screening agents, introduced the concept of ‘on-
protein peptide growing’ (OPPG). This strategy was designed to grow a peptide beginning 
from a short fluorinated dipeptide, which are generally not used in conventional screening 
approaches. The use of fluorine as a probe molecule allows the sensitive detection of weak 
affinity molecules for further optimisation. A successful reverse proof-of-concept study was 
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achieved with detection of a weak affinity dipeptide peptidomimetic to survivin by 19F NMR. 
It was also shown that increased affinity towards survivin could be observed using 19F NMR 
by extension of the dipeptide to the corresponding tripeptide and tetrapeptide. The aim was 
to use the knowledge acquired via the proof-of-concept peptidomimetic study on survivin to 
develop a fluorinated dipeptide library using the UbE2L3 target in an initial study. For peptide 
ligand discovery, two key parameters for optimisation of ligand affinity were applied: the 
length of the peptide and the nature of the side chains. Therefore, screening a dipeptide 
library, i.e. the shortest peptide possible, and a library of amino acids, i.e. different side chain 
containing peptides, tackles both parameters simultaneously. Using solid-phase peptide 
synthesis (SPPS) a 16 member fluorinated dipeptide library was synthesised for 19F ligand-
observed NMR screening. A fluorinated amino acid, a para-fluoro-L-phenylalanine (pfF), was 
used as the fluorine containing moiety and these were screened against the UbE2L3 protein. 
However, initial hit dipeptides showed very low binding affinity and maybe unspecific 
binding. The most active hit dipeptide was taken forward and a library of 32 C- and N-
terminal extended tripeptides were synthesised by SPPS. These were screened for activity 
against UbE2L3 by 19F NMR however, binding was further reduced.  
6.1.2. Fragments 
The development of inhibitors for PPI targets has been achieved through a variety of 
strategies, however, small molecule inhibition remains the preferred method of choice for the 
pharmaceutical industry. The difficulties of small molecule inhibition of PPIs is that the size 
of the surface to be covered by the molecule is very large compared to a small active site 
pocket. However, in fragment-based ligand discovery (FBLD), even though hit compounds 
are generally weak in affinity, they usually form “high quality” interactions.244 FBLD has 
therefore emerged as an attractive option for efficient chemical starting points. One of the first 
steps in establishing a successful fragment-based approach to ligand discovery is in the design 
of the library. Fragment libraries can more efficiently probe chemical space and it is this 
unique trait we wanted to exploit. The aim of this part of the project was to design, construct 
and evaluate new fluorinated, small fragment libraries and to test them against difficult PPI 
drug targets. This would ideally result in a more cost effective collection of highly diverse, 
highly focused fragment libraries, ideally suited for 19F FBS screening in academic labs. 
A short analysis of the available commercial fragment libraries allowed us to focus on 
producing a high quality, affordable and diverse set of fragments. Three separate methods of 
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fragment library design were implemented in parallel to maximise the quality and diversity 
of selected fragment sets.  The first approach was to select fragments based on the knowledge 
that they were active in previous biochemical assays. Fragments extracted from the ChEMBL 
database conforming to a set of criteria were purchased and used to construct the RAFL set of 
compounds. The second approach, used a common clustering algorithm to explore the entire 
commercial fragment space. Fragment criteria were defined and these filters were applied to 
the eMolecules database of commercially available compounds. Fragments that conformed to 
the selected criteria were clustered according to their 2D molecular similarity. A subjective set 
of compounds were purchased from cluster sets to maximally represent the fragment space. 
The third approach to library design introduced a simple metric to ensure maximal diversity 
when selecting fragments. This was called the A2A score and was used to measure the 
diversity within commercial and selected fragment sets. This was the core principal of the 
DDFL library and led to the purchase of fragments that maintained high quality and diversity 
as a function of cost. The relatively small library sizes described here were created using 
established methods and shown to be far less expensive than a commercially available library. 
Regarding the aim of this work, it is likely that the designed, fluorine fragment libraries would 
not hit PPIs with the same success. Therefore, evaluating the libraries against multiple targets, 
can assess the quality of diversity and fragments as this eliminates the possibility of frequent 
hitters and ‘bad-acting’ compounds. 
The designed fluorine fragment libraries (RAFL, CFL and DDFL, collectively known as CTB, 
chapter 3) were established for use in a 19F NMR-based screen by QC analysis using multiple 
biochemical methods (HPLC, LCMS and 19F NMR). This rigorous QC analysis was necessary 
to determine purity and identity and eliminate insoluble or potential aggregating compounds. 
The assembly of the highest quality 19F fragments formed the basis for the final libraries. The 
UbE2L3 protein target was screened by 19F NMR, however this fragment screen yielded few 
hits with high likelihood of mM affinity. Chemical expansion was considered too demanding 
to tackle in this thesis, and gains from SAR analysis were not thought to present a worthwhile 
advantage given the limited capacity. It was therefore decided that it would be more 
important to switch efforts to another PPI target, of different structural and disease context, to 
exploit and analyse the fragment libraries and gain as much knowledge of their future 




6.1.2.1. NusEΔ/NusB Fragment Screening 
The second PPI target introduced was the bacterial antitermination complex NusE/NusB. 
NusE/NusB is involved at the interface of transcription and translation in prokaryotic species 
and inhibiting this PPI could lead to new antibiotic therapies. This is a novel, orphan target 
that at the start of this work, no known inhibitors were currently in existence. From a primary, 
19F NMR screen with the CTB fragment libraries two fragments that bind the NusEΔ/NusB 
PPI were identified from a 19F NMR-based fragment screen. The hit fragments were validated 
separately and by orthogonal 19F NMR T2 relaxation experiments. A “SAR by catalogue” 
approach was used to purchase close analogue fragment series and two analogues were found 
to bind with increased affinity (CFL02f and CFL17a) to the initial hit compounds. 
Microdialysis was adopted as a secondary binding assay to validate the hit compounds from 
the 19F NMR screen, however, only one compound, CFL02f, was shown to be amenable to this 
method. The method was validated for determining CFL02f compound affinity for the 
NusEΔ/NusB protein complex.  The fragment series analogues for initial hits CFL02 and 
CFL17 were analysed by protein-observed NMR [1H, 15N]-HSQC titration methods for 
chemical shift mapping and KD determination. The clustered amide resonances that showed 
chemical shift changes prove that there is a distinct binding site for each of these fragments. 
As outlined previously, the NusG binding site, to NusE, is located on the opposite face to the 
NusB site (figure 6.1). To ascertain whether the compound (CFL02f) affects the NusG binding 
capability, a competition binding experiment using 15N-labelled NusE in a similar HSQC assay 
would determine the effect on NusG. The KD of the NusE/NusB/CFL02f complex is known 
(~150 μM), therefore a titration with NusG would allow on to calculate the KD of the NusG 
interaction if they were to bind at the same site. In a competitive binding titration experiment, 
this would result in a cubic algebraic equation, which would be difficult to solve by non-linear 
least square regression, as in the case of a simple quadratic.245 Also, another experiment to 
determine dissociation of the NusE/NusB/NusG complex would be to analyse the transverse 
relaxation rates of the labelled NusG protein in the presence and absence of inhibitor CFL02f. 
The formation of the large NusE/NusB/NusG complex would cause increased transverse 
relaxation times, leading to broadening (and even disappearance) of NMR resonances. 
Addition of a compound that dissociates the complex to the NusE/NusB heterodimer and 
NusG protein would restore the HSQC resonances of NusG, whereas a weak or no binder 
would have no effect on the HSQC spectrum of the complex. Furthermore, this PPI directly 
binds ssRNA, therefore it is valid to compare the CSP map with the RNA binding track of the 
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complex. This is shown in figure 6.1 (B and C), where it can be seen that the RNA binding 
track is located away from fragment binding site and would not appear to be affected by small 
conformational changes. The ssRNA, shown in figure 6.1 (B and C), is a model complex based 
on the alignment of two crystal structures from separate organisms (PDB 3D3B and 3R2D). 
 
Figure 6.1. Model structure of the NusEΔ/NusB/NusG/RNA complex based on alignment of 
three separate crystal structures (PDB 3D3B, 2KVQ and 3R2D). NusB is the green ribbon, 
NusG is the magenta ribbon, NusEΔ is the white surface structure, colour coded according to 
CFL02f affected residues and the ssRNA is orange/blue. A. The NusEΔ/NusB (PDB ID 3D3B) 
is aligned to NusEΔ/NusG-CTD (PDB ID 2KVQ). Both structures are from E. coli. B. The rear 
face of NusEΔ/NusB/NusG complex. Also shown is an ssRNA aligned from PDB ID 3R2D 
(Organism Aquifex aeolicus). C. Another view of the RNA binding track of the 
NusEΔ/NusB/NusG-CTD heterotrimeric complex.  
Also, it is worth examining the specificity of these fragments for the NusE/NusB binding 
interaction between bacterial species. ConSurf is an online bioinformatics tool that allows one 
to assess the evolutionary conservation rate of amino acids in a protein based on the 
phylogenetic relations between homologous sequences.246–250 The degree with which an amino 
acid in a protein is conserved is greatly dependent on its functional and structural significance. 
Therefore, conservation analyses of this type across species can reveal the importance of the 
amino acid to its function. Figure 6.2 shows the degree to which the amino acids in NusE are 





binding. As can be seen from the figure, the orange patch of moderately affected residues (E32, 
K35, R36, Q40 and V41) are shown to be variable across species, indicating these residues are 
not important to the binding interaction. 
 
Figure 6.2: Comparison of NusE CSP map (left) and ConSurf results (right).  
The most common approach to targeting PPI complexes is to develop a compound that 
inhibits or completely dissociates the interaction. Therefore, further experiments to determine 
the effect on the NusEΔ/NusB complex are required. Although there is no evidence for 
dissociation of the NusE/NusB PPI complex by these small fragments, further methods to 
elucidate the mode of action might include fluorescence-based assays.  
 
Figure 6.3: Schematic of the AlphaScreen™. 1. Excitation of the donor bead causes release of 
singlet oxygen. In the presence of a biological PPI, the acceptor bead is in close proximity and 
emission occurs. 2. In the presence of an inhibitor, the acceptor bead is too far for singlet 





































For example, the AlphaScreen™ (Amplified Luminescent Proximity Homogeneous Assay, 
PerkinElmer) is a fluorescent assay based on the use of donor and acceptor beads 
functionalised with the target proteins (figure 6.3). In the presence of a biological interaction, 
the singlet state oxygen produced by excitation of the donor bead reacts with fluorophores in 
the acceptor bead to generate a fluorescent response. However, a decrease in signal would be 
observed in the presence of an inhibitor of this interaction. This could be used to identify if, at 
all, the NusE/NusB PPI is disrupted on binding of the hit fragments. A further experiment to 
determine the binding site would be to utilise site-directed mutatgenesis to change one of the 
affected residues and observe the binding effect of the ligand. For example, the most strongly 
affected residues is R73, therefore incorporating an alanine in this position and measuring the 
KD would provide information on the binding site.  Also, as shown previously, the fragment 
CFL02f appears to reduce the growth of E. coli cells at high concentrations (section 5.2.6). To 
examine if the fragment disrupts the NusE/NusB PPI, one could use a strain that 
overexpresses one component of the complex. To compare both strains, using a constant 
inhibitor concentration, bacterial growth may be restored in the overexpression strain. 
The fragments identified here show a promising starting point for development. The most 
potent fragment, CFL02f, certainly has potential for medicinal chemistry to produce a lead 
compound. The identified fragments also prove that this PPI is a druggable target and small 
molecule intervention is certainly a possibility.  
6.2. Summary and Future Outlook 
The discovery of ligands for PPI targets is a challenging area. The methods employed in this 
thesis aimed to maximise the value of established techniques for use in an academic setting. 
19F NMR is acknowledged as a valuable primary screening method in industrial and academic 
drug discovery and the peptide and fragment approaches to ligand discovery both deserve 
merit. Establishment of a PPI screening platform using small libraries of fluorinated 
compounds, either peptides or fragments, for novel ligand discovery was shown to be well 
suited and easily implemented in an academic lab. 
The peptide and peptidomimetic approach to ligand discovery offers the advantage that 
straightforward synthesis methods can lead to many thousands of compounds in a short 
timescale. The OPPG approach described here is novel in that it uses ‘fragment-sized’ 
compounds (dipeptides) and a highly sensitive probe to detect binding. Simple C- or N-
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terminal peptidic extension can quickly lead to high affinity peptides for applications in basic 
and translational science, particularly for the set-up of competitive HTS, for structural biology 
and for drug delivery. To develop the OPPG approach further, additional E2 enzymes could 
be screened with the first fluorine dipeptide library. This would provide a measure of the 
druggability of this family of proteins and, if successful, would offer vital information for the 
pharma industry. It would also indicate how represented pockets able to accommodate the 
core mCF3-Phe amino acid derivative are on E2 enzymes. However, this approach can easily 
be extended to using different fluorinated amino acids as the chemical probe and non-natural 
amino acids in the ‘N’ and ‘C’ positions. This novel approach to ‘on-protein peptide growing’ 
can theoretically be used against any target. The relative ease of peptide synthesis, coupled 
with the assay sensitivity is a useful novel approach to peptide ligand discovery. 
The fluorinated fragment libraries were designed to be affordable, high quality and highly 
diverse and the results herein are evidence of this. The A2A metric described here is a simple 
measure of diversity that can be exploited by other, small academic groups looking to 
construct small, focussed, affordable fragment libraries. It can also be further implemented to 
expand the chemical space of existing fragment libraries for efficient drug discovery. The 
designed in-house CTB fragment libraries produced two novel fragment hits for an under-
explored PPI target, NusE/NusB. This is a hit rate of 2.3 % for the fluorine libraries which is a 
comparable result to many fragment-based screens.23 Structural data for PPI targets is almost 
always mandatory251, therefore, the extension to this work is to use CSP-guided docking 
techniques, such as the HADDOCK approach, to determine the binding mode of fragments 
and to establish the key interactions.241,242 Docking studies to identify the binding site would 
also determine the potential for inhibiting the NusE/NusG interaction pathway. To extend this 
work further, these medium affinity ligands are useful as probe molecules and a competition 
binding assay with non-fluorinated analogues is a feasibility, such as the FAXS approach 
(described by Dalvit et al, see chapter 4).The detailed SAR analysis and cheminformatics 
capabilities of the Auer group will facilitate in optimising the compounds further. Such small 
molecular ligands of this novel PPI target will help validate this target as a potential 
therapeutic strategy. 
Although fluorine containing chemical space only covers a small fraction of overall chemical 
space, 19F FBS as a primary NMR screening method to detect medium affinity ligands allows 
one to expand the chemical space for competition-based assays with non-fluorinated 
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analogues. Ideally, one would have a small, diverse set of fluorinated fragments, and each 
fragment would have a sub-library of non-fluorinated analogues (i.e. SAR-related sub-
library). Discovery of an initial fluorinated fragment hit, the SAR sub-library could be used in 
competition-based assays. 19F NMR may hold the key for more efficient ligand discovery of 
PPI targets. 
 





















































Materials and Methods 
This chapter details the experimental methods and reagents used for each chapter. The 
methods are separated into specific chapters. All commercially available reagents were 
purchased from Sigma Aldrich or VWR unless otherwise stated and used as received after 




7.1. General Analytical and Synthetic Methods 
7.1.1. LCMS Analysis 
LCMS analyses (p were performed on an Agilent 1100 micro-HPLC system, equipped with a 
capillary pump (G1376A), a micro-autosampler (G1377A) and a diode-array detector (DAD; 
G1315B) and combined with a Finnigan Deka CP Plus ESI-MS detector. The system was run 
with a spray voltage of 5 kV, capillary temperature of 275 °C and a capillary voltage of 15 V 
in positive single-ion MS mode. The HPLC system consisted of a Zorbax-SB-C18 column (0.5 
x 35 mm) with a 3.5 μm particle size and the solvent system used was: A (H2O, 0.1 % TFA) 
and B (MeCN, 0.1 % TFA). The standard gradient used for compound analysis was: 1.5 min 0 
% B, 14 mins 0 – 100 % B, 15 mins 100 % B at a flow rate of 60 μl.min-1. HPLC-ESI-MS data 
were processed using the Xcalibur software package (version 2.0, Thermo Electron 
Corporation, MA, USA). 
7.1.2. Analytical HPLC 
HPLC compound analyses were performed on an Agilent 1100 series HPLC system, equipped 
with a quaternary pump (G1311A), a degasser (G1322A), a well-plate autosampler (G1367A), 
a fluorescence detector (FLD; G1321A) and a DAD (G1315B). Solvent system: A (H2O, 0.1% 
TFA) and B (MeCN, 0.1% TFA). 
 
Method 1: Column: Agilent ZORBAX SB-C18 (4.6 x 150 mm) with a 3.5 μm particle size 
diameter and 80 μm pore size. Gradient: 0 - 5 min, 5 % B; 5 – 24 min, 5 - 100 % B, 24 – 26 min, 
100 % B; 26 - 27 min, 100 - 5 % B; 27 – 30 min, 5 % B with a flow rate of 0.8 ml.min-1. 
 
Method 2: Column: Vydac C4 (RP-C4; 2 x 125 mm). Gradient: 0 - 5 min, 5 % B; 5 – 24 min, 5 - 
100 % B, 24 – 26 min, 100 % B; 26 - 27 min, 100 - 5 % B; 27 – 30 min, 5 % B with a flow rate of 
0.8 ml.min-1. 
 
Method 3: Column: Vydac C4 (RP-C4; 2  x 125 mm). Gradient: 0 - 5 min, 5 % B; 5 – 35 min, 5 - 
95 % B; 35 – 40 min, 95 % B; 40 - 45 min, 95 - 5 % B; 45 – 50 min, 5 % B with a flow rate of 0.8 
ml.min-1. 
The retention time (tR) for analytes is given in minutes and purity is calculated using the peak 
integral. DAD HPLC trace measurements were taken at 210, 220, 254 and 280 nm. For TMR 
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labelled peptides, a fluorescence trace was measured using an excitation wavelength (λex) of 
555 nm and emission wavelength (λem) of 575 nm on the FLD. For Cy5-labelled protein, a 
fluorescence trace was measured using an excitation wavelength (λex) of 650 nm and emission 
(λem) wavelength of 670 nm on the FLD. 
7.1.3. NMR Spectroscopy 
The University of Edinburgh, School of Chemistry has a range of liquid state Bruker Avance 
III NMR spectrometers with a variety of probes for characterisation of compounds. NMR 
experiments were performed, where stated, using spectrometers: Deuterated solvents used 
for compound analyses were MeOD and DMSO-d6 where stated. 
 Bruker Avance III 400 MHz spectrometer (AVA 400), equipped with BBFO+ room 
temperature probe and two channels, 1H and 19F (optimised) 
 Bruker Avance III 500 MHz (PRO 500) spectrometer equipped with Prodigy 
CryoProbe and two channels 1H/19F and X nuclei (optimised) 
 Bruker Avance III 500 MHz (AVA 500) spectrometer equipped with DCH Probe and 
two channels: 1H and 13C (optimised) 
 Bruker 800 MHz spectrometer (AVA 800) equipped with TCI CryoProbe and three 
channels: 1H (optimised), 13C and 15N. 
Two dimensional [1H, 15N]-HSQC NMR for binding site mapping and KD determination of 
compounds against the NusEΔ/NusB protein was completed at the University of Bayreuth, 
Germany, using a Bruker Aeon 1 GHz (AEON 1000) spectrometer. 
Chemical shifts (δ) are quoted in parts per million (ppm) downfield of tetramethylsilane, using 
residual protonated solvent as internal standard (CDCl3 at 7.27 ppm or acetonitrile-d3 at 1.94 
ppm). Abbreviations used in the description of resonances are: s (singlet), d (doublet), t 
(triplet), q, (quartet), app (apparent), br (broad). Proton-decoupled 13C NMR spectra were 
recorded on a Bruker AV500 (125.8 MHz) spectrometer or a Bruker AVA400 (100.6 MHz) 
spectrometer. Chemical shifts (δ) are quoted in parts per million (ppm) downfield of 
tetramethylsilane, using deuterated solvent as internal standard (CDCl3 at 77.0 ppm or 





7.1.3.1. 19F NMR Parameters 
Fluorine NMR peptide and fragment screening and QC analyses were recorded at 300 K on a 
Bruker Avance 400 MHz spectrometer with BBFO+ room temperature probe for direct 19F 
detection. One dimensional 19F spectra were acquired for each sample with 1H decoupling 
according to the parameters described in table 7.1. Sample preparation for peptide and 
fragment pools are given in section 7.2.12 and 7.3.1 respectively.  
Experiment SFO1 (MHz) SW (Hz) TD NS AQ (s) 
19F NMR 376.47 111111.1 262144 256 1.18 
Table 7.1: 19F NMR spectroscopy parameters. SFO1: Irradiation frequency channel 1; SW; 
Spectral width; TD: Time domain; NS; Number of scans; AQ: Acquisition time. 
7.1.3.2. [1H, 15N]-HSQC NMR Experiments 
15N-HSQC experiments were recorded at 300 K on Bruker Avance 800 MHz for the ATAD2 
studies and Bruker Aeon 1 GHz NMR spectrometer for NusEΔ/NusB. Both spectrometers are 
equipped with cryogenically cooled probes for optimum sensitivity. Sample preparation is 
given in the respective sections. 
7.1.4. Software 
All PDB protein structures are analysed and illustrated using PyMol (The PyMOL Molecular 
Graphics System, Version 2.0 Schrödinger, LLC). Processing of 1D NMR data and analysis of 
chemical shifts and intensities was performed using in-house routines and visualised using 
MestReNova NMR software package (v10.0.2-15465, Mestrelab Research, S.L.). Processing of 
2D NMR spectra was performed using NMRViewJ (v. 9.2.0-b11, One Moon Scientific Inc.). 
Charts and graphs were illustrated using Microsoft Excel (2013) and Origin 9.0 (OriginLab 
Corporation) where stated. KD simulations and fittings were performed in GraFit 7.0.3 
(Erithacus Software Ltd.). Chemical structures were drawn using ChemDraw (v 14.0.0.117, 
CambridgeSoft Corporation, PerkinElmer, Inc). 
7.1.5. General Fmoc Solid-phase Peptide Synthesis (SPPS) Methods 
TentaGel™ rink amide resin (0.26 mmol.g-1, 90 μm, TG-RAM) was supplied by Rapp Polymer. 
Amino acids and all other reagents required for SPPS were supplied by Novabiochem, Chem 
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Impex and Sigma Aldrich. There are three steps to Fmoc-based SPPS: 1) amino acid coupling, 
2) Fmoc deprotection and 3) cleavage from the resin. 
Resin preparation 
TentaGel™ (TG) resin (0.23 mmol.g-1 90 μm or 0.3 mmol.g-1 140 μm resin, Polymer) is weighed 
out for the desired yield of peptide. The resin is added to an SPE fitted with a frit and swollen 
in DMF (1 ml/100 mg resin) for 30 minutes. 
Amino Acid Coupling 
To a solution of amino acid (3 eq.) and HATU (2.5 eq.) in DMF (1 ml/100 mg resin) is added 
DIPEA (6 eq.). The solution is then transferred to an SPE containing the resin fitted with a frit. 
The SPE is capped and shaken for 20 – 30 minutes, then the solution drained and the coupling 
reaction repeated. The resin is then washed extensively with DMF, H2O, MeOH and finally 
DCM to remove any traces of coupling agents. The resin is either dried overnight in vacuo in 
preparation for cleavage, or swollen again in DMF for the next amino acid.  
Fmoc Deprotection 
To the Fmoc-protected amino acid resin, a solution of 20 % piperidine in DMF (1 ml/100 mg 
resin) is added. The mixture is shaken for 15 minutes then the resin drained and rinsed with 
10 column volumes of DMF. The deprotection reaction is repeated once again for a further 10 
minutes. 
TNBS test for primary amines 
The TNBS test is a sensitive test to monitor the completion of the coupling reaction.252 It can 
only be used for the detection of primary amines which are visualised by an intense orange 
colour under a microscope. Only the beads with a primary amino group will turn orange/red 
and the intensity of the colour does not depend on the nature of the N-terminal amino acid.  
A small sample of resin is placed into a glass vial and suspended in 200 μl of 10 % DIPEA in 
DMF. A small drop of 5 % trinitrobenzenesulfonic acid (TNBS) in water is added to the resin 
and the mixture shaken. The vial is then viewed under a microscope to determine the coupling 
reaction or the Fmoc deprotection efficiency. If any orange beads are present, the coupling 




Standard cleavage from rink resin 
The resin is dried overnight in vacuo to remove any traces of DCM from the previous washing 
steps. A solution of 2.5 % H2O, 2.5 % TIS in TFA (1 ml/100 mg resin) is prepared and added 
directly to the resin and shaken for 3 hours. The resulting solution is drained into a glass vial 
and volatiles removed under reduced pressure (Savant SpeedVac ® Plus SC110A, equipped 
with Refrigerated Vapor Trap, RVT400) . Following this, ice-cold diethyl ether is added to the 
residue and sonicated to break up any large clumps. The solution is centrifuged briefly and 
the supernatant is discarded. This process is repeated 3 times and the remaining solid is dried 
overnight in vacuo.  
7.2. Experimental Section for Chapter 2 
7.2.1. ATAD2 Expression and Purification 
Reagents and buffers for ATAD2 expression and purification are indicated in table 7.2 
Chemically Competent Cell Preparation 
A starter culture (5 ml) of E. coli expression strain Rosetta (DE3)pLysS was grown overnight 
at 37 °C. The cells were harvested by centrifugation at 3000 g for 15 minutes at 4 °C. The cell 
pellets were then resuspended in 50 ml of ice cold CaCl2 (30 mM) by vigorous vortexing. The 
cells were centrifuged at 3000 g for 15 minutes at 4 °C. The supernatant was discarded and 
cells resuspended in 50 ml ice cold CaCl2 (30 mM). The cells were left on ice for 20 minutes 
then harvested by centrifugation at 3000 g for 15 minutes at 4 °C. The supernatant was 
discarded, and the pellet carefully resuspended in 50 ml ice cold 85 mM CaCl2 with 15 % v/v 
glycerol. The cells were left on ice for 20 minutes then harvested by centrifugation at 3000 g 
for 15 minutes and 4 °C. Again, the supernatant was discarded, and the cells resuspended in 
2 ml ice cold 85 mM CaCl2 with 15 % v/v glycerol. The cells were then divided into 50 μl 
aliquots in pre-chilled micro test tubes and flash frozen in liquid nitrogen. The competent cell 







Table 7.2: Reagents and components of buffers used for the purification of ATAD2 protein. 
Transformation 
A 1 μl solution of prepared ATAD2 plasmid (supplied by SGC, Oxford, 10 ng.μl-1) was added 
to 50 μl of chemically competent cells. The cell/plasmid solution was mixed gently by flicking 
and the mixture left on ice for 30 minutes. The micro test tube containing the cell/plasmid 
mixture was then submerged in a water bath at 42 °C for 45 seconds exactly then immediately 
returned to ice and left for 5 minutes. The transformed cell solution was then added to 25 ml 
of pre-warmed LB broth and incubated for 1 hour at 37 °C. After 1 hour, Kanamycin was 
added to a final concentration of 50 μg.ml-1 and the solution grown overnight at 37 °C. The 
next day a 25 % glycerol stock was made by adding 1 ml of 50 % glycerol to 1 ml of culture 
and the stock stored at – 80 °C. 
Expression and Purification 
A small aliquot of the ATAD2 glycerol stock was inoculated into 5 ml LB broth containing 50 
μg.ml-1 Kanamycin. The culture was grown overnight at 37 °C with agitation (180 rpm). A 1 
ml aliquot from the overnight culture was inoculated into 1 L of LB broth. The culture was 
incubated at 37 °C until the OD600 reached 0.5 AU and then the temperature adjusted to 18 °C. 
Expression was induced by adding IPTG to a final concentration of 0.5 mM and the culture 
incubated overnight at 18 °C with shaking (180 rpm). 
ATAD2 Buffers Components 
Binding buffer 50 mM HEPES, 500 mM NaCl, 5 mM imidazole, 0.5 
mM TCEP, pH 7.5. 
Wash buffer 50 mM HEPES, 500 mM NaCl, 20 mM imidazole, 0.5 
mM TCEP, pH 7.5. 
M9 minimal stock solution (5X) 30 g.L-1 Na2HPO4, 15 g.L-1 KH2PO4, 2.5 g.L-1 NaCl 
TS2-Trace element stock solution 100 mg.L-1 ZnSO4.7H2O, 30 mg.L-1 MnCl2.4H2O, 300 
mg.L-1 H3BO3, 200 mg.L-1 CoCl2.6H2O, 10 mg.L-1 
CuCl2.2H2O, 20 mg.L-1 NiCl2.6H2O, 900 mg.L-1 
Na2MoO4.2H2O, 20 mg.L-1 Na2SeO3 
M9-minimial medium 1X M9-stock solution, 1.5 g.L-1 (15NH4)2SO4, 2 mM 
MgSO4, 0.2 % (v/v) TS2-trace element solution, 10 
μM Fe(III) citrate, 100 μM CaCl2, 0.4 % (w/v) 
glucose, 1X MEM-vitamins. 
194 
 
The 1 L culture was harvested by centrifugation (Sorvall RC 5C Plus) at 3500 g for 15 minutes 
and 4 °C, the supernatant was discarded. The pellet was resuspended in 50 ml of binding 
buffer and mixed vigorously by vortexing. The cell culture was incubated on ice for 30 minutes 
prior to sonication. The cells were kept on ice and sonicated for 1 minute with 10 second pulses 
(at 50 % amplitude) with 10 second intervals. The lysate was incubated at 4  °C for 5 minutes 
with gentle rotation and then sonicated again as above. The lysate was cleared by 
centrifugation at 4 °C and 4000 rpm (3500 g) for 1 hour. 
For protein purification of ATAD2 see section 7.2.4. 
7.2.2. 15N Labelling and Expression of ATAD2 
E. coli (BL21) expression strain transformed with the ATAD2 containing plasmid (~20 μl) was 
plated onto LB agar plates containing Kanamycin (50 μg.ml-1) and grown overnight at 37 °C 
in an incubator. A single colony was picked and inoculated into 5 ml LB broth containing 
Kanamycin (50 μg.ml-1) and incubated overnight at 37 °C with agitation at 180 rpm. This 5 ml 
culture was then used to inoculate a 1 litre culture of M9-minimal media (containing 
(15NH4)2SO4 (Sigma Aldrich 299286) as the sole nitrogen source) which was incubated at 37 °C 
until the OD600 reached 0.5 AU (with agitation at 180 rpm). Induction of expression was 
achieved by supplementing the media with a final concentration of 0.5 mM IPTG and the 
culture incubated overnight at 18 °C with agitation (180 rpm). 
Cell harvest and lysis 
The cell culture was pelleted in a centrifuge (Sorvall RC 5C Plus) at 4 °C and 4000 rpm (3010 
g) for 30 minutes. The supernatant was removed, and the cell pellet resuspended in 40 ml of 
ice cold PBS (by vortexing) and then centrifuged again at 4 °C and 4000 rpm (3010 g) for 30 
minutes. The cell pellet was then stored before purification at – 20 °C. The frozen cell pellet 
was left to thaw at room temperature for approximately 1 hour prior to lysis. The cell pellet 
was resuspended (by vortexing) in 50 ml of binding buffer and incubated on ice for 30 minutes 
prior to sonication. The cells were kept on ice and sonicated for 1 minute with 10 second pulses 
(at 50 % amplitude) with 10 second intervals. The lysate was incubated at 4  °C for 5 minutes 
with gentle rotation and then sonicated again as above. The lysate was cleared by 
centrifugation at 4 °C and 4000 rpm for 60 minutes.  
For purification of 15N-ATAD2 see section 7.2.4 
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7.2.3. Ubiquitin Conjugating Enzyme L3 (UbE2L3) Expression and Purification 
Reagents and buffers for UbEL3 expression and purification are indicated in table 7.3 
UbE2L3 Buffers Components 
Minimal buffer 50 mM sodium phosphate, 500 mM NaCl, 5 mM imidazole, 10% 
glycerol, pH 7.5 
Lysis buffer 1X minimal buffer, 5 mM β-mercaptoethanol, protease inhibitor 
cocktail (1 tablet.50 ml-1 EDTA free, Roche), lysozyme (from chicken 
egg white, 43000 units.mg-1 solid, Sigma Aldrich), benzonase nuclease 
(> 250 units.μl-1, Sigma Aldrich), pH 7.5 
Wash buffer 1X minimal buffer, 15 mM imidazole, 5 mM β-mercaptoethanol, pH 
7.5 
Elution buffer 1X minimal buffer, 250 mM imidazole, pH 7.5 
Dialysis buffer 20 mM HEPES, 100 mM NaCl, pH 7.5 
Table 7.3: Components of buffers used in the purification of UbE2L3. 
Protein Expression 
E. coli BL21(DE3) bacterial expression strain transformed with the E2 sequence containing 
plasmid (supplied by Joanna Koszela, pET28a) (10 μl) was plated onto LB agar plates 
containing Kanamycin (50 μg.ml-1) and grown overnight at 37 °C in an incubator. A single 
colony was picked and inoculated into 10 ml LB broth containing Kanamycin (50 μg.ml-1) and 
incubated overnight at 37 °C with agitation at 180 rpm. The next day, 10 ml of culture was 
inoculated into 1 L of fresh LB broth supplemented with Kanamycin (50 μg.ml-1) and grown 
at 37 °C with agitation (180 rpm) until the culture reached an OD600 of 0.3 - 0.5 AU. Induction 
of expression was achieved by supplementing the media with a final concentration of 0.5 mM 
IPTG and the culture incubated overnight at 20 °C with shaking (180 rpm). 
Cell harvest and lysis 
The overnight culture was spun down in a centrifuge (Sorvall RC 5C Plus) at 4 °C and 4000 
rpm (3010 g) for 30 minutes. The supernatant was removed, and the cell pellet resuspended in 
40 ml of ice cold PBS (by vortexing) and then centrifuged again at 4 °C and 4000 rpm (3010 g) 
for 30 minutes. The cell pellet was then stored before purification at – 20 °C. The frozen cell 
pellet was left to thaw at room temperature for approximately 1 hour prior to lysis. The cell 
pellet was resuspended (by vortexing) in 30 ml of lysis buffer, supplemented with protease 
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inhibitor cocktail, 30 mg lysozyme and 0.5 μl Benzonase® nuclease (Sigma Aldrich, E1014, 250 
units.μl-1). The cell suspension was incubated on ice for 30 minutes prior to sonication. The 
cells were kept on ice and sonicated for 1 minute with 10 second pulses (at 50 % amplitude) 
with 10 second intervals. The lysate was incubated at 4 °C for 5 minutes with gentle rotation 
and then sonicated again as above. The lysate was cleared by centrifugation at 4 °C and 4000 
rpm for 30 minutes, the supernatant removed, then centrifuged at 10000 rpm for 15 minutes. 
For protein purification of UbE2L3 see section 7.2.4. 
7.2.4. General Protein Purification Protocol 
The proteins (ATAD2, [15N]-ATAD2 and UbE2L3) were expressed with a 6 x His-tag at the C-
terminus for purification by Nickel NTA affinity chromatography. Nickel (II)-NTA agarose 
beads (1 ml, 50 % slurry) (Qiagen, 30250) were washed with wash buffer (3 x 15 ml) to remove 
excess ethanol and the cleared lysate incubated with the resin at 4 °C for 2 hours with gentle 
rotation. The bead mixture was poured over a 20 ml column (BioRad) and the beads left to 
settle at the bottom. The flow through was collected by gravity flow for analysis by SDS-PAGE 
and the column washed twice with 20 times bed volume of lysis buffer containing 20 mM 
imidazole (and preventing the beads from drying out). The 6xHis-tagged proteins were eluted 
in 8 x 2 ml fractions using a stepwise gradient of 50 – 250 mM imidazole (50, 75, 100, 150, 200, 
250, 250, 250 mM). The fractions were run on SDS-PAGE to assess purity. Fractions containing 
protein were pooled and dialysed (3500 MWCO, Thermo Scientific Slide-A-Lyzer dialysis 
cassette) into 1 L of dialysis buffer (see table 7.3) for 1 hour at 4 °C with gentle stirring. The 
cassette was then transferred into 4 L of fresh dialysis buffer and left overnight at 4 °C, with 
stirring. The following day, the dialysed protein solution was concentrated in a 20 ml protein 
concentrator spin column (Thermo Scientific Pierce, PES MWCO 10,000) using a bench top 
centrifuge set at 4000 rpm and 4 °C until the volume was reduced to 500 μl. After concentration 
determination (see section 7.2.5), to UbE2L3 DTT was added to a final concentration of 1 mM 
(UbE2L3). The pooled protein fractions were then aliquoted into 30 μl fractions and flash 
frozen in liquid nitrogen and stored at - 80 °C. 
The proteins were analysed by HPLC (Method 2 for UbE2L3 and Method 3 for ATAD2) and 




7.2.5. Concentration determination by UV-Vis Spectroscopy 
The protein concentration was determined by making a 1:10 dilution of purified protein in 
elution buffer and then measured using a NanoDrop 1000 spectrophotometer (PEQLAB 
biotechnologie GmBH). The volume of the sample is 2 μl and the measurement was recorded 
three times and averaged for accurate concentration determination. The protein extinction 
coefficients  
7.2.6. SDS-PAGE 
SDS-PAGE analysis was carried out according to standard methods and procedures. The gels 
used were precast polyacrylamide Bolt 12 % Bis-Tris Plus Gels (1.0 mm, 17 well, Invitrogen, 
Thermo Fisher Scientific) and run using MES SDS Running buffer (20x, Novex, Life 
Technologies). The gel was run using 200 V Bio-Rad Power Pac 3000 for 30 min, the loading 
buffer was Bolt™ LDS sample buffer (4x, Novex, Life Technologies), molecular weight ladder 
was SeeBlue Plus2 Prestained (Invitrogen, Thermo Fisher Scientific). Standard procedure 
involves mixing sample with loading buffer under reducing conditions (1 M DTT) and heating 
the sample for 10 minutes at 70 °C. The gel is then visualised by staining with SimplyBlue 
SafeStain (Invitrogen, Thermo Fisher Scientific). 
Protein Dialysis buffer Final concentration 
ATAD2 
10 mM HEPES, 500 mM NaCl, pH 7.0, 0.5 mM 
TCEP, 5 % glycerol 
171 μM 
[15N]-ATAD2 
10 mM HEPES, 500 mM NaCl, pH 7.0, 0.5 mM 
TCEP, 5 % glycerol 
65 μM 
UbE2L3 20 mM HEPES, 100 mM NaCl, pH 7.5, 1 mM DTT 208 μM 
Table 7.4: Final buffer conditions and concentration of purified proteins. 
7.2.7. Fluorescent labelling of ATAD2 
A frozen aliquot of ATAD2 in storage buffer was thawed on ice. Precipitation however, was 
observed after thawing, and therefore the solution was centrifuged (13000 rpm) to remove 
aggregated protein. The concentration was re-measured by UV/Vis spectroscopy (NanoDrop 
1000 spectrophotometer (PEQLAB biotechnologie GmBH)). The Cy5-maleimide dye (50 mM 
stock in DMSO, final protein:dye ratio of 1:7) was added to 750 μg of ATAD2 protein in buffer 
(325 μl) with 0.5 mM of TCEP and left overnight at 4 °C with shaking.  The next day a NAP-5 
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column (GE Healthcare illustra™) was equilibrated with protein buffer (10 mM HEPES, pH 
7.0, 500 mM NaCl, 0.5 mM TCEP, 5 % glycerol) and the labelling mixture applied directly to 
the column. Fractions were collected (~200 μl) by gravity flow by applying buffer directly to 
the centre of the column. Separation on the column of labelled protein and free dye was 
observed by eye and 8 fractions were collected in total. Fractions were analysed by HPLC, 
method 2 (section X), and fractions 1 – 4 were pooled. To determine the concentration of 
labelled protein, the absorbance was measured at 280 nm and 330 nm (to correct for stray light, 
since folded proteins do not absorb at this wavelength, any absorbance observed at 330 nm 
therefore arises due to scattering) and 650 nm (optimal absorption of Cy5 dye). Sample buffer 
was used as a blank reference solution. The average absorbance measurements, stray light 
corrections, Cy5 correction factors (CF280 = 0.0415; CF330 = 0.0509) and extinction coefficients for 
ATAD2 (8940 M-1.cm-1) and Cy5 dye (250,000 M-1.cm-1) were used to calculate the degree of 
labelling according to the following equations: 
𝐴280 𝑐𝑜𝑟𝑟𝑒𝑐𝑡𝑒𝑑 = 𝐴280 − (𝐴650 × 𝐶𝐹280) 
𝐴330 𝑐𝑜𝑟𝑟𝑒𝑐𝑡𝑒𝑑 = 𝐴330 − (𝐴650 × 𝐶𝐹330) 
𝐴280 𝑠𝑡𝑟𝑎𝑦 𝑙𝑖𝑔ℎ𝑡 𝑐𝑜𝑟𝑟𝑒𝑐𝑡𝑒𝑑 = 𝐴280 𝑐𝑜𝑟𝑟𝑒𝑐𝑡𝑒𝑑 − (𝐴330 𝑐𝑜𝑟𝑟𝑒𝑐𝑡𝑒𝑑 × 1.93) 
Where A280 corrected is the corrected absorbance at 280 nm of the protein, A330 corrected is the corrected 
absorbance for the protein at 330 nm and A280 stray light corrected is the absorbance. The total 
concentration of protein (M) in the sample is then given by: 
[𝑃]0 =
𝐴280 𝑠𝑡𝑟𝑎𝑦 𝑙𝑖𝑔ℎ𝑡 𝑐𝑜𝑟𝑟𝑒𝑐𝑡𝑒𝑑
8940 × 0.1
 





The ratio of the protein concentration and the dye concentration is then used to calculate the 
labelling efficiency. The correction factors for the free Cy5 dye have been previously calculated 




Figure 7.1: Chemical structure of Cyanine-5 maleimide dye. This dye was chosen for its 
favourable fluorescent properties namely, high molar extinction coefficient (250,000 M-1.cm-1). 
7.2.8. Synthesis of Nα-Fmoc-Nε-acetyl-L-lysine-OH 
Nα-Fmoc-Nε-acetyl-L-Lysine-OH was synthesised in house for use in SPPS of the H4K5 and 
H4 peptides. 
Figure 7.2: Synthetic scheme to  Nα-Fmoc-Nε-acetyl-L-Lysine-OH . Protocol adapted from 
Altamore et al.253 
Synthesis of Nα-Fmoc-L-lysine-OH (2.2) 
TFA (6.0 ml, 78.4 mmol) was added to a solution of commercially 
available Fmoc-L-Lysine(Boc)-OH (2.1, 2.1 g, 4.5 mmol) in DCM 
(60 ml). The resulting solution was stirred at room temperature for 
3 hours. Thereafter, the reaction mixture was concentrated in vacuo  
on a Rotavap at 40 °C, and the residual TFA was removed by 
suspending the solution in diethyl ether (20 ml) followed by concentration  in vacuo (repeated 
three times). The resulting residue was suspended in diethyl ether and the precipitate filtered 
to give title compound (2.2, 2.3 g, 4.8 mmol, 100 % yield) as a white solid (TFA salt). MS (ESI) 





Synthesis of Nα-Fmoc-Nε-acetyl-L-lysine-OH (2.3) 
Ac2O (900 μl, 9.5 mmol, 2 eq) was added to a solution of 2.2 (2.3 
g, 4.8 mmol, 1 eq.) and NEt3 (731 μl, 5.2 mmol, 1.1 eq.) in DCM 
(25 ml) at 0 °C and the resulting solution stirred for 2 hours. The 
mixture was then concentrated in vacuo and the residue 
redissolved in DCM (20 ml). The organic phase was washed with 
brine (10 ml), dried over Na2SO4, filtered and concentrated in 
vacuo. The residue was then purified by flash chromatography (Biotage ZIP® KP-Sil column 
(120 g), DCM:MeOH:AcOH, 96:2:2). The fractions were leuted with a gradient of 0 – 2 % 
methanol. The peak fractions (as analysed by TLC) were combined and concentrated under 
reduced pressure using a Rotavap. The residue was azeotroped three times with cyclohexane 
to remove excess acetic acid. The residue was then dissolved in methanol (10 ml) and purified 
by precipitating in an excess of water. The precipitate was filtered and dried in vacuo (using 
vacuum oven) to yield the title compound as a white solid (2.3, 1.7 g, 4.1 mmol, 87 %). MS 
(ESI) exact mass calculated for C23H26N2O5: [M+H]+calc 411.2; [M+H]+obs 411.02. HPLC (Method 
1) tR 15.9 mins; > 95 % purity as measured by peak area  1H NMR (500 MHz, MeOD) δ 7.80 
(2H, d), 7.69 (2H, t), 7.40 (2H, t), 7.32 (2H, t), 4.37 (2H, t) , 4.24 (1H, t), 4.16 (1H, m), 3.22 (1H, 
dd), 3.18 (1H, t), 1.93 (3H, s), 1.86 (1H, m), 1.72 (1H, m), 1.49 (4H, m), 1.32 (1H, t). 13C NMR 
(126 MHz, MeOD) δ 174.5, 171.8, 157.3, 144.0, 143.8, 141.2, 127.4, 126.8, 124.9, 119.5, 66.5, 53.9, 
38.8, 31.0, 28.4, 22.9, 21.2. 
7.2.9. Solid-phase peptide synthesis 
7.2.9.1. Preparation of Pra functionalised resin (TG-Pra) 
TG-RAM resin was prepared by swelling 1 equivalent of 
dry resin (0.3 mmol.g-1, 90 μm,) in DMF for 30 minutes 
with shaking. The resin was then treated twice with a 
solution of 20 % (v/v) piperidine in DMF at room 
temperature with shaking for 10 and 15 minutes 
respectively, with washing in between (10 column 
volumes of DMF). The resin was then washed thoroughly with 10 successive column volumes 
of DMF, DCM, MeOH and H2O, to ensure complete removal of excess piperidine. The resin 
was then treated with a solution of Fmoc-Pra (6 eq.), HATU (5.5 eq.), DIPEA (12 eq.) in DMF 
for 30 minutes with shaking. The reaction was drained and rinsed with 10 column volumes of 
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DMF and the coupling reaction repeated. The Pra-functionalised resin was then washed 
thoroughly with DMF, H2O, MeOH and DCM and a small amount of resin used for the TNBS 
test (see section 7.1.5). The resin is then dried overnight in vacuo. 
7.2.9.2. Preparation of Pra-DOA-functionalised resin (TG-Pra-DOA) 
TG-Pra resin (section 7.2.9.1) was 
prepared by swelling 1 equivalent of 
dry resin (0.3 mmol.g-1, 90 μm,) in 
DMF for 30 minutes with shaking. The 
resin was then treated twice with a 
solution of 20 % (v/v) piperidine in 
DMF at room temperature with 
shaking for 10 and 15 minutes respectively, with washing in between (10 column volumes of 
DMF). The resin was then washed thoroughly with 10 successive column volumes of DMF, 
DCM, MeOH and H2O, to ensure complete removal of excess piperidine. The resin was then 
treated with a solution of Fmoc-DOA (6 eq.), HATU (5.5 eq.), DIPEA (12 eq.) in DMF for 30 
minutes with shaking. The reaction was drained and rinsed with 10 column volumes of DMF 
and the coupling reaction repeated. The Pra-functionalised resin was then washed thoroughly 
with DMF, H2O, MeOH and DCM and a small amount of resin used for the TNBS test (see 
section 7.1.5). The resin is then dried overnight in vacuo. 
7.2.9.3. Peptide H4K5 (H2N-RGKacGG-DOA-βCF3F-PRA-CONH2) 
The title peptide was synthesised by standard solid-phase synthesis methods, outlined in 
section 7.1.5, using prepared TG-Pra resin (100 mg, 0.3 mmol.g-1). Fmoc protected amino acids 
(Gly, Lys(Ac), Arg(Pbf), β(CF3)Phe) were used at 6 eq, HATU (5.5 eq.), DIPEA (12 eq.). 
Cleavage from the resin was carried out according to section 7.1.5. MS (ESI) exact mass 
calculated for C42H64F3N13O11: [M+H]+calc 985.4; [M+H]+obs 985.6. HPLC (Method 1) gives a tR of 
15.6 mins. Absorbance is measured at 210 nm, and purity is > 90% (as measured by peak area). 
The final peptide was stored as a white powder at 4 °C (yield 11 mg, ~ 37 %). HPLC 





7.2.9.4. Peptide H4 (H2N-RGKacGGKacGLGKacG-DOA-PRA-CONH2) 
The title peptide was synthesised by standard solid-phase synthesis methods, outlined in 
section 7.1.5, using prepared TG-Pra-DOA resin (200 mg, 0.26 mmol.g-1). Fmoc protected 
amino acids (Gly, Lys(Ac), Arg(Pbf), β(CF3)Phe) were used at 6 eq, HATU (5.5 eq.), DIPEA (12 
eq.). Cleavage from the resin and purification of the peptide was carried out according to 
section 7.1.5 .MS (ESI) exact mass calculated for  C59H102N20O18:  [M+H]+calc 1378.8; [M+H]+obs 
1380.8. HPLC (Method 1) gives a tR of 11.7 mins. Absorbance is measured at 210 nm, and purity 
is > 90% (as measured by peak area). The peptide was stored as a white powder at 4 °C (yield 
9 mg, ~ 11% yield). HPLC chromatogram and mass spectrum are given in appendix 8.1.6 . 
7.2.9.5. Peptide H2N-hoA-(mCF3)F-E-R-CONH2 
The title peptide was synthesised by standard solid-phase synthesis methods, outlined in 
section 7.1.5 using TG-RAM resin (120 mg, 0.26 mmol.g-1). Fmoc protected amino acids (homo-
Ala, meta(CF3)Phe, Arg(Pbf), Glu(OtBu)) were used at 3 eq, HATU (2.5 eq.), DIPEA (6 eq.). 
Cleavage from the resin and purification of the peptide was carried out according to section 
7.1.5. MS (ESI) exact mass calculated for C25H37F3N8O6:  [M+H]+calc 603.3; [M+H]+obs 603.4. HPLC 
(Method 1) gives a tR of 12.1 mins. Absorbance is measured at 210 nm, and purity is > 90% (as 
measured by peak area). The peptide was stored as a white powder at 4 °C (final yield 10 mg 
~ 53 %). HPLC chromatogram and mass spectrum are given in appendix 8.1.7. 
7.2.9.6. Dipeptide and tripeptide truncates: H2N-hoA-(mCF3)-CONH2 and H2N-hoA-
(mCF3)-E-CONH2 
The title peptides were synthesised by standard solid-phase synthesis methods, outlined in 
section 7.1.5 using TG-RAM resin (50 mg, 0.26 mmol.g-1). Fmoc protected amino acids (homo-
Ala, meta(CF3)Phe, Arg(Pbf), Glu(OtBu)) were used at 3 eq, HATU (2.5 eq.), DIPEA (6 eq.). 
Cleavage from the resin and purification of the peptide was carried out according to section 
7.1.5. MS (ESI) exact mass calculated for: H2N-hoA-(mCF3)-CONH2 [M+H]+calc 603.3; [M+H]+obs 
603.4. HPLC (Method 1) gives a tR of 12.1 mins. Absorbance is measured at 210 nm, and purity 
is > 90% (as measured by peak area). The peptide was stored as a white powder at 4 °C (final 
yield 10 mg ~ 53 %). HPLC chromatogram and mass spectrum are given in appendix 8.1.7. 
7.2.9.7. Fluorinated Dipeptide and Tripeptide Library synthesis 
The fluorinated dipeptides, and C- and N-terminal tripeptides were synthesised by standard 
solid-phase synthesis methods, outlined in section 7.1.5. Each peptide was synthesised using 
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TG-RAM resin (25 mg; 0.23 mmol.g-1). After cleavage and drying overnight, peptides were 
dissolved in 500 μl 25 % ACN in H2O and analysed by HPLC and LCMS. Peptides were then 
flash frozen in liquid N2 and dried overnight in a freeze drier (Christ, Alpha 1-2 LD Plus) 
operating at 0.2 mbar and – 52 °C (for the ice condenser). Following this, solid peptides were 
weighed and DMSO added to a final concentration of 10 mM. Peptides are stored at -20 °C as 
DMSO stock solutions and 4 °C as a white powder. The chemical structures, HPLC and LCMS 
QC data for all fluorinated di- and tripeptides are given in appendix 8.1.10-12. 
7.2.9.8. Solid-phase Synthesis of OBOC Lysine-PTM Library 
The SCAL2-PRA-DOA functionalised resin was synthesised using standard solid-phase 
synthesis methods. SCAL2 was prepared in-house by Peter Dodd and used as needed.  
 
Figure 7.3: Chemical structure of OBOC library. SCAL-2 functionalised resin and R1 = 
randomised L amino acid; R2 = randomized lysine derivative amino acid; R3 = fixed position 
L amino acid/sub-library). 
Using the functionalized resin, tripeptide sub-libraries were prepared by the solid-phase 
method on a 365 mg (110 μmol) scale following the Fmoc strategy and using standard Fmoc-
derivatized amino acids (6 eq). Activation of amino acids was achieved using HATU-DIPEA 
(5.5 and 12 eq. respectively), and Fmoc deprotection was carried out using a 20% (v⁄v) 
piperidine solution in DMF. All couplings were performed for 2 x 30 minutes and 
deprotections for 1x10 + 1x15 minutes. Fixed positions (R3) were introduced using 6 eq of a 
single protected amino acid derivative. Building blocks for randomized positions (R1, R2) 
were coupled using 4 or 6 eq of a single protected amino acid derivative (see table 7.5 and 7.6 
respectively) then a split and mix strategy was applied. The resin was split into 16 SPEs (~20 
mg per sublibrary, 6.6 μmol) and the first amino acid coupling performed in parallel. 
Following thorough washing steps beads were thoroughly mixed in a SPE (10 ml volume) by 
inverting several times. The bead mixture was deprotected and then split further into 12 sub-
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libraries. The second amino acid coupling was performed, mixed and deprotected as before. 
The resin was mixed thoroughly again and then split into the final 16 sub-libraries. The final 
amino acid coupling was performed and the resin washed and dried in vacuo, then stored 
under reduced pressure in a desiccator prior to QC analysis. 








1 0.006 20   
HATU 380.2 
 
5.5 0.033 12.5   
DIPEA 129.2 0.742 12 0.072  12.6  
DMF 73.1 0.948 
 
   
1 L-ALA 311.3 
 
6 0.036 11.2  
2 L-ARG(pbf) 648.8 
 
6 0.036 23.4  
3 L-ASN(trt) 596.7 
 
6 0.036 21.5  
4 L-ASP(Otbu) 411.5 
 
6 0.036 14.8  
5 L-GLN(trt) 610.7 
 
6 0.036 22.0  
6 L-GLU(Otbu) 425.5 
 
6 0.036 15.3  
7 L-HIS(trt) 619.7 
 
6 0.036 22.3  
8 L-LEU 353.4 
 
6 0.036 12.7  
9 L-LYS(boc) 468.5 
 
6 0.036 16.9  
10 L-PHE 387.4 
 
6 0.036 13.9  
11 L-PRO 337.4 
 
6 0.036 12.1  
12 L-SER(Otbu) 383.4 
 
6 0.036 13.8  
13 L-THR(Otbu) 397.5 
 
6 0.036 14.3 
 
14 L-TRP(boc) 526.6 
 
6 0.036 19.0  
15 L-TYR(Otbu) 459.6 
 
6 0.036 16.5  
16 L-VAL 339.4 
 
6 0.036 12.2  
Table 7.5: Equivalents and amounts of L-amino acids used for the coupling reaction in 
construction of the OBOC library (coupling reactions were performed twice). This was used 


















1 0.006    
HATU 380.2 
 
5.5 0.033 12.5   
HATU 380.2 
 
3.5 0.021 8.0   
DIPEA 129.2 0.742 12 0.072  12.6  
DIPEA 129.2 0.742 8 0.048  8.4  
DMF 73.1 0.948 
 
   
1 Lys-DEV-1 410.5 
 
6 0.036 14.8  
2 Lys-DEV-2 464.4 
 
6 0.036 16.7  
3 Lys-DEV-3 472.5 
 
6 0.036 17.0  
4 Lys-DEV-4 584.6 
 
4 0.024 14.0  
5 Lys-DEV-5 480.6 
 
4 0.024 11.5  
6 Lys-DEV-6 480.6 
 
4 0.024 11.5  
7 Lys-DEV-8 482.6 
 
4 0.024 11.6  
8 Lys-DEV-10 587.7 
 
4 0.024 14.1  
9 Lys-DEV-11 601.7 
 
4 0.024 14.4  
10 Lys-DEV-12 473.5 
 
6 0.036 17.0  
11 Lys-DEV-15 482.6 
 
4 0.024 11.6  
12 Lys-DEV-16 524.6 
 
6 0.036 18.9  
Table 7.6: Equivalents and amounts of Lysine-DEV (DEV = derivative) amino acids used in 
the coupling reaction at position R2 of the OBOC library (figure 7.3). Lysine-DEV structures 
are given in appendix 8.1.9. Lys-DEVs 7, 9, 13, 14 failed QC checks, therefore were not 
included in the final library. 
Library Summary:  
 Solid support: SCAL linker functionalised TentaGel™ beads (0.3 mmol.g-1loading 
capacity, 140 μm). 20 mg resin per sub (theoretical 6.6 μmol). 
 3072 member compound library, 16 x 12 x 16 tripeptide sequences in 16 sub-libraries. 
After the last amino acid coupling, the resins are retained in 16 SPE vials, this means 
that the last residue of the library sequence is known, hence 16 sub-libraries. 
Therefore, screening pools of 192 compounds per sub-library. 
 16 x FMOC protected L-amino acids: L-ALA, L-ARG(pbf), L-ASN(trt), L-ASP(Otbu), 
L-GLN(trt), L-GLU(Otbu), L-HIS(trt), L-LEU, L-LYS(boc), L-PHE, L-PRO, L-
SER(Otbu), L-THR(Otbu), L-TRP(boc), L-TYR(Otbu), L-Val. 







Lysine, Nα-Fmoc-Nε-nicotinyl-D-Lysine, Fmoc-N-methyl-Lysine(Boc), (2S,5R)-
Fmoc-2-amino-4-(3-Boc-2,2-dimethyl-oxazolidin-5-yl)-butyric acid (structures given 
in appendix 8.1.9). 
7.2.9.9. QC analysis of library 
For purity and loading determination of the OBOC library a small amount of resin (~1 mg) 
from each sub-library was placed into a glass vial and labelled via the N-terminus with TMR-
acid (6-TAMRA). The 6-TAMRA is used exactly as an amino acid and coupling reaction 
performed as described in section 7.1.5. The coupling reaction was performed in a glass MS 
vial for ease of bead picking. After the labelling reaction, the resin was thoroughly washed 
and dried overnight in vacuo. The 16 vials containing the TMR labelled beads were treated 
with an excess of TFA (200 μl), twice for 1 hour each with shaking. The TFA was then removed 
under reduced pressure in a Speed Vac and the 16 batches were suspended in 50 % ACN in 
H2O (1 ml) and left overnight at 4 °C. Following this, the supernatant was removed and single 
beads were picked using a Gilson pipette, with 10 μl pipette tip and placed into a separate 
vial. The vial containing a single bead were treated with a 12 %(v/v) solution of TMSBr in TFA 
for 2 hours. The TFA was removed under reduced pressure in a speed vac and 20 μl of a 50 % 
ACN solution in H2O was added. The solution is left to stand for 15 minutes prior to injection 
for HPLC analysis (injection volume, 15 μl). HPLC analysis was performed using Method 1 
(section 7.1.2) and fluorescence detection at λex 555 nm, and λem 575 nm. The purity was 
calculated from the percentage peak area of the labelled peptide and the loading capacity is 
calculated from the TAMRA standard curve (shown in appendix 8.1.8). 
7.2.10. [1H, 15N]-HSQC Experimental analysis of ATAD2 with peptide H4 
The synthesised peptide H4 was dissolved in NMR buffer (10 mM HEPES, 500 mM NaCl, 2 
mM DTT, pH 7.0, 10 % D2O) to a final stock concentration of 10 mM.  [15N]-ATAD2 (65 μM) 
was analysed by 2D-HSQC NMR experiments on the AVA 800 MHz spectrometer. The 
starting volume was 400 μl in a 5 mm NMR tube (Norell® standard series). Spectra were 
acquired with the following parameters: spectral width 27 ppm, time domain 256 (in F1), 
number of scans 8, receiver gain 128 and D1 = 1.4 s. A titration with peptide H4 according to 




Titration Point [P]0 final (μM) [L]0 final (μM) Molar Ratio (L:P) 
1 65 0 0 
2 59.7 50 0.83 
3 59.4 100 1.68 
4 58.8 200 3.40 
5 57.7 400 6.93 
6 54.5 1000 18.35 
Table 7.7: Experimental set-up of [15N]-HSQC ATAD2 titration with peptide H4.  
7.2.11. OPPG Proof of concept experiments with H2N-hoA-(mCF3)F-E-R-CONH2 
The survivin protein was supplied by Dr Nhan Pham (Auer group) at a concentration of 134 
μM in buffer (20 mM HEPES, 100 mM NaCl, pH 7.5). A stock solution of peptide was made in 
non-deuterated DMSO (final concentration 50 mM). Two samples were prepared in NMR 
buffer (20 mM HEPES, 100 mM NaCl, pH 7.5, 10 % D2O) with final concentration of peptide 
at 100 μM (final DMSO concentration 0.2 %). To one sample, survivin was added to a final 
concentration of 10 μM and to the other, equal volume of NMR buffer. The 19F NMR spectra 
were recorded (see section 7.1.3.1) and analysed in MestReNova (see section 7.1.4).  
7.2.12. Fluorine Dipeptide/Tripeptide Screening against UbE2L3 
Fluorinated dipeptides were screened against UbE2L3 using the 19F NMR experimental 
parameters described in section 7.1.4. Peptides were pooled based on their minimal 19F 
resonance overlap (peptide pools are given in appendix 8.1.10). The peptides were dissolved 
in NMR assay buffer (20 mM HEPES, 100 mM NaCl, pH 7.5, 10 % D2O) to a final concentration 
of 100 μM of each peptide (final DMSO concentration of pool is 4 %) and final volume of 1.1 
ml. The peptide pools were aliquoted into two separate Eppendorf tubes then protein was 
added to one at a final concentration of 10 μM and an equivalent amount of buffer added to 
the control. Samples were pipetted into NMR tubes and placed in the sample changer of the 
AVA 400 MHz spectrometer for analysis. 1D 19F NMR spectra were processed using 
MestReNova and the chemical shifts recorded in a table. The 19F chemical shifts (in Hz) from 
the protein containing sample were subtracted from the control sample and the data plotted 





7.3. Experimental Methods for Chapter 4 
7.3.1. Fragment compound handling and storage 
Fragment compounds were purchased from various commercial vendors, specifically: 
Fluorochem Ltd, Enamine Ltd, Vitas M Chemical Ltd and Selleck Chemicals. 
Stock solutions of each commercial fragment compound were constructed by weighing 1 - 5 
mg of compound and adding the calculated amount of non-deuterated, anhydrous DMSO to 
a final fragment concentration of either 10 or 100 mM, where stated. Solubility was confirmed 
by visual inspection. For compounds that were liquids, the compound density was used to 
calculate the amount of DMSO required for a final concentration 100 mM using a 5 μl aliquot 
of compound. DMSO fragment stocks were stored at - 20 °C and solid fragments stored at 4 
°C. Quality control of the fragments was performed using three orthogonal standard methods: 
HPLC, MS (ESI) and 19F-NMR. 
Sample preparation for HPLC and LCMS: Fragment stocks were diluted into 25 % ACN to a 
final concentration of 100 μM (1:1000 dilution of 100 mM stock). Samples were analysed using 
the HPLC method 1 and LCMS methods described (section 7.1.2) with an injection volume of 
25 μl and 4 μl, respectively. 
Sample preparation for 19F NMR: Soluble fragments, from DMSO stocks, were further diluted 
to 100 μM in NMR minimal buffer (20 mM HEPES, 100 mM NaCl, pH 7.5, 10 % D2O) and their 
individual 1D 19F NMR spectrum recorded using the AVA 400 MHz spectrometer as described 
in section 7.1.3.1. 
The chemical structures and QC data for all fragments are given in appendix 8.3.3-5. 
7.3.2. HSA Experimental Methods 
HSA (Human Serum Albumin, recombinant, expressed in rice, A9731, Sigma Aldrich), was 
supplied as a lyophilised powder and dissolved in NMR assay buffer (20 mM HEPES, 100 mM 
NaCl, pH 7.5, 10 % D2O) to a final concentration of 300 μM (monomer Mw ~67 kDa). Fragment 
stock solutions of 3-fluoro-2-hydroxy benzoic acid (FHBA), 4-(trifluoromethyl)benzylamine 
(TFBA), 4-(fluoro)benzylamine (FBA) were made by dissolving the compounds in 100 % 
DMSO at a final concentration of 100 mM. A 1D 19F NMR spectrum of FHBA was recorded 
according to the parameters set out in section 7.1.3.1, with a varying number of scans, ranging 
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from: 128, 256, 512, 1024 and 2048. Spectra were processed and analysed using MestReNova 
NMR software. For the HSA concentration series of experiments, 6 samples were prepared in 
NMR buffer (100 μM FHBA, 20 mM HEPES, 100 mM NaCl, pH 7.5, 10 % D2O), then HSA was 
added to a final concentration of: 0 M, 100 nM, 500 nM, 1 μM, 2.5 μM and 5 μM. The 19F NMR 
spectra were recorded as described in section 7.1.3.1 and spectra processed in the same way. 
7.3.3. UbE2L3 enzymatic activity assay (Performed with Dr. Joanna Koszela) 
The reagents for the gel-based ubiquitination assay (see table 7.8) were prepared on ice. A 
master mix for volume of 5 wells was made containing 5 μM ubiquitin and 50 nM E1 enzyme 








For 5 X wells 
(μl) 
H2O   16.58 82.89 
10x buffer 10 1 2.20 11.00 
WT Ub 100 5 1.10 5.50 
E1 5 0.05 0.22 1.10 
UbE2L3 137 5 0.80  
ATP (mM) 100 5 1.10  
  Total Volume 22 100.5 
Table 7.8: Reagents for the SDS-PAGE assay were prepared on ice. A master mix with enough 
material for 5 experiments was made to maintain equal concentrations of E1 and ubiquitin 
across samples. 
The master mix was split between 4 microtubes in 20.1 μl aliquots and 0.8 μl of UbE2L3 (137 
μM) or buffer was added according to the appropriate tubes. Also, 1.1 μl of ATP (100 mM in 
H2O) was added to the appropriate tubes for a final concentration of 5 mM. The reactions were 
then incubated at 37 °C for 2 hours and the reactions quenched by addition of 8 μl SDS loading 
buffer (Bolt® LDS sample loading buffer) and 2 μl H2O or 2 μl DTT (1 M) (table 7.9). The 
samples were resolved by SDS-PAGE and visualised by Coomassie staining (SimplyBlue™, 





Lane 2 3 4 5 
Buffer + + + + 
Ub + + + + 
E1 + + + + 
E2 + - + + 
ATP - + + + 
DTT - - - + 
Table 7.9: SDS-PAGE gel lane map of components in ubiquitination assay. 
7.3.4. Compound pools and sample preparation 
A 19F spectrum of each fragment in aqueous buffer (20 mM HEPES, 100 mM NaCl, pH 7.5, 10 
% D2O) at 100 μM was measured and the chemical shift recorded in a table. Fragment library 
pools were constructed by minimal overlap analysis of 19F-NMR chemical shifts. The table was 
then sorted by chemical shift from lowest to highest. The lowest compound was taken and 
placed into pool 1, the second compound placed into pool 2 etc until the desired number of 
pools had been reached. Fragment pools are given in appendix 8.3.3 - 5. 
For screening purposes, the volume of the solution has to be 500 μl (the AVA 400 spectrometer 
has a 5 mm probe and using less volume will make the samples difficult to shim and lead to 
broader peaks). Care must be taken to maintain equal concentrations of fragments between 
protein and non-protein containing pools, as minute changes in DMSO concentration and pH 
can affect the resonance signal. A 1.1 ml fragment pool solution is made up (for example, 1.1 
μl of 100 mM fragment stock is added to 1.1 ml of NMR buffer, to give final fragment 
concentration of 100 μM). The fragment pool is then divided equally into two Eppendorf tubes 
and the required amount of protein volume is added to the protein-containing pool and 
protein dialysis buffer added to the other Eppendorf tube. This maintains equal amounts of 
fragment and DMSO concentration, between the control and protein-containing samples 
therefore any changes in the spectra can be interpreted as a ligand binding interaction. The 
samples in Eppendorf tubes are centrifuged briefly, then pipetted directly into 5 mm NMR 
tubes. The tubes are placed in the sample rack of the AVA 400 NMR spectrometer and the 1D 




7.3.5. Fragment screening of UbE2L3 
Fragment pools were prepared as described (section 7.3.4) in UbE2L3 buffer (20 mM HEPES, 
100 mM NaCl, pH 7.5, 10 % D2O). The fragments pools were analysed by 19F NMR (section 
7.1.3.1) in the presence and absence of 10 μM UbE2L3. NMR spectra were analysed by 
overlaying the pools with and without protein for indications of chemical shift changes and/or 
line broadening using MestReNova. The chemical shift changes were calculated by 
subtracting the protein containing 19F resonance (in Hz) from the control sample. The data was 
then plotted as a bar chart using Microsoft Excel.  
7.4. Experimental Methods for Chapter 5 
7.4.1. NusEΔ/NusB Protein Handling 
The NusEΔ/NusB protein was supplied as a lyophilised powder in buffer (25 mM Tris.HCl, 
150 mM NaCl, pH 7.5). A 500 μl aliquot of deionised H2O was added to the Eppendorf tube 
and the sample left to stand for 2 minutes. The solution was mixed by gentle pipetting and 
then centrifuged for 5 minutes at 4 °C and 13200 rpm in a table-top centrifuge. The supernatant 
was transferred to a new Eppendorf and the concentration measured by UV-Vis spectroscopy 
(NanoDrop 1000 spectrophotometer (PEQLAB biotechnologie GmBH)). The details and 
parameters for concentration determination of the NusE/NusB complex are given in table 7.10. 
The protein was divided into 30 μl aliquots at 208 μM and flash frozen in liquid N2 for storage 
at – 80 °C. 
The Δ represents a deletion of a 21 amino acid loop (and replaced with a single serine) that 
has been shown to increase the solubility and stability of the NusE/NusB complex, however, 
the KD of the NusEΔ/NusB complex in this form is not known. The deleted region is thought 












(residues 46-67 replaced by a Ser, highlighted in red). 
No. of amino acids 87 
Molecular Weight (Da) 9593.1 










No. of amino acids 159 
Molecular Weight (Da) 17852.4 




Table 7.10: NusEΔ/NusB parameters as calculated by ExPASy ProtParam. The molar 
extinction coefficient here was used to determine protein concentration of the complex. 
7.4.2. 19F NMR Fragment Screening 
Fragment pools were prepared as described (section 7.3.4) in NusEΔ/NusB buffer (25 mM 
Tris/HCl, 150 mM NaCl, pH 7.5, 10 % D2O). The fragments pools (100 μM each compound) 
were analysed by 19F NMR in the presence and absence of 10 μM protein as described in 
section 7.1.3.1. 
7.4.3. Experiments to Validate Fragment Binding  
NMR samples were prepared at 100 μM and 200 μM fragment concentration (500 μl volume) 
in NMR buffer (25 mM Tris/HCl, 150 mM NaCl, pH 7.5, 10 % D2O) for the controls, and 
another sample was prepared including 5 μM protein. The dCSP measurements were 
conventional 1D 19F NMR spectra (recorded according to section 7.1.3.1). The chemical shifts 
were analysed by MestReNova software and KD calculated using equation 4.10. 
The CPMG T2 filtered experiments were a modified version of the 1D 19F NMR experiment 
and utilised a spin echo period of the form [D1-90x-(Δ-180y- Δ)n-acquire] before acquisition 
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where D1 = 8.5 s, Δ = 10 ms, n = 2, 4, 8, 20, 40 (for a total SL time of 2𝑛 × 10, see table 7.11). The 
data were collected with a SW of 22727 Hz and 256 scans. The absolute intensities of the 
fluorine resonance were analysed using MestReNova and plotted against the total length of 
the spin lock period in ms (data were plotted using Origin 9.0). 






Table 7.11: Number of 180 ° pulses (n) in the spin echo period of the CPMG pulse sequence. 
The spin lock time (ms) is therefore calculated by: 2𝑛 × ∆. Where Δ is the delay between pulses 
(10 ms). 
7.4.4. Fragment NOESY experiments 
2D homonuclear 19F-19F NOESY and 1H-1H NOESY spectra were recorded on the PRO 500 
MHz spectrometer and AVA 800 MHz spectrometer respectively. Samples were prepared in 
NMR buffer (500 μl final volume; 25 mM Tris/HCl, 150 mM NaCl, pH 7.5, 10 % D2O; final 
DMSO concentration 0.02 %) using 100 μM CFL02 and CFL17, and 5 μM protein 
concentration, also a no-protein containing control sample was also measured. Spectra were 
recorded with the parameters laid out in table 7.12. 
Parameter 19F-19F NOESY (SFO1 470 MHz) 1H-1H NOESY (SFO1 799 MHz) 
t1 increments 256 1024 
NS 32 32 
SW (ppm) 10 11 
Mixing time (ms) 0.5 0.6 





7.4.5. CFL analogue QC (HPLC, 1H, 13C NMR) 
Compound analogues (CFL02a, CFL02b, CFL02c, CFL02d, CFL02e, CFL02f, and CFL17a) were 
purchased from Fluorochem Ltd (all chemical structures are shown in appendix X), and QC 
analysis was performed using HPLC, to determine purity, and NMR for identification. Stock 
compound solutions were made up at 100 mM concentration in 100 % DMSO. For HPLC 
analysis compounds were diluted in 25 % ACN to a final concentration of 100 μM and 0.1 % 
DMSO concentration (method 1). For identification by NMR, compounds were dissolved in 
deuterated DMSO-d6 at a concentration of 10 mg.ml-1 and analysed by 1H and 13C NMR using 
the AVA 500 spectrometer. QC data is given in appendix 8.4.2. 
7.4.6. Bacterial Inhibition Assay 
Assay optimisation 
To optimise the assay, two parameters, the starting cell OD and final DMSO concentration, 
were adjusted for the best results. A preliminary experiment was performed with starting OD 
measurements at 0.01, 0.005, 0.001 and 0 (test control) AU. DMSO concentration optimisation 
is necessary as compound fragments are routinely stored at 100 mM in 100 % DMSO. Final 
DMSO concentration for optimisation studies ranged from 0, 1, 2, 3 and 4 %.  
A 50 μl aliquot of E. coli BL21(DE3) cells was thawed and inoculated into 5 ml of LB broth. The 
cell suspension was then incubated overnight at 37 °C with shaking (180 rpm). A 1 ml aliquot 
was taken and the optical density (OD) was measured at 600 nm wavelength (Beckman DU 
530 Life Science UV/Vis Spectrophotometer). Cells were diluted accordingly to final OD 
concentrations and aliquoted (100 μl) to a 96 well plate (Whatman, Glass Bottom, Polystyrene 
Microplate). DMSO was added to the final concentration as above. The plate was then inserted 
into a plate reader (TECAN infinite M200 PRO) and incubated at 37 °C. The plate was shaken 
(orbital amplitude 2 mm) for 800 s prior to measurement at 600 nm wavelength, with a settle 
time of 100 ms and measurements were taken every 15 minutes. The data is plotted with 
Microsoft Excel and the growth curves are shown in appendix 8.4.4. 
Final assay conditions 
A 50 μl aliquot of E. coli BL21(DE3) cells was thawed and inoculated into 5 ml of LB broth. The 
cell suspension was then incubated overnight at 37 °C with shaking (180 rpm). A 1 ml aliquot 
was taken and the OD was measured at 600 nm wavelength. Cells were then diluted to OD 
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0.01 in LB medium. Fragment hit compounds (CFL02, CFL02f, CFL17 and CFL17a) were 
dissolved in LB medium to final concentrations of 100 μM, 500 μM and 1 mM with a final 
DMSO concentration of 1 % in all samples and a blank sample as a control. Also, compound 
CFL23, which did not show binding activity in the 19F NMR assay was used as a negative 
control compound. Compounds were plated in 100 μl aliquots on a 96 well plate in triplicate. 
A 10 μl aliquot of cells was then added to each well, to give a final OD of 0.001. Negative 
controls were included with no cells and compound only. The plate was measured using the 
same script as above.  
7.4.7. Quantitative Equilibrium Microdialysis (qμD) 
Quantitative equilibrium microdialysis (qμD) was used as an orthogonal, complimentary 
assay to confirm binding of the hit fragments and compound analogues.  
Calibration curve and dialysis control 
A calibration curve for compounds CFL02, CFL02f, CFL17 and CFL17a was achieved by 
constructing a series of increasing compound concentrations to determine the linear range of 
the spectrometer. Compound samples containing 10 nM, 50 nM, 100 nM, 500 nM, 1 μM, 5 μM 
and 10 μM were made up in assay buffer (20 mM Tris/HCl, 50 mM NaCl, 2 % DMSO and 0.1 
% pluronic acid). The compounds were then tested using the LCMS method described below. 
Following this, compounds were tested for their ability to dialyse across the membrane. Rapid 
equilibrium device (RED) inserts (MWCO 8 kDa) were placed in the well of a compatible base 
plate (P89811, Thermo Fisher Scientific) and 100 μl of 40 μM compound in assay buffer (20 
mM Tris/HCl, 50 mM NaCl, 2 % DMSO and 0.1 % pluronic acid) was added to the sample 
chamber (red compartment, V1) and 300 μl of assay buffer was added to the dialysis chamber 
(white compartment, V2). The plate was sealed with PlateSealing Tape for 96-well plates 
(15036, Thermo Fisher Scientific) and incubated at room temperature overnight (~16 hours) 
with rotation (300 rpm). Following overnight incubation, 50 μl of sample is removed from 
each compartment and added to a MS vial (VWR, 300 μl). The samples were run using LCMS 
analysis described below. 
Equilibrium Microdialysis with CFL02f 
Equilibrium microdialysis was used for determination of the dissociation constant of fragment 
hit CFL02f against the NusEΔ/NusB protein complex. Rapid equilibrium device (RED) inserts 
216 
 
(MWCO 8 kDa) were placed in the well of a compatible base plate (P89811, Thermo Fisher 
Scientific). NusEΔ/NusB protein was diluted to 40 μM in assay buffer (20 mM Tris/HCl, 50 
mM NaCl, and 0.1 % pluronic acid) and compound was added to a final concentration of 40 
μM with a final DMSO concentration of 2 %. A 100 μl aliquot of protein-ligand solution was 
added to the sample chamber (red compartment) and 300 μl of assay buffer added to the 
dialysis chamber (white compartment). The plate was sealed with PlateSealing Tape for 96-
well plates (15036, Thermo Fisher Scientific) and incubated at room temperature overnight 
(~16 hours) with rotation (300 rpm). The dialysis experiment was performed in triplicate for 
the control (no protein) and compound containing samples. Following this, a 10 μl aliquot 
from each sample chamber was taken and diluted 1:20 into assay buffer, containing 0.1 % 
formic acid, in a MS vial. The samples were then analysed by LCMS on an Orbitrap system. 
LCMS analysis 
The vials were placed in the refrigerated (10 °C) sample injector drawer of the Acquity UPLC 
(Waters) and 2 μl of sample injected onto the C18 HPLC column. The solvent system for 
elution is: Buffer A – H2O (0.1 % FA). Buffer B – ACN (0.1 % FA). The standard gradient 
program used for analysis was: 0 – 3 min, 0.5 % B; 3 – 18 min, 70 % B; 18 – 22 min, 95 % B; 22 
– 25 min 0.5 % B; with a flow rate of 8 μl.min-1. The mass analyser is an LTQ Orbitrap (Thermo 
Finnigan) with ESI injection. This method was used to quantify the peak intensity response as 
a function of concentration in both compartments of the RED apparatus following dialysis. 
Thermo Xcalibur software was used to analyse the mass spectra and calculate intensities for 
generation of calibration curves and KD determination from equilibrium microdialysis. The 
compound CFL17a did not produce a signal, indicating that the compound did not ionise.  
7.4.8. NusEΔ/NusB HSQC Titrations 
15N-labelled NusEΔ/NusB protein was kindly supplied by the Department of Biopolymers at 
the University of Bayreuth. When required, a 500 μl aliquot of approximately 200 μM protein 
was thawed and transferred to a 2 ml micro test tube. A piece of dialysis membrane (MWCO 
3 kDa) was placed over the top and the tube placed upside down into dialysis buffer (25 mM 
Tris/HCl, 150 mM NaCl, pH 7.5). The protein was left to dialyse overnight at 4 °C with gentle 
mixing. The protein was then centrifuged briefly and the concentration measured by UV-Vis 
spectroscopy (extinction coefficient given in table X). Dialysed protein was stored at 4 °C and 
this process was repeated when necessary. 
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NMR samples of 550 μl in volume were prepared for 2D 15N-HSQC experiments. The final 
protein concentration was 100 μM in NMR assay buffer (25 mM Tris/HCl, 150 mM NaCl, 10% 
D2O, 0.01 % NaN3). Compound fragments were dissolved in 100 % DMSO to final 
concentrations of 10 and 25 mM. Compound titrations for fragments CFL02, CFL02a, CFL02b, 
CFL17 and CFL17a were completed according to table 7.13. Spectra were acquired with the 
following parameters: spectral width 20 ppm, time domain 256 (in F1), number of scans 16, 



















1 100 0 0 0 0 550.0 
2 99.55 45.25 0.45 0.45 2.5 552.5 
3 98.57 143.37 1.45 1.43 8 558 
4 97.26 274.09 2.82 2.74 15.5 565.5 
5 95.07 492.65 5.18 4.93 28.5 578.5 
6 93.46 909.09 9.73 6.54 38.5 588.5 
7 89.65 1890.79 21.09 10.35 63.5 613.5 
Table 7.13: The titration points used for compounds CFL02, CFL02a, CFL02b, CFL17 and 
CFL17a. [P]0 final protein concentration; [L]0 final ligand concentration. 
For each titration, the compound was added directly to the NMR tube. The tube was then 
inverted several times and shaken vigorously. The sample was then centrifuged in a manual, 
table-top centrifuge to ensure all the sample mixed thoroughly and at the bottom of the tube. 
The compound titration for CFL02f was carried out according to table 7.14: 
Titration Point [P]0 final [L]0 final Molar Ratio Final DMSO % 
1 100 0 0 1 
2 99.55 45.25 0.45 1.45 
3 99.10 90.09 0.91 1.90 
4 98.65 134.53 1.36 2.35 
5 98.21 178.57 1.82 2.79 
6 97.78 222.22 2.27 3.22 
7 96.92 308.37 3.18 4.08 
8 96.07 524.017 5.45 4.93 
9 95.24 735.93 7.73 5.76 
10 94.42 944.21 10 6.58 
11 90.53 1934.16 21.36 10.47 
Table 7.14: Titration data for CFL02f. [P]0 final protein concentration; [L]0 final ligand 
concentration. 
A DMSO control experiment was also carried out according to table 7.15. 
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Titration Point [P]0 final Final DMSO % 
1 100 0 
2 99.55 0.45 
3 99.10 1.43 
4 98.65 1.87 
5 98.21 2.74 
6 97.78 4.01 
7 96.92 4.93 
8 96.07 6.54 
9 95.24 10.35 
Table 7.15: Titration data for DMSO. The final DMSO concentration used was to equal the 
concentration used in compound titrations. 
For KD determination and binding site mapping the backbone assignments were taken from 
previous studies in the Biopolymer group, University of Bayreuth.237 To evaluate HSQC 
titration experiments, the calculated normalised chemical shift changes can be quantified for 
a specific resonance at each titration point (Δδnorm) using the formula: 
∆𝛿𝑛𝑜𝑟𝑚 = √(∆𝛿
1𝐻)2 + (0.1 × ∆𝛿15𝑁)2 
Equation 4.11 
Where Δδ1H and Δδ15N are the chemical shift changes of amide proton and nitrogen, 
respectively. The ‘0.1’ constant is a scaling factor used to balance the contributions of 1H and 
15N to the magnitude of the perturbation.178 As a control, the normalised chemical shifts for 
the DMSO titration are subtracted from the compound containing titrations. This is to correct 
for changes in backbone residues that are caused by changes in DMSO concentration. 
Dissociation constants can then be obtained by monitoring these changes over the course of a 
titration at different ligand concentrations. The fitting is performed using equation 4.12 (using 
Grafit v 7.0) for each amide resonance showing fast exchange on the chemical shift timescale.  
∆𝜈𝑜𝑏𝑠 = ∆𝜈𝑚𝑎𝑥





Where Δνobs is the normalised resonance frequency difference in Hz and Δνmax is the 
normalised resonance frequency between the free and fully bound protein in Hz, KD is the 
dissociation constant, [P]0 the total concentration of 15N-labelled protein and [L]0 is the total 
ligand concentration. The KD and Δνmax were used as fitting parameters. [1H, 15N]-HSQC 
spectra were processed and analysed using NMRView.254 For chemical shift mapping, PDB 
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structures (PDB ID: 3D3B) are analysed in PyMol, the backbone amide residues have 
previously been assigned by the Rösch group in the Department of Biopolymers, University 
of Bayreuth. A threshold value of Δδ(1H/15N) = 0.04 ppm is considered to indicate that the 
corresponding amino acid is directly involved in the binding interaction.178 The residues in the 
crystal structure (PDB ID: 3D3B) are then colour coded according to the Δδnorm: yellow (0.04 – 















8.1. Appendix for chapter 2 






No. of amino acids 151 
Molecular Weight (Da) 18114 




Table 8.1: Calculated parameters of ATAD2 using ExPASy ProtParam online calculator. 




Figure 8.1: SDS-PAGE gel image of ATAD2 fractions 1 to 6 (Lanes 2-7). Fractions were pooled 
and aliquoted for storage at -80 °C. Lane 1: molecular weight marker (SeeBlue™ Plus2 Pre-
















Figure 8.2: 15N-labelled ATAD2 SDS-PAGE gel. Fractions after pooling at three different 
loading volumes. Lane 1: molecular weight ladder. Lane 2: 1 μg 15N-ATAD2. Lane 3: 5 μg 15N-
ATAD2. Lane 4: 10 μg 15N-ATAD2. 
8.1.2. Fluorescent Labelling of ATAD2 
Parameter Value 
Average absorbance 280 nm 0.047 
Average absorbance 330 nm, 0.036 
Average absorbance 650 nm 0.407 
A280 corrected 0.031 
A330 corrected 0.015 
A280 stray light corrected 0.001 
Total Protein Concentration 1.61 μM 
Total Dye Concentration 16.2 μM 
Ratio 1:10 (10 %) 
















1      2       3        4 
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No. of amino acids 167 
Molecular Weight (Da) 19433.2 




Table 8.3: Protein parameter results as calculated using the online computational tool ExPASy 
Protparam. The protein sequence is used as an input to calculate the molecular weight, 
theoretical pI and extinction coefficients.  
 
Figure 8.3: SDS-PAGE analysis of UbE2L3 purification. Lane 1: Molecular weight marker 
(SeeBlue Plus2 Pre-stained, ThermoFisher); Lane 2: Lysate; Lane 3: Column flow through; Lane 
4: Column wash 1; Lane 5: Column wash 2; Lane 6: Fraction 1; Lane 7: Fraction 2; Lane 8: Fraction 
3; Lane 9: Fraction 4; Lane 10: Fraction 5; Lane 11: Fraction 6; Lane 12: Fraction 7; Lane 13: Fraction 
8. 
 
1      2       3    4      5      6     7     8     9     10    11    12    13 
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8.1.4. Synthesis of Fmoc-ε-acetyl-L-lysine 
 
Figure 8.4: LCMS mass spectrum of Nα-Fmoc-L-lysine-OH. [M+H]+calc 369.2; [M+H]+obs 369.4.  
 































































Figure 8.6: HPLC chromatogram Fmoc-Nε-acetyl-L-lysine-OH. tR  15.9 mins; > 95 % purity as 
measured by peak area. 
8.1.5. Synthesis of Peptide H4K5 
 
Figure 8.7: LCMS mass spectrum of peptide H4K5 (H2N-RGKacGG-DOA-β(mCF3)F-Pra). 

























































Figure 8.8: HPLC chromatogram of peptide H4K5. tR = 15.6 mins. Absorbance is measured at 
254 nm, and purity is > 95% (as measured by peak area). 
8.1.6. Synthesis of Peptide H4 
 
Figure 8.9: LCMS mass spectrum of peptide H4: C59H102N20O18 (H2N-RGKacGGKacGLGKacG-






























































Figure 8.10: HPLC chromatogram of peptide H4. tR = 11.7 mins. Absorbance is measured at 
210 nm, and purity is > 90% (as measured by peak area). 
8.1.7. Synthesis of Peptide hoA-(mCF3)F-E-R and di/tripeptide truncates 
 
Figure 8.11: HPLC chromatogram of peptide H2N-hoA-(mCF3)F-E-R-CONH2. tR = 12.1 mins, 























































Figure 8.12: LCMS mass spectrum of peptide H2N-hoA-(mCF3)F-E-R-CONH2. C25H37F3N8O6:  
[M+H]+calc 603.3; [M+H]+obs 603.4. 
 
Figure 8.13: HPLC chromatogram of peptide H2N-hoA-(mCF3)F-E-CONH2. tR = 12.2 mins, > 





























































Figure 8.14: LCMS mass spectrum of peptide H2N-hoA-(mCF3)F-E-CONH2. C19H25F3N4O5:  
[M+H]+calc 447.2; [M+H]+obs 447.1. 
 
Figure 8.15: HPLC chromatogram of peptide H2N-hoA-(mCF3)F-CONH2. tR = 13.5 mins, > 95 





























































Figure 8.16: LCMS mass spectrum of peptide H2N-hoA-(mCF3)F-CONH2. C14H18F3N3O2:  
[M+H]+calc 318.1; [M+H]+obs 318.0. 
8.1.8. OBOC Purity analysis by TAMRA Concentration  
 

































y = 0.0704x + 1.362
R² = 0.9999
































8.1.9. OBOC Lysine-derivative library compounds 








































Table 8.4: Chemical structures of lysine derivatives used in synthesis of OBOC library. Lys-















































 FDL16  
FDL01. ApF. MS (ESI): [M+H]+calc 254.3; [M+H]+obs 254.0. HPLC: tR 10.3 mins (> 95 %). NMR 19F 
(376 MHz, 10 % D2O) δ Hz -43768.4. FDL02. RpF. MS (ESI): [M+H]+calc 339.4; [M+H]+obs 339.2. 
HPLC: tR 10.9 mins (> 95 %). NMR 19F (376 MHz, 10 % D2O) δ Hz -43769.55. FDL03. NpF. MS 
(ESI): [M+H]+calc 297.3; [M+H]+obs 297.0. HPLC: tR 10.7 mins (> 95 %). NMR 19F (376 MHz, 10 % 
D2O) δ Hz -43787.93. FDL04. DpF. MS (ESI) [M+H]+calc 298.3; [M+H]+obs 298.1. HPLC: tR 10.8 
mins (> 95 %). NMR 19F (376 MHz, 10 % D2O) δ Hz -43784.05. FDL05. QpF. MS (ESI) [M+H]+calc 
311.3; [M+H]+obs 311.0. HPLC: tR 10.7 mins (> 95 %). NMR 19F (376 MHz, 10 % D2O) δ Hz -
43757.28. FDL06. EpF. MS (ESI) [M+H]+calc 312.2; [M+H]+obs 312.0. HPLC: tR 10.9 mins (> 95 %). 
NMR 19F (376 MHz, 10 % D2O) δ Hz -43750.73. FDL07. HpF. MS (ESI) [M+H]+calc 320.3; [M+H]+obs 
320.2. HPLC: tR 10.8 mins (> 95 %). NMR 19F (376 MHz, 10 % D2O) δ Hz -43780.85. FDL08. LpF. 
MS (ESI) [M+H]+calc 296.4; [M+H]+obs 295.99. HPLC: tR 12.9 mins (> 95 %). NMR 19F (376 MHz, 
10 % D2O) δ Hz -43792.75. FDL09. KpF. MS (ESI) [M+H]+calc 311.4; [M+H]+obs 311.2. HPLC: tR 
10.6 mins (> 95 %). NMR 19F (376 MHz, 10 % D2O) δ Hz -43786.08. FDL10. FpF. MS (ESI) 
[M+H]+calc 330.4; [M+H]+obs 330.0. HPLC: tR 13.3 mins (> 95 %). NMR 19F (376 MHz, 10 % D2O) δ 
Hz -43795.27. FDL11. PpF. MS (ESI) [M+H]+calc 280.3; [M+H]+obs 280.1. HPLC: tR 11.3 mins (> 95 
%). NMR 19F (376 MHz, 10 % D2O) δ Hz -43743.99. FDL12. SpF. MS (ESI) [M+H]+calc 270.3; 
[M+H]+obs 270.0. HPLC: tR 10.6 mins (> 95 %). NMR 19F (376 MHz, 10 % D2O) δ Hz -43788.53. 
FDL13. TpF. MS (ESI) [M+H]+calc 284.3; [M+H]+obs 283.9. HPLC: tR 10.9 mins (> 95 %). NMR 19F 
(376 MHz, 10 % D2O) δ Hz -43785.86. FDL14. WpF. MS (ESI) [M+H]+calc 369.4; [M+H]+obs 369.0. 
HPLC: tR 14.0 mins (> 95 %). NMR 19F (376 MHz, 10 % D2O) δ Hz -43779.53. FDL15. YpF. MS 
(ESI) [M+H]+calc 346.4; [M+H]+obs 346.0. HPLC: tR 12.2 mins (> 95 %). NMR 19F (376 MHz, 10 % 
D2O) δ Hz -43779.61. FDL16. VpF. MS (ESI) [M+H]+calc 282.3; [M+H]+obs 282.0. HPLC: tR 11.7 
mins (> 95 %). NMR 19F (376 MHz, 10 % D2O) δ Hz -43775.20. 
FDL Pools. FDL-Pool-1: 10, 11, 13, 16. FDL-Pool-2: 02, 04, 08. FDL-Pool-3: 01, 07, 12. FDL-Pool-4: 

























































C-FTL01. VpFA. MS (ESI): [M+H]+calc 353.2; [M+H]+obs 353.2. HPLC: tR 11.0 mins (> 95 %). NMR 
19F (376 MHz, 10 % D2O) δ Hz -43688.12. C-FTL02. VpFR. MS (ESI): [M+H]+calc 438.3; [M+H]+obs 
438.3. HPLC: tR 11.0 mins (> 95 %). NMR 19F (376 MHz, 10 % D2O) δ Hz -43657.09. C-FTL03. 
VpFN. MS (ESI): [M+H]+calc 396.2; [M+H]+obs 396.2. HPLC: tR 11.0 mins (> 95 %). NMR 19F (376 
MHz, 10 % D2O) δ Hz -43668.39. C-FTL04. VpFD. MS (ESI): [M+H]+calc 397.2; [M+H]+obs 397.2. 
HPLC: tR 11.3 mins (> 95 %). NMR 19F (376 MHz, 10 % D2O) δ Hz -43718.09. C-FTL05. VpFQ. 
MS (ESI): [M+H]+calc 410.2; [M+H]+obs 410.6. HPLC: tR 11.0 mins (> 95 %). NMR 19F (376 MHz, 10 
% D2O) δ Hz -43656.87. C-FTL06. VpFE. MS (ESI): [M+H]+calc 411.2; [M+H]+obs 411.2. HPLC: tR 
11.3 mins (> 95 %). NMR 19F (376 MHz, 10 % D2O) δ Hz -43708.41. C-FTL07. VpFH. MS (ESI): 
[M+H]+calc 419.2; [M+H]+obs 419.3. HPLC: tR 10.8 mins (> 95 %). NMR 19F (376 MHz, 10 % D2O) δ 
Hz -43681.60. C-FTL08. VpFL. MS (ESI): [M+H]+calc 395.2; [M+H]+obs 395.2. HPLC: tR 13.6 mins 
(> 95 %). NMR 19F (376 MHz, 10 % D2O) δ Hz -43676.48. C-FTL09. VpFK. MS (ESI): [M+H]+calc 
410.2; [M+H]+obs 410.3. HPLC: tR 10.7 mins (> 95 %). NMR 19F (376 MHz, 10 % D2O) δ Hz -
43668.50. C-FTL10. VpFF. MS (ESI): [M+H]+calc 429.2; [M+H]+obs 429.2. HPLC: tR 14.2 mins (> 95 
%). NMR 19F (376 MHz, 10 % D2O) δ Hz -43704.91. C-FTL11. VpFP. MS (ESI): [M+H]+calc 379.2; 
[M+H]+obs 379.2. HPLC: tR 12.4 mins (> 95 %). NMR 19F (376 MHz, 10 % D2O) δ Hz -43676.30. 
C-FTL12. VpFS. MS (ESI): [M+H]+calc 369.2; [M+H]+obs 369.2. HPLC: tR 11.0 mins (> 95 %). NMR 
19F (376 MHz, 10 % D2O) δ Hz -43672.87. C-FTL13. VpFT. MS (ESI): [M+H]+calc 383.2; [M+H]+obs 
383.2. HPLC: tR 11.4 mins (> 95 %). NMR 19F (376 MHz, 10 % D2O) δ Hz -43660.71. C-FTL14. 
VpFW. MS (ESI): [M+H]+calc 468.2; [M+H]+obs 468.3. HPLC: tR 14.5 mins (> 95 %). NMR 19F (376 
MHz, 10 % D2O) δ Hz -43691.05. C-FTL15. VpFY. MS (ESI): [M+H]+calc 445.2; [M+H]+obs 445.2. 
HPLC: tR 12.7 mins (> 95 %). NMR 19F (376 MHz, 10 % D2O) δ Hz -43691.66. C-FTL16. VpFV. 
MS (ESI): [M+H]+calc 381.2; [M+H]+obs 381.2. HPLC: tR 12.5 mins (> 95 %). NMR 19F (376 MHz, 10 

























































QC Data for all N-FTL library compounds 
N-FTL01. AVpF. MS (ESI): [M+H]+calc 353.2; [M+H]+obs 353.3. HPLC: tR 12.4 mins (> 95 %). NMR 
19F (376 MHz, 10 % D2O) δ Hz -43857.32. N-FTL02. RVpF. MS (ESI): [M+H]+calc 438.3; [M+H]+obs 
438.3. HPLC: tR 12.3 mins (> 95 %). NMR 19F (376 MHz, 10 % D2O) δ Hz -43846.06. N-FTL03. 
NVpF. MS (ESI): [M+H]+calc 396.2; [M+H]+obs 396.2. HPLC: tR 12.9 mins (> 95 %). NMR 19F (376 
MHz, 10 % D2O) δ Hz -43869.67. N-FTL04. DVpF. MS (ESI): [M+H]+calc 397.2; [M+H]+obs 397.2. 
HPLC: tR 12.9 mins (> 95 %). NMR 19F (376 MHz, 10 % D2O) δ Hz -43850.50. N-FTL05. QVpF. 
MS (ESI): [M+H]+calc 410.2; [M+H]+obs 410.2. HPLC: tR 12.4 mins (> 95 %). NMR 19F (376 MHz, 10 
% D2O) δ Hz -43801.93. N-FTL06. EVpF. MS (ESI): [M+H]+calc 411.2; [M+H]+obs 411.2. HPLC: tR 
12.5 mins (> 95 %). NMR 19F (376 MHz, 10 % D2O) δ Hz -43785.33. N-FTL07. HVpF. MS (ESI): 
[M+H]+calc 419.2; [M+H]+obs 419.3. HPLC: tR 12.2 mins (> 95 %). NMR 19F (376 MHz, 10 % D2O) δ 
Hz -43841.73. N-FTL08. LVpF. MS (ESI): [M+H]+calc 395.2; [M+H]+obs 395.2. HPLC: tR 14.0 mins 
(> 95 %). NMR 19F (376 MHz, 10 % D2O) δ Hz -43761.46. N-FTL09. KVpF. MS (ESI): [M+H]+calc 
410.2; [M+H]+obs 410.3. HPLC: tR 12.1 mins (> 95 %). NMR 19F (376 MHz, 10 % D2O) δ Hz -
43840.07. N-FTL10. FVpF. MS (ESI): [M+H]+calc 429.2; [M+H]+obs 429.3. HPLC: tR 14.5 mins (> 95 
%). NMR 19F (376 MHz, 10 % D2O) δ Hz -43814.32. N-FTL11. PVpF. MS (ESI): [M+H]+calc 379.2; 
[M+H]+obs 379.3. HPLC: tR 13.0 mins (> 95 %). NMR 19F (376 MHz, 10 % D2O) δ Hz -43888.68. 
N-FTL12. SVpF. MS (ESI): [M+H]+calc 369.2; [M+H]+obs 369.2. HPLC: tR 12.8 mins (> 95 %). NMR 
19F (376 MHz, 10 % D2O) δ Hz -43863.87. N-FTL13. TVpF. MS (ESI): [M+H]+calc 383.2; [M+H]+obs 
383.2. HPLC: tR 12.6 mins (> 95 %). NMR 19F (376 MHz, 10 % D2O) δ Hz -43889.70. N-FTL14. 
WVpF. MS (ESI): [M+H]+calc 468.2; [M+H]+obs 468.2. HPLC: tR 15.0 mins (> 95 %). NMR 19F (376 
MHz, 10 % D2O) δ Hz -43803.25. N-FTL15. YVpF. MS (ESI): [M+H]+calc 445.2; [M+H]+obs 445.2. 
HPLC: tR 13.6 mins (> 95 %). NMR 19F (376 MHz, 10 % D2O) δ Hz -43816.58. N-FTL16. VVpF. 
MS (ESI): [M+H]+calc 381.2; [M+H]+obs 381.2. HPLC: tR 13.1 mins (> 95 %). NMR 19F (376 MHz, 10 

















8.1.13. Fluorine Dipeptide Library Screening against UbE2L3 
     
     
 
Figure 8.18: 1D 19F NMR spectra of fluorinated dipeptides. Superposition of dipeptides (100 
uM) in absence (red) and presence (blue) of 10 μM UbE2L3. Top left: FDL-Pool-1. Top right: 








8.1.14. C-terminal Extended Fluorine Tripeptide Library (C-FTL) Screening 
     
     
Figure 8.19: 1D 19F NMR spectra of C-terminal extended fluorinated tripeptides (C-FTL). 
Superposition of tripeptides (100 μM)  in absence (red) and presence (blue) of 10 μM UbE2L3. 















8.1.15. N-terminal Extended Fluorine Tripeptide Library (N-FTL) Screening 
     
     
Figure 8.20: 1D 19F NMR spectra of N-terminal extended fluorinated tripeptides (N-FTL). 
Superposition of tripeptides (100 μM) in absence (red) and presence (blue) of 10 μM UbE2L3. 







8.2. Appendix for Chapter 3 
8.2.1. Recognised Active Fragment Library (RAFL) Compound Structures 
 





















































































































































































   
DDFL21 DDFL22 DDFL23 DDFL24 
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8.3. Appendix for Chapter 4 













[𝑃]𝑓 = [𝑃]0 − [𝑃𝐿] 
[𝐿]𝑓 = [𝐿]0 − [𝑃𝐿] 
𝐾𝐷 =
([𝑃]0 − [𝑃𝐿])([𝐿]0 − [𝑃𝐿])
[𝑃𝐿]
 
𝐾𝐷[𝑃𝐿] = [𝐿]0[𝑃]0 − [𝐿]0[𝑃𝐿] − [𝑃]0[𝑃𝐿] + [𝑃𝐿]
2 
If [P]0 << [L]0, then [PL][P]0 + [PL]2 can be neglected: 
𝐾𝐷[𝑃𝐿] = [𝐿]0[𝑃]0 − [𝐿]0[𝑃𝐿] 
[𝑃𝐿](𝐾𝐷 + [𝐿]0) = [𝐿]0[𝑃]0 
[𝑃𝐿]
[𝐿]0
(𝐾𝐷 + [𝐿]0) = [𝑃]0 
















8.3.2. Derivation of Equation 4.10 
𝑝𝐿𝑏,1(𝐾𝐷 + [𝐿]1) = [𝑃]0 
































Equations reproduced from Supplementary Data, Jordan et al.45 
8.3.3. Recognised Active Fragment Library (RAFL) QC Data 
RAFL01. Formula: C8H10FNO2S (HCl). Mw 203.23 Da. MS (ESI): [M+H]+calc 204.23; [M+H]+obs 
N/A. HPLC: tR 13.1 mins; > 95% purity. NMR: 19F (376 MHz, 10 % D2O) δ ppm N/A. RAFL02. 
Formula: C7H4ClFO2. Mw 174.56 Da. MS (ESI): [M+H]+calc 175.56; [M+H]+obs N/A. HPLC: tR 14.5 
mins; > 95% purity. NMR: 19F (376 MHz, 10 % D2O) δ ppm -116.44. RAFL03. Formula: 
C7H8FN3S. Mw 185.22 Da. MS (ESI): [M+H]+calc 186.22 ; [M+H]+obs N/A. HPLC: tR N/A; purity 
N/A. NMR: 19F (376 MHz, 10 % D2O) δ ppm N/A. RAFL04. Formula: C8H7F3N2O. Mw 204.15 
Da. MS (ESI): [M+H]+calc 205.15; [M+H]+obs 205.04. HPLC: tR 15.6 mins; > 95% purity. NMR: 19F 
(376 MHz, 10% D2O) δ ppm -62.36. RAFL05. Formula: C9H10F3N. Mw 189.18 Da. MS (ESI): 
[M+H]+calc 190.18; [M+H]+obs 189.97. HPLC: tR 14.2 mins; > 95% purity. NMR: 19F (376 MHz, 10% 
D2O) δ ppm -62.23. RAFL06. Formula: C9H10F3N. Mw 189.18 Da. MS (ESI): [M+H]+calc 190.18; 
[M+H]+obs 189.96. HPLC: tR 14.3 mins; > 95% purity. NMR: 19F (376 MHz, 10% D2O) δ ppm -
62.06. RAFL07. Formula: C8H8F3N. Mw 175.15 Da. MS (ESI): [M+H]+calc 176.15; [M+H]+obs 175.94. 
HPLC: tR 13.0 mins; > 95% purity. NMR: 19F (376 MHz, 10% D2O) δ ppm -62.38. RAFL08. 
Formula: C8H8F3N. Mw 175.15 Da. MS (ESI): [M+H]+calc 176.15; [M+H]+obs 175.94. HPLC: tR 13.2 
mins; > 95% purity. NMR: 19F (376 MHz, 10% D2O) δ ppm -62.38. RAFL09. Formula: C6H6FN. 
Mw 111.12 Da. MS (ESI): [M+H]+calc 112.12; [M+H]+obs N/A. HPLC: tR 6.0 mins; > 95% purity. 
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NMR: 19F (376 MHz, 10% D2O) δ ppm N/A. RAFL10. Formula: C7H7FO2S. Mw 174.19 Da. MS 
(ESI): [M+H]+calc 175.19; [M+H]+obs N/A. HPLC: tR 17.9 mins; > 95% purity. NMR: 19F (376 MHz, 
10% D2O) δ ppm N/A. RAFL11. Formula: C9H10F3N. Mw 189.2 Da. MS (ESI): [M+H]+calc 190.1; 
[M+H]+obs 190.0. HPLC: tR 13.4 mins; > 95% purity. NMR: 19F (376 MHz, 10% D2O) δ ppm -62.41. 
RAFL12. Formula: C9H10F3N. Mw 189.2 Da. MS (ESI): [M+H]+calc 190.1; [M+H]+obs 190.0. HPLC: 
tR 13.6 mins; > 95% purity. NMR: 19F (376 MHz, 10% D2O) δ ppm -62.46. RAFL13. Formula: 
C9H8F3NO2. Mw 219.2 Da. MS (ESI): [M+H]+calc 220.1; [M+H]+obs 220.0. HPLC: tR 16.5 mins; > 95% 
purity. NMR: 19F (376 MHz, 10% D2O) δ ppm -57.94. RAFL14. Formula: C10H12F3N. Mw 203.2 
Da. MS (ESI): [M+H]+calc 203.1; [M+H]+obs N/A. HPLC: tR 10.4 mins; > 95% purity. NMR: 19F (376 
MHz, 10% D2O) δ ppm -62.40. RAFL15. Formula: C10H12F3N. Mw 203.2 Da. MS (ESI): [M+H]+calc 
203.1; [M+H]+obs N/A. HPLC: tR N/A. NMR: 19F (376 MHz, 10% D2O) δ ppm N/A. RAFL16. 
Formula: C8H6F3NO2. Mw 205.1 Da. MS (ESI): ): [M+H]+calc 206.0; [M+H]+obs N/A. HPLC: tR 11.2 
mins; > 95 % purity. NMR: 19F (376 MHz, 10% D2O) δ ppm -59.20. RAFL17. Formula: 
C6H7FN2O2S. Mw 190.2 Da. MS (ESI): [M+H]+calc 191.0; [M+H]+obs N/A. HPLC: tR 6.2 mins; > 95% 
purity. NMR: 19F (376 MHz, 10% D2O) δ ppm N/A. RAFL18. Formula: C11H9F3N2O2S. Mw 290.3 
Da. MS (ESI): [M+H]+calc 291.0; [M+H]+obs 291.0. HPLC: tR 20.0 mins; > 95% purity. NMR: 19F (376 
MHz, 10% D2O) δ ppm -63.97. RAFL19. Formula: C12H12F3NO3. Mw 275.2 Da. MS (ESI): 
[M+H]+calc 276.1; [M+H]+obs 276.1. HPLC: tR 18.2 mins; > 95% purity. NMR: 19F (376 MHz, 10% 
D2O) δ ppm -62.43. RAFL20. Formula: C10H10F3N3O2. Mw 261.2 Da. MS (ESI): [M+H]+calc 261.1; 
[M+H]+obs N/A. HPLC: tR 17.2 mins; > 95% purity. NMR: 19F (376 MHz, 10% D2O) δ ppm -62.45. 
RAFL21. Formula: C10H14F3N3O2. Mw 265.2 Da. MS (ESI): [M+H]+calc 265.1; [M+H]+obs N/A. 
HPLC: tR 11.9 mins; > 95% purity. NMR: 19F (376 MHz, 10% D2O) δ ppm -58.95. RAFL22. 
Formula: C10H7F3O4. Mw 248.2 Da. MS (ESI): [M+H]+calc 248.0; [M+H]+obs N/A. HPLC: tR N/A. 
NMR: 19F (376 MHz, 10% D2O) δ ppm N/A. 
Scored out compounds did not pass QC checks, therefore were not included in the final 
screening pools. RAFL Fragment Pools. RAFL-Pool-1: 02, 07, 16, 19, 20. RAFL-Pool-2: 05, 08, 11, 
18, 21. RAFL-Pool-3: 04, 06, 12, 13, 14. 
8.3.4. Clustered Fragment Library (CFL) QC Data 
CFL01. Formula: C8H7FO2. Mw 154.14 Da. HPLC: tR 13.1 mins; > 95 % purity. NMR: 19F (376 
MHz, 10 % D2O) δ ppm -137.61. CFL02. Formula: C11H11F3N2O3. Mw 276.2 Da. MS (ESI): 
[M+H]+calc 277.1; [M+H]+obs 277.1. HPLC: tR 20.0 mins; > 95 % purity. NMR: 19F (376 MHz, 10 % 
D2O) δ ppm -61.91. CFL03. Formula: C9H6FNO2. Mw 179.15 Da. HPLC: 16.1 mins; > 95 % purity. 
NMR: 19F (376 MHz, 10 % D2O) δ ppm -124.27. CFL04. Formula: C12H17FN2. Mw 208.3 Da. 
HPLC: tR 8.0 mins; > 95 % purity. NMR: 19F (376 MHz, 10 % D2O) δ ppm -115.03. CFL05. 
Formula: C13H19FN2O. Mw 238.3 Da. HPLC: tR 8.8 mins; > 95 % purity. NMR: 19F (376 MHz, 10 
% D2O) δ ppm N/A. CFL06. . Formula: C10H13FN2O2S. Mw 244.3 Da. HPLC: tR 12.8 mins; > 95 
% purity. NMR: 19F (376 MHz, 10 % D2O) δ ppm -109.79. CFL07. Formula: C6H5FO. Mw 112.1 
Da. HPLC: tR 13.7 mins; > 95 % purity. NMR: 19F (376 MHz, 10 % D2O) δ ppm -137.61. CFL08. 
Formula: C6H4BrFO. Mw 191.0 Da. HPLC: tR 16.9 mins; > 95 % purity. NMR: 19F (376 MHz, 10 
% D2O) δ ppm -123.63. CFL09. Formula: C6H4BrFO. Mw 191.0 Da. HPLC: tR 17.2 mins; > 95 % 
purity. NMR: 19F (376 MHz, 10 % D2O) δ ppm -114.13. CFL10. Formula: C6H4ClFO. Mw 146.5 
Da. HPLC: tR 16.7 mins; > 95 % purity. NMR: 19F (376 MHz, 10 % D2O) δ ppm -114.61. CFL11. 
Formula: C6H5FO. Mw 112.1 Da. HPLC: tR 14.1 mins; > 95 % purity. NMR: 19F (376 MHz, 10 % 
D2O) δ ppm -112.33. CFL12. Formula: C6H5FO. Mw 112.1 Da. HPLC: tR 14.0 mins; > 95 % purity. 
NMR: 19F (376 MHz, 10 % D2O) δ ppm -124.90. CFL13. Formula: C6H4BrFO. Mw 191.0 Da. 
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HPLC: tR 17.4 mins; > 95 % purity. NMR: 19F (376 MHz, 10 % D2O) δ ppm -106.69. CFL14. 
Formula: C6H4ClFO. Mw 146.5 Da. HPLC: tR 16.8 mins; > 95 % purity. NMR: 19F (376 MHz, 10 
% D2O) δ ppm N/A. CFL15. Formula: C8H7FO2. Mw 154.1 Da. HPLC: tR 18.2 mins; > 95 % purity. 
NMR: 19F (376 MHz, 10 % D2O) δ ppm -105.18. CFL16. Formula: C7H4F4O. Mw 180.1 Da. HPLC: 
tR 17.9 mins; > 95 % purity. NMR: 19F (376 MHz, 10 % D2O) δ ppm N/A. CFL17. Formula: 
C8H5F3N2OS. Mw 234.2 Da. HPLC: tR 15.2 mins; > 95 % purity. NMR: 19F (376 MHz, 10 % D2O) 
δ ppm -58.16. CFL18. Formula: C6H5F3N2O. Mw 178.1 Da. HPLC: tR 11.8 mins; > 95 % purity. 
NMR: 19F (376 MHz, 10 % D2O) δ ppm -70.78. CFL19. Formula: C5H3F3N2OS. Mw 196.1 Da. 
HPLC: tR 12.8 mins; > 95 % purity. NMR: 19F (376 MHz, 10 % D2O) δ ppm -71.10. CFL20. 
Formula: C7H8F3N3O. Mw 207.2 Da. HPLC: tR 15.4 mins; > 95 % purity. NMR: 19F (376 MHz, 10 
% D2O) δ ppm -71.05. CFL21. Formula: C6H5F3N2OS. Mw 210.2 Da. HPLC: tR 15.7 mins; > 95 % 
purity. NMR: 19F (376 MHz, 10 % D2O) δ ppm -70.21. CFL22. Formula: C5H4F3N3O. Mw 179.1 
Da. HPLC: tR 17.5 mins; > 95 % purity. NMR: 19F (376 MHz, 10 % D2O) δ ppm -71.20. CFL23. 
Formula: C5H5F3N2O. Mw 166.1 Da. HPLC: tR 15.2 mins; > 95 % purity. NMR: 19F (376 MHz, 10 
% D2O) δ ppm -60.78. CFL24. Formula: C7H7FO2. Mw 142.1 Da. HPLC: tR 11.6 mins; > 95 % 
purity. NMR: 19F (376 MHz, 10 % D2O) δ ppm -136.83. 
Scored out compounds did not pass QC checks, therefore were not included in the final 
screening pools. CFL Fragment Pools. CFL-Pool-1: 01, 04, 11, 12, 15. CFL-Pool-2: 03, 06, 07, 10. 
CFL-Pool-3: 08, 09, 13, 24. CFL-Pool-4: 20, 21, 22, 23. CFL-Pool-5: 02, 17, 18, 19. 
8.3.5. Directed Diversity Fragment Library (DDFL) QC Data 
DDFL01. Formula: C13H15F3N2O. MS (ESI): [M+H]+calc 273.1; [M+H]+obs 273.0. HPLC tR 13.1 mins; 
> 95 % purity. NMR: 19F (376 MHz, 10 % D2O) δ ppm -68.81. DDFL02. Formula: C11H7F3N2O3. 
MS (ESI): [M+H]+calc 273.0; [M+H]+obs 273.0. HPLC tR 13.1 mins; > 95 % purity. NMR: 19F (376 
MHz, 10 % D2O) δ ppm -63.09. DDFL03. Formula: C8H10F3NO3. MS (ESI): [M+H]+calc 226.1; 
[M+H]+obs 226.0. HPLC tR 13.9 mins; > 95 % purity. NMR: 19F (376 MHz, 10 % D2O) δ ppm -
68.77. DDFL04. Formula: C7H4ClF3N2O2. MS (ESI): [M+H]+calc 241.0; [M+H]+obs 241.0. HPLC tR 
18.5 mins; > 95 % purity. NMR: 19F (376 MHz, 10 % D2O) δ ppm -66.49. DDFL05. Formula: 
C9H6ClF3O2. MS (ESI): [M+H]+calc 239.0; [M+H]+obs N/A. HPLC tR 18.6 mins; > 95 % purity. NMR: 
19F (376 MHz, 10 % D2O) δ ppm -62.40. DDFL06. Formula: C8H9F3N2O2. MS (ESI): [M+H]+calc 
223.1; [M+H]+obs N/A. HPLC tR 17.7 mins; > 95 % purity. NMR: 19F (376 MHz, 10 % D2O) δ ppm 
-68.80. DDFL07. Formula: C11H10F3N3O. MS (ESI): [M+H]+calc 258.1; [M+H]+obs 258.0. HPLC tR 
15.8 mins; > 95 % purity. NMR: 19F (376 MHz, 10 % D2O) δ ppm -73.22. DDFL08. Formula: 
C13H18F3N3. MS (ESI): [M+H]+calc 274.2; [M+H]+obs 274.0. HPLC tR 10.1 mins; > 95 % purity. NMR: 
19F (376 MHz, 10 % D2O) δ ppm -58.23. DDFL09. Formula: C8H6F3NO2. MS (ESI): [M+H]+calc 
206.0; [M+H]+obs 206.0. HPLC tR 15.1 mins; > 95 % purity. NMR: 19F (376 MHz, 10 % D2O) δ ppm 
-62.86. DDFL10. Formula: C8H5F3N4. MS (ESI): [M+H]+calc 215.0; [M+H]+obs 215.0. HPLC tR 16.0 
mins; > 95 % purity. NMR: 19F (376 MHz, 10 % D2O) δ ppm -61.99. DDFL11. Formula: 
C9H6F3N3O. MS (ESI): [M+H]+calc 230.0; [M+H]+obs N/A. HPLC tR 12.0 mins; > 80 % purity. NMR: 
19F (376 MHz, 10 % D2O) δ ppm -74.79, -75.39. DDFL12. Formula: C8H7F3N2O. MS (ESI): 
[M+H]+calc 205.1; [M+H]+obs 205.0. HPLC tR 8.3 mins; > 95 % purity. NMR: 19F (376 MHz, 10 % 
D2O) δ ppm -58.73. DDFL13. Formula: C8H7F3N2O. MS (ESI): [M+H]+calc 205.1; [M+H]+obs 205.1. 
HPLC tR 13.4 mins; > 95 % purity. NMR: 19F (376 MHz, 10 % D2O) δ ppm -57.58. DDFL14. 
Formula: C3H5F3O3S. MS (ESI): [M+H]+calc 179.0; [M+H]+obs 178.7. HPLC tR N/A. NMR: 19F (376 
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MHz, 10 % D2O) δ ppm -78.66. DDFL15. Formula: C6H9F3N2O. MS (ESI): [M+H]+calc 183.1; 
[M+H]+obs 183.1. HPLC tR 4.4 mins; > 95 % purity. NMR: 19F (376 MHz, 10 % D2O) δ ppm -75.51. 
DDFL16. Formula: C8H11F3N2. MS (ESI): [M+H]+calc 193.1; [M+H]+obs 193.0. HPLC tR 19.9 mins; 
> 95 % purity. NMR: 19F (376 MHz, 10 % D2O) δ ppm -61.35. DDFL17. Formula: C8H9F3N2. MS 
(ESI): [M+H]+calc 191.1; [M+H]+obs N/A. HPLC tR 13.5 mins; > 95 % purity. NMR: 19F (376 MHz, 
10 % D2O) δ ppm -62.14. DDFL18. Formula: C6H3F3N2O2. MS (ESI): [M+H]+calc 193.0; [M+H]+obs 
N/A. HPLC tR 14.0 mins; > 95 % purity. NMR: 19F (376 MHz, 10 % D2O) δ ppm -70.03. DDFL19. 
Formula: C8H8F3N3O2. MS (ESI): [M+H]+calc 236.1; [M+H]+obs 236.1. HPLC tR 12.3 mins; > 95 % 
purity. NMR: 19F (376 MHz, 10 % D2O) δ ppm -76.62. DDFL20. Formula: C6H5F3N2O. MS (ESI): 
[M+H]+calc 179.0; [M+H]+obs 178.7. HPLC tR 11.8 mins; > 95 % purity. NMR: 19F (376 MHz, 10 % 
D2O) δ ppm -70.78. DDFL21. Formula: C12H13F3N2O2. MS (ESI): [M+H]+calc 275.1; [M+H]+obs 
275.1. HPLC tR 14.1 mins; > 95 % purity. NMR: 19F (376 MHz, 10 % D2O) δ ppm -60.99. DDFL22. 
Formula: C9H9ClF3N3. MS (ESI): [M+H]+calc 252.0; [M+H]+obs 252.1. HPLC tR 23.2 mins; > 95 % 
purity. NMR: 19F (376 MHz, 10 % D2O) δ ppm -70.20. DDFL23. Formula: C8H8F3N3. MS (ESI): 
[M+H]+calc 204.1; [M+H]+obs 204.1. HPLC tR 13.7 mins; > 95 % purity. NMR: 19F (376 MHz, 10 % 
D2O) δ ppm -62.13. DDFL24. Formula: C7H9F3N4O. MS (ESI): [M+H]+calc 223.1; [M+H]+obs 223.0. 
HPLC N/A. NMR: 19F (376 MHz, 10 % D2O) δ ppm -60.21. DDFL25. Formula: C7H8F3NO2. MS 
(ESI): [M+H]+calc 196.1; [M+H]+obs N/A. HPLC tR 11.8 mins; > 95 % purity. NMR: 19F (376 MHz, 
10 % D2O) δ ppm -68.80, -69.30. DDFL26. Formula: C11H7F3N2O3. MS (ESI): [M+H]+calc 273.0; 
[M+H]+obs 273.0. HPLC tR 16.9 mins; > 95 % purity. NMR: 19F (376 MHz, 10 % D2O) δ ppm -
62.98. DDFL27. Formula: C6H9F3N2O. MS (ESI): [M+H]+calc 182.1; [M+H]+obs N/A. HPLC tR 4.6 
mins; > 95 % purity. NMR: 19F (376 MHz, 10 % D2O) δ ppm -69.00, -75.40. DDFL28. Formula: 
C9H9F3O2S. MS (ESI): [M+H]+calc 239.0; [M+H]+obs N/A. HPLC tR 17.5 mins; > 95 % purity. NMR: 
19F (376 MHz, 10 % D2O) δ ppm -57.61. DDFL29. Formula: C11H12F3N3O. MS (ESI): [M+H]+calc 
260.1; [M+H]+obs 260.0. HPLC tR 15.4 mins; > 95 % purity. NMR: 19F (376 MHz, 10 % D2O) δ ppm 
-61.08. DDFL30. Formula: C11H9F3N2O. MS (ESI): [M+H]+calc 243.1; [M+H]+obs 243.0. HPLC tR 
13.4 mins; > 95 % purity. NMR: 19F (376 MHz, 10 % D2O) δ ppm -62.34. DDFL31. Formula: 
C9H7F3O2. MS (ESI): [M+H]+calc 205.0; [M+H]+obs N/A. HPLC tR 19.5 mins; > 95 % purity. NMR: 
19F (376 MHz, 10 % D2O) δ ppm -57.46. DDFL32. Formula: C11H13F3N4O. MS (ESI): [M+H]+calc 
275.1; [M+H]+obs 275.1. HPLC tR 16.7 mins; > 95 % purity. NMR: 19F (376 MHz, 10 % D2O) δ ppm 
-70.44. DDFL33. Formula: C8H11F3O3. MS (ESI): [M+H]+calc 213.1; [M+H]+obs N/A. HPLC N/A. 
NMR: 19F (376 MHz, 10 % D2O) δ ppm -84.19. DDFL34. Formula: C9H10F3N. MS (ESI): [M+H]+calc 
190.1; [M+H]+obs 190.0. HPLC tR 12.7 mins; > 95 % purity. NMR: 19F (376 MHz, 10 % D2O) δ ppm 
-77.10. DDFL35. Formula: C10H13F3N4. MS (ESI): [M+H]+calc 247.1; [M+H]+obs 247.1. HPLC tR 14.2 
mins; > 95 % purity. NMR: 19F (376 MHz, 10 % D2O) δ ppm -70.42. DDFL36. Formula: 
C9H8F3N3O2. MS (ESI): [M+H]+calc 248.1; [M+H]+obs N/A. HPLC N/A. NMR: 19F (376 MHz, 10 % 
D2O) δ ppm -62.43. DDFL37. Formula: C5H5F3N2. MS (ESI): [M+H]+calc 151.0; [M+H]+obs 151.0. 
HPLC tR 15.6 mins; > 95 % purity. NMR: 19F (376 MHz, 10 % D2O) δ ppm N/A. DDFL38. 
Formula: C11H9F3N2O. MS (ESI): [M+H]+calc 243.1; [M+H]+obs 243.1. HPLC tR 18.0 mins; > 95 % 
purity. NMR: 19F (376 MHz, 10 % D2O) δ ppm -62.31. DDFL39. Formula: C5H4F3N3O. MS (ESI): 
[M+H]+calc 180.0; [M+H]+obs N/A. HPLC tR 11.1 mins; > 95 % purity. NMR: 19F (376 MHz, 10 % 
D2O) δ ppm -71.19. DDFL40. Formula: C10H7F3N2O2S. MS (ESI): [M+H]+calc 278.0; [M+H]+obs 
277.0. HPLC tR 17.7 mins; > 95 % purity. NMR: 19F (376 MHz, 10 % D2O) δ ppm -58.67. DDFL41. 
Formula: C11H9F3N2O2S. HPLC tR 20.9 mins; > 75 % purity. NMR: 19F (376 MHz, 10 % D2O) δ 
ppm N/A. DDFL42. Formula: C8H5F3N2. HPLC tR 17.7 mins; > 95 % purity. NMR: 19F (376 MHz, 
10 % D2O) δ ppm -68.20. DDFL43. Formula: C10H8F3N5. HPLC tR 14.9 mins; > 95 % purity. 
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NMR: 19F (376 MHz, 10 % D2O) δ ppm -62.37. DDFL44. Formula: C4H4F3N3. HPLC tR 10.7 mins; 
> 95 % purity. NMR: 19F (376 MHz, 10 % D2O) δ ppm N/A. DDFL45. Formula: C6H2F3Cl2N. 
HPLC tR 19.8 mins; > 95 % purity. NMR: 19F (376 MHz, 10 % D2O) δ ppm -56.56. DDFL46. 
Formula: C9H9F3N2O. HPLC tR 13.4 mins; > 95 % purity. NMR: 19F (376 MHz, 10 % D2O) δ ppm 
-62.76. DDFL47. Formula: C9H5F3N2O. HPLC tR 19.7 mins; > 85 % purity. NMR: 19F (376 MHz, 
10 % D2O) δ ppm -65.50, -73.18. DDFL48. Formula: C12H12F3NO3. HPLC tR 17.6 mins; > 95 % 
purity. NMR: 19F (376 MHz, 10 % D2O) δ ppm -62.32. DDFL49. Formula: C5H2F3N5O2. HPLC 
tR 17.1 mins; > 95 % purity. NMR: 19F (376 MHz, 10 % D2O) δ ppm -65.50, -75.40. DDFL50. 
Formula: C8H6ClF3O. HPLC tR 22.1 mins; > 95 % purity. NMR: 19F (376 MHz, 10 % D2O) δ ppm 
-62.59. DDFL51. Formula: C11H12F3N3. HPLC tR 19.4 mins; > 95 % purity. NMR: 19F (376 MHz, 
10 % D2O) δ ppm -57.69. DDFL52. Formula: C8H5F3O2. HPLC tR 16.5 mins; > 95 % purity. NMR: 
19F (376 MHz, 10 % D2O) δ ppm -62.70. DDFL53. Formula: C11H6F3NO3. HPLC tR 16.6 mins; > 
95 % purity. NMR: 19F (376 MHz, 10 % D2O) δ ppm -61.81. DDFL54. Formula: C4H5F3O. HPLC 
N/A. NMR: 19F (376 MHz, 10 % D2O) δ ppm -67.33. DDFL55. Formula: C12H14F3NO. HPLC tR 
14.1 mins; > 95 % purity. NMR: 19F (376 MHz, 10 % D2O) δ ppm -62.17. DDFL56. Formula: 
C8H11F3N2. HPLC tR 19.0 mins; > 95 % purity. NMR: 19F (376 MHz, 10 % D2O) δ ppm -61.73. 
DDFL57. Formula: C9H5F3N2O3. HPLC tR 16.2 mins; > 95 % purity. NMR: 19F (376 MHz, 10 % 
D2O) δ ppm -57.96. DDFL58. Formula: C12H10F3N3O2. HPLC tR 18.0 mins; > 95 % purity. NMR: 
19F (376 MHz, 10 % D2O) δ ppm -66.32. DDFL59. Formula: C7H6F3NO. HPLC tR 8.5 mins; > 95 
% purity. NMR: 19F (376 MHz, 10 % D2O) δ ppm -62.47. DDFL60. Formula: C12H16FN. HPLC 
tR 12.2 mins; > 95 % purity. NMR: 19F (376 MHz, 10 % D2O) δ ppm N/A. DDFL61. Formula: 
C6H6FN. HPLC N/A. NMR: 19F (376 MHz, 10 % D2O) δ ppm N/A. DDFL62. Formula: C6H11FO2. 
HPLC N/A. NMR: 19F (376 MHz, 10 % D2O) δ ppm N/A. DDFL63. Formula: C7H6FN. HPLC tR 
13.4 mins; < 50 % purity. NMR: 19F (376 MHz, 10 % D2O) δ ppm -75.40, -119.66. 
Scored out compounds did not pass QC checks, therefore were not included in the final 
screening pools. DDFL Fragment Pools. DDFL-Pool-1: 07, 10, 21, 22, 26, 33, 42, 45, 48, 57, 59. 
DDFL-Pool-2: 09, 14, 18, 24, 36, 38, 39, 51, 53, 54. DDFL-Pool-3: 01, 04, 05, 12, 20, 28, 34, 46, 55, 











8.3.6. 19F NMR Fragment Screening of UbE2L3 
8.3.6.1. RAFL Fragment Screening of UbE2L3 
    
 
Figure 8.21: 1D 19F NMR spectra of RAFL Screening against UbE2L3. Superposition of 
fragments in absence (red) and presence (blue) of 10 μM UbE2L3 protein. Top left: RAFL-Pool-














8.3.6.2. CFL Fragment Screening of UbE2L3 
    
     
 
Figure 8.22: 1D 19F NMR spectra of CFL screening against UbE2L3. Superposition of fragments 
in absence (red) and presence (blue) of 10 μM UbE2L3 protein. Top Left: CFL-Pool-1. Top 








8.3.6.3. DDFL Fragment Screening of UbE2L3 
     
     
 
Figure 8.23: 1D 19F NMR spectrum of DDFL Pool 1. Superposition of fragments in absence 
(red) and presence (blue) of 10 μM UbE2L3 protein. Top Left: DDFL-Pool-1. Top right: DDFL-




8.4. Appendix for chapter 5 
8.4.1. 19F NMR Fragment Screening of NusEΔ/NusB 
8.4.1.1. RAFL Fragment Screening of NusEΔ/NusB 
     
 
Figure 8.24: 1D 19F NMR spectra of RAFL Screening against NusEΔ/NusB. Superposition of 
fragments in absence (red) and presence (blue) of 10 μM protein. Top left: RAFL-Pool-1. Top 
right: RAFL-Pool-2. Bottom left: RAFL-Pool-3. 
8.4.1.2. CFL Fragment Screening of NusEΔ/NusB 
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Figure 8.25: 1D 19F NMR spectra of CFL Screening against NusEΔ/NusB. Superposition of 
fragments in absence (red) and presence (blue) of 10 μM NusEΔ/NusB protein. Top Left: CFL-
Pool-1. Top right: CFL-Pool-2. Middle left: CFL-Pool-3. Middle right: CFL-Pool-4. Bottom left: 
CFL-Pool-5. 
   
Figure 8.26: 1D 19F CPMG NMR spectra of CFL-Pool-5. Left: compound only spectra. Right: 







8.4.1.3. DDFL Fragment Library Screening of NusEΔ/NusB 
    
    
 
Figure 8.27: 1D 19F NMR spectrum of DDFL Pool 1. Superposition of fragments in absence 
(red) and presence (blue) of 10 μM NusEΔ/NusB protein. Top Left: DDFL-Pool-1. Top right: 








8.4.2. Compound Analogue structures and QC data 
CFL02a. Formula: C11H13F3N2O. HPLC tR 18.0 mins, > 95 % purity. NMR: 
1H (500 MHz, DMSO-d6) δ ppm 7.01 (d, 1H, ArH), 6.98 (d, 1H, ArH), 6.85 
(m, 1H, ArH), 5.19 (s, 2H, NH2), 3.77 (m, 4H, CH2), 2.84 (m, 4H, CH2). 13C 
(125 MHz, DMSO-d6) δ ppm 143.27 (s, 1C), 141.48 (s, 1C), 125.25 (q, 1C), 
124.81(q, 1C), 119.59 (s, 1C), 113.35 (q, 1C), 110.68 (q, 1C), 66.88 (s, 2C), 50.72 
(s, 2C). 19F NMR (376 MHz, 10 % D2O) δ ppm -61.78. 
CFL02b. Formula: C12H11F3N2O. HPLC tR 19.5 mins, > 95 % purity. NMR: 
1H NMR (500 MHz, DMSO) δ 8.13 (d, 1H, ArH), 7.91 (dd, 1H, ArH), 7.31 
(d, 1H, Ar), 3.78 (m, 4H, CH2), 3.32 (m, 4H, CH2). 13C NMR (126 MHz, 
DMSO-d6) δ ppm 157.76 (s, 1C), 132.38 (q, 1C), 131.45 (q, 1C), 124.01 (q, 1C), 
121.88 (q, 1C), 119.79 (s, 1C), 117.74 (s, 1C), 103.77 (s, 1C), 66.40 (s, 4C), 51.16 (s, 4C). 19F NMR 
(376 MHz, 10 % D2O) δ ppm -62.07. 
CFL02c. Formula: C10H10F3NO2. HPLC tR 17.7 mins, > 95 % purity. NMR: 
1H NMR (500 MHz, DMSO-d6) δ ppm 7.81 (q, 4H, ArH), 3.33 (s, 3H, CH3), 
3.29 (s, 3H, CH3). 13C NMR (126 MHz, DMSO-d6) δ ppm 139.02 (C), 130.74 
(C), 128.83 (C), 125.54 (C), 61.41 (C). 19F NMR (376 MHz, 10 % D2O) δ ppm 
-62.67. 
CFL02d. Formula: C10H10F3NO. HPLC tR 16.9 mins, > 95 % purity. NMR: 1H 
NMR (500 MHz, DMSO-d6) δ ppm 7.72 (dd, 4H, ArH), 3.01 (s, 3H, CH3), 2.88 
(s, 3H, CH3). 13C NMR (126 MHz, DMSO-d6) δ ppm 169.23 (s, 1C), 141.10 (s, 
1C), 129.95 (q, 1C), 128.18 (s, 2C), 125.80 (q, 2C), 124.40 (q, 1C), 39.27 (s, 1C), 
35.14 (s, 1C). 19F NMR (376 MHz, 10 % D2O) δ ppm -62.54. 
CFL02e. Formula: C12H12F3NO3. HPLC tR 15.6 mins, > 95 % purity. NMR: 
1H NMR (500 MHz, DMSO-d6) δ ppm 13.89 (b. s, 1C, COOH), 7.94 (d, 1H, 
ArH), 7.80 (dd, 1H, ArH), 7.36 (d, 1H, ArH), 3.74 (t, 4H, CH2), 3.12 (t, 4H, 
CH2). 13C NMR (126 MHz, DMSO-d6) δ ppm 167.95 (s, 1C), 154.18 (s, 1C), 
129.67 (q, 1C), 128.34 (q, 1C), 124.52 (q, 1C), 124.33 (s, 1C), 121.85 (q, 1C), 120.31 (s, 1C), 66.45 
(s, 1C), 52.01 (s, 1C). 19F NMR (376 MHz, 10 % D2O) δ -61.30. 
CFL02f. Formula: C11H12F3N3O2. MS (ESI): [M+H]+calc 276.1; [M+H]+obs 
276.1. HPLC tR 15.3 mins, > 95 % purity. NMR: 1H NMR (500 MHz, DMSO-
d6) δ ppm 8.12 (d, 1H, ArH), 7.82 (dd, 1H, ArH), 7.41 (d, 1H, ArH), 3.05 (t, 
4H, CH2), 2.80 (t, 4H, CH2). 13C NMR (126 MHz, DMSO-d6) δ ppm 148.34 
(s, 1C), 139.82 (s, 1C), 130.51 (q, 1C), 124.20 (q, 1C), 124.17 (q, 1C), 121.73 (s, 1C), 119.48 (q, 1C), 
51.95 (s, 2C), 45.70 (s, 2C). 19F NMR (376 MHz, 10 % D2O) δ ppm -62.06. 
CFL17a. Formula: C8H5F3N2S2. MS (ESI): [M+H]+calc 251.0; [M+H]+obs 
251.1. HPLC tR 16.4 mins, > 95 % purity. NMR: 1H NMR (500 MHz, 
DMSO-d6) δ ppm 8.08 (d, 1H, ArH), 7.86 (s, 2H, NH2), 7.51 (dd, 1H, 








2𝑉2 + [𝐿]0𝑉1𝑟𝑏𝑟𝑜 + [𝐿]0𝑉2𝑟𝑏𝑟𝑜 − [𝑃]0𝑉1𝑟𝑏𝑟𝑜 − [𝑃]0𝑉2𝑟𝑏
(𝑟𝑏 − 𝑟𝑜)(𝑟𝑜𝑉1 + 𝑉2)
 
Variable Description 
KD Dissociation constant 
[L]0 Total ligand concentration over whole system 
[P]0 Total protein concentration in red well 
V1 Red volume 
V2 White volume 
rb 
Ratio of ligand in red/white chamber in 







Ratio of ligand in red/white chamber in 






Raw Data (CFL02f) 
Control experiment 
Well Number Peak intensity pmoles Concentration (μM) Intensity Ratio 
Red 1 5.01 x106 0.815 0.408 
1.008 
White 1 4.97 x106 0.808 0.404 
Red 2 6.24 x106 1.020 0.508 
0.943 
White 2 6.62 x106 1.080 0.538 
Red 3 6.95 x106 1.130 0.565 
1.012 
White 3 6.87 x106 1.120 0.559 
Average 0.987 
With 40 μM total protein concentration 
Well Number Peak intensity pmoles Concentration (μM) Intensity Ratio 
Red 1 5.17 x106 0.841 0.421 
1.222 
White 1 4.23 x106 0.688 0.344 
Red 2 6.79 x106 1.100 0.552 
1.157 
White 2 5.87 x106 0.955 0.477 
Red 3 9.83 x106 1.600 0.800 
1.255 
White 3 7.83 x106 1.270 0.637 
Average 1.211 
Table 8.4: Raw data from LCMS analysis of qμD for compound CFL02f. 
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8.4.4. Bacterial inhibition assay 
 
Figure 8.28: Plots of bacterial growth curves under different conditions. The starting OD600 is 








































































8.4.5. 15N HSQCs from all titrations with active CFL compounds 
 
Figure 8.29: [1H, 15N] HSQC DMSO titration of 15N-labelled NusEΔ in the NusEΔ/NusB 

















































Figure 8.30: [1H, 15N] HSQC DMSO stability test of 15N-labelled NusEΔ in the NusEΔ/NusB 
complex. NusEΔ/NusB (100 μM) in the presence of 10 % DMSO. 13 spectra acquired over 72 































Figure 8.31: [1H, 15N] HSQC spectrum of a series of titration points with compound CFL02 and 
15N-labelled NusEΔ in the NusEΔ/NusB complex. From light to dark shows the change in 
chemical shift on increasing concentration of ligand. Concentration of ligand ([L]0) ranges 































Figure 8.32: [1H, 15N] HSQC spectrum of a series of titration points with compound CFL02a 
and 15N-labelled NusEΔ in the NusEΔ/NusB complex. From light to dark shows the change in 
chemical shift on increasing concentration of ligand. Concentration of ligand ([L]0) ranges 































Figure 8.33: [1H, 15N] HSQC spectrum of a series of titration points with compound CFL02b 
and 15N-labelled NusEΔ in the NusEΔ/NusB complex. From light to dark shows the change in 
chemical shift on increasing concentration of ligand. Concentration of ligand ([L]0) ranges 

































Figure 8.34: [1H, 15N] HSQC spectrum of a series of titration points with compound CFL02f 
and 15N-labelled NusEΔ in the NusEΔ/NusB complex. From light to dark shows the change in 
chemical shift on increasing concentration of ligand. Concentration of ligand ([L]0) ranges 
































Figure 8.35: [1H, 15N] HSQC spectrum of a series of titration points with compound CFL17 and 
15N-labelled NusEΔ in the NusEΔ/NusB complex. From light to dark shows the change in 
chemical shift on increasing concentration of ligand. Concentration of ligand ([L]0) ranges 































Figure 8.36: [1H, 15N] HSQC spectrum of a series of titration points with compound CFL17a 
and 15N-labelled NusEΔ in the NusEΔ/NusB complex. From light to dark shows the change in 
chemical shift on increasing concentration of ligand. Concentration of ligand ([L]0) ranges 
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